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NCBI     National Center for Biotechnology Information 
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NGS     next generation sequencing 
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1 Summary 
 
The main aim of this work was identification of novel molecular mechanisms 
causing hemophilia A, with a special focus on patients without detectable mutations. 
In most of hemophilia A patients, mutations could be identified in the coding 
sequence of F8. However, despite tremendous improvements in mutation screening 
techniques, in a small number of patients no mutation is found. Therefore, the focus 
of this work was to analyze changes in regions of F8 that are usually ignored in the 
routine screening. These variations involve regions such as introns that are not 
assessed by current routine molecular diagnostic techniques. 
 
In this study a multistep experimental protocol was designed to screen the 
whole F8 locus for novel genetic abnormalities and alternations. This protocol 
combined several mutation screening tools. Multiple ligation-dependent probe 
amplification and comparative genomic hybridization were used to detect copy 
number variations. Next generation sequencing (NGS) was applied in combination 
with long range (LR-) PCRs to re-sequence the whole genomic region of F8. The LR-
PCR approach identified two novel breakpoints. Moreover, several unique deep 
intronic variations were found. Later, mRNA analysis was performed to prove the 
causality of these intronic variations.  
 
Using this experimental strategy, causative mutations in most of the patients 
were found and characterized. Interestingly, all causal mutations were within the F8 
locus. The results of this work show once more the variety and complexity of 
mutations causing hemophilia A. Moreover, the data presented here show the 
association of deep intronic mutations with hemophilia A phenotype. To diminish the 
number of mutation negative patients, there is a need to apply several techniques. 
Based on the results of this work, an extended diagnosis flowchart is proposed. This 
flowchart demonstrates techniques for successful identification and confirmation of 
novel mutations in hemophilia A patients and could serve as a model for genetic 
analysis of other monogenic diseases, where no pathogenic mutation is found. 
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2 Introduction 
 
Hemophilia A is a common X-linked recessive bleeding disorder (OMIM 306700). 
Typically, affected patients experience prolonged bleeding caused by lack or reduced 
activity of the coagulant Factor VIII (FVIII:C). Various types of mutations in the factor 
8 gene (F8) are known to be responsible for the FVIII deficiency. Despite tremendous 
improvements in mutation screening methods, in a small group of hemophilia A 
patients no DNA change could be found. The presented work includes F8 mutation 
analysis in hemophilia A patients beyond routine diagnosis to identify underlying 
mechanisms leading to FVIII deficiency in these patients. 
 
2.1 Hemostasis and the blood coagulation cascade 
 
Hemostasis is the protective physiological response to injury that results in exposure 
of blood to the subendothelial layers of the vessel wall. Hemostasis is a complicated 
and highly regulated process involving several coagulation factors and cofactors 
present in blood plasma. The generation of fibrin depends upon the exquisitely 
controlled interplay of the following cellular components: five proteases (Factor 7 
(FVII), Factor 9 (FIX), Factor 10 (FX), protein C and prothrombin) interacting with five 
cofactors (tissue factor (TF; CD142)), thrombomodulin, protein S, Factor 5 (FV) and 
FVIII). The coagulation factors are designated by Roman numerals ranging from I to 
XIII with a lowercase “a” indicating the active form (reviewed in [1-3]). The role of 
each coagulation factor is best illustrated by the classical coagulation cascade 
(Figure 1), which consists of two distinct pathways; the contact pathway (also known 
as the intrinsic pathway), and the tissue factor pathway (also known as the extrinsic 
pathway), were first described 1964 by two independent groups [4, 5]). These 
pathways are assayed clinically using the activated partial thromboplastin time 
(aPTT) and the prothrombin time (PT), respectively. Factor 12 (FXII) and Factor VIIa 
(FVIIa) initiate the intrinsic and extrinsic pathways, respectively.  
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Figure 1: Simplified scheme of the coagulation cascade and clot formation via intrinsic and 
extrinsic pathways. The two pathways merge after the formation of FXa. The coagulation factors are 
abbreviated with capital F followed by their Roman numbers, HMK: high molecular weight kininogen, 
a: activated, Ca2+= Calcium, TF=tissue factor. 
 
After injury of a blood vessel, the coagulation cascade is initiated by the contact of 
blood with TF, a non-enzymatic lipoprotein present in the membrane of cells 
surrounding the vascular bed. Once in contact with blood the TF-dependent 
activation of coagulation, i.e. the extrinsic pathway, is initiated. When a vessel is 
injured, membrane bound TF is exposed. As a consequence the circulating FVII is 
activated, and binds to TF and results in formation of the FVIIa-TF complex. This 
complex acts as a cofactor and in converts circulating FIX and FX to the active serine 
proteases FIXa and FXa, respectively, which in turn activates TF-bound to FVII in a 
feedback mechanism (Figure 1). FXa works with its cofactor activated Factor V 
(FVa). A small amount of prothrombin activates thrombin, which works in a positive 
feedback loop itself. Thrombin can activate FV and FVIII [6], which activates FXI. FXI 
itself activates in turn FIX and allows activation of more thrombin. This will lead to 
releases of FVIII from being bound to von Willebrand Factor (vWF). Subsequently, 
after sufficient amount of thrombin is present in the circulation, fibrinogen is activated 
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and becomes fibrin. In the presence of activated factor 13 (FXIIIa), fibrin is 
polymerized and a fibrin clot is formed at the site of injury [7].  
 
The described extrinsic pathway is responsible for trauma-initiated coagulation, 
whereas the physiological importance of the alternative "intrinsic" pathway is not fully 
understood. However, when activated, the procoagulant activities of the coagulation 
system are increased. The intrinsic pathway begins with formation of the primary 
complex on collagen which involves high molecular weight kininogen (HK)-dependent 
prekallikrein (PKK)/kallikrein (KK) regeneration cycle for FVIIa-dependent FXII 
activation (Figure 1). Through the sequential activation of several zymogens (FXII, 
FXI, FIX and FX), prothrombin is activated via the prothrombinase complex. FXII is 
activated and converts FXI into FXIa, following the activation of FIX which forms the 
tenase complex with its cofactor FVIIIa. At this point the intrinsic tenase shunts into 
the extrinsic pathway by generation of FXa [8]. 
 
2.2  Hemophilia A 
 
Hemophilia A which is the most common bleeding disorder has a occurrence of 1 in 
every 5,000 males [9]. It is caused by lack or defective function of the coagulant FVIII 
protein. Endogenous FVIII is present in trace amounts of 100-200 ng/mL [10] and its 
blood-circulating form is bound to vWF. The severity of disease is related to the 
amount of residual FVIII. Bleeding occurs mainly in joints and muscles as well as 
internal organs. Although most of the factors involved in the coagulation cascade 
have been discovered in the 20th century, the earliest written references concerning 
hemophilia are attributed to Jewish writing of the 2nd century AD [11]. However, first 
in the 18th century, the three important characteristics of the disease where defined; 
bleeding, male gender and heredity [12]. Hemophilia has often been called the 
“Royal Disease” since Queen Victoria of England was carrier of hemophilia and 
passed the disease through her daughters to the Spanish, German, and Russian 
royal families [13].  
 
The disease is classified as severe (FVIII:C< 1%), moderate (1%< FVIII:C< 5%), and 
mild (5%< FVIII:C< 35%) which represent about 40%, 10%, and 50% of patients with 
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hemophilia A, respectively [14, 15]. The severity of disease depends on the effect of 
the mutation on FVIII:C and protein levels. Although it is rare for women to suffer 
from hemophilia A, there are several reports describing molecular mechanisms 
behind the phenotype in females. This is caused by whether unbalanced X 
chromosome inactivation in [16-18] or de novo F8 mutations [19-22] in obligate 
carriers of hemophilia A. 
 
Broad spectrums of mutations cause a qualitative or quantitative defect leading to 
hemophilia A. Severely affected patients experience recurrent spontaneous 
excessive bleeding after trauma due to a lack of FVIII protein. The most common F8 
mutations leading to a severe phenotype are inversions. One in 30,000 males is born 
with an inversion in F8 with a residual FVIII:C less than 1%. In about 90% of such 
severe hemophilia A cases, patients have an inversion involving intron 22. In the 
remaining 10%, an inversion of intron 1 is responsible for the severe phenotype [23, 
24]. Rest of the patients carry a variety of missense, nonsense, and splice site 
mutations, as well as deletions and insertions [25]. Cases of moderate and mild 
phenotype are mainly due to missense mutations [26]. These patients are suffering 
from frequent bruising and bleeding into joints (mainly knee, ankle, hip and elbow).  
 
Both, life expectancy and quality of life in hemophiliacs improved after therapy with 
fresh whole blood or fresh frozen plasma was available. After low success of the first 
trials with porcine and bovine plasma in the beginning of 1950s due to allergic 
reactions, human-derived plasma was successfully used to treat patients. However, 
as a consequence of receiving plasma from donors without an adequate donor 
screening and infective agent testing, a large number of hemophiliacs became 
infected with hepatitis C virus [27] and human immunodeficiency virus (HIV) [28]. At 
this time, AIDS became the major cause of death in hemophiliacs whereas until 
1970s-1990s intracranial bleeding was the main cause. Later, additional virus 
inactivation steps (heating or solvent treatment) were included in the manufacture of 
plasma-derived FVIII products. Although plasma-derived FVIII replacement therapy is 
still used, an even safer option for the therapy became available after Gitschier et. al 
[29] and Toole et. al [30] independently cloned and characterized F8 in 1984. Ten 
years later, recombinant FVIII (rFVIII) products were produced in cell culture, using 
baby hamster kidney (BHK) or chinese hamster ovary (CHO) cells. Since then rFVIII 
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products are widely used as a major source of the protein for the treatment. 
However, this therapy is extremely expensive due to the cost of in vitro production 
and purification. The variety of fractionation techniques used for the production of 
plasma-derived FVIII products make these also quite expensive. Because of the high 
costs and limited availability of FVIII products (both plasma-derived and 
recombinant), most of the patients worldwide are not under prophylaxis treatment.  
 
Another alternative therapy method is gene therapy. Hemophilia A, as a monogenic 
disease, is a good candidate for gene therapy. This method has several advantages 
in comparison to the conventional substitution therapy. It is a safe and effective long-
term treatment, which will avoid infection risks. Moreover, the disease can be 
corrected with as low as only 1-2% of FVIII levels. However, most of the clinical trials 
using different gene delivery systems [31, 32] do not guarantee to achieve the long-
term availability of circulating FVIII in plasma, but for many patients even a temporary 
improvement of hemostasis would could be considered as a success. However, lack 
of long-term expression and the absence of a safe and effective viral delivery system 
are the limitations that still need to be improved.  
 
2.3 Genomic organization of F8  
 
In 1984, after cloning and characterization of the ‘large’ gene encoding FVIII, for the 
first time [29, 30], the precise and direct mutation screening of patients with 
hemophilia A became available. The genomic region of F8 spans 186 kb and codes 
for a mRNA of 9.1 kb. It is mapped to the most distal band of the long arm of the X 
chromosome (Xq28) on the minus strand. The gene consists of 26 exons (Figure 2). 
Comparing all exons, which vary in size from 69 bp to 262 bp, exon 26 and exon 14 
are remarkably huge with a size of 1959 bp and 3106 bp, respectively. Exon 26 
mostly codes for the 3´ untranslated region (UTR), and exon 14 encodes the large B 
domain of FVIII protein. The introns vary in size between 200 bp and 32.5 kb 
(reviewed in [25]).  
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Figure 2: Genomic organization of F8 at Xq28. The black arrows show the orientation of 
transcription of F8a, as well as the intron 1 and intron 22 homologous regions within and outside of F8. 
The gray arrows indicate the orientation of transcription of F8 and F8b. The intron 1 repeats (int1h-1 
and int1h-2) are involved in the intron 1 inversion. The two intragenic transcripts in the F8a and F8b 
are shown in a magnification. The first exon of each gene is shown with green and red blocks, 
respectively. Graph is not to scale. Modified from Oldenburg and El-Maarri [25].  
 
Interestingly, the intron 22 of F8 is not only very large (32 kb), but it also contains a 
CpG island that acts as a bidirectional promoter for two additional genes nested in 
the body of F8. The intronless F8a (OMIM 305423) and F8b (OMIM 305424). F8a is 
transcribed in the opposite and F8b in the same direction to F8 [33, 34].  
 
F8a codes for a protein called huntingtin-associated protein (HAP40), a 40 kD protein 
[35] that interacts with huntington protein. F8b is spliced to exons 23 through 26 by 
creating a transcript of 2.5 kb with the F8 reading frame. The protein encoded by F8b 
transcript would include the C2 domain of FVIII, which is the phospholipid-binding 
region and essential for the coagulant activity. However, the biological function of 
F8b is obscure due to the fact that patients with a deletion comprising this part of the 
gene do not suffer from any other disease than hemophilia A. Transcripts of both 
genes have been detected in many tissues. However, the function of these two 
genes is still not well understood [33-35]. 
 
Of interest is also the location of these genes (F8a and F8b). Their promoter is 
located within a 9.5 kb region, about 5.78 kb downstream of exon 22 of F8, 
designated as intron 22 homologous region 1; int22h-1 [36] (Figure 2). This region is 
present in two other copies distal to 5´ end of F8: int22h-2 and int22h-3 that are 
located approximately 300 kb and 400 kb distal to F8, respectively. These homolog 
regions are hotspots of intrachromosomal recombination resulting in inversion of the 
intervening sequences, which interrupts F8 at intron 22. This mutation is responsible 
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for 50% of severe hemophiliacs [24]. A similar pair of inverted repeats is present 
within intron 1 of F8 about 15.26 kb downstream of exon 1 (annotated as int1h-1) and 
125 kb upstream of exon 1 (annotated as int1h-2) [23] (Figure 2). This repeat is a ∼1 
kb element. Inversions involving this region are the causative mutation in 5 % of 
patients with severe hemophilia A. This inversion results in a short F8 mRNA 
consisting of only exon 1 of F8. Both inversions can be diagnosed using PCR based 
mutation screening methods [37]. 
 
2.4 Molecular basis of hemophilia A 
 
The spectrum of mutations causing hemophilia A includes a wide range of mutations 
scattered through the whole genomic region of F8. Most of the mutations are listed in 
the hemophilia A mutation database (HAMSTeRS) at http://hadb.org.uk/. In addition 
to the inversions described above, which account for gross rearrangements, various 
types of point mutations: missense (amino acid substitution), nonsense (premature 
termination of the peptide chain), and splice site mutations (altered mRNA), small 
and large deletions, insertions, and duplications have been reported. Another group 
of mutations include C>T and G>A substitutions at CpG dinucleotide hotspots. These 
mutations are caused by spontaneous methylation-induced deamination of the 5-
methylcytosine [38, 39]. Hotspots for such mutations are codons 1689, 1941, 1966, 
2147, 2150, 2159, and 2163. Small deletions and insertions caused by polymerase 
slippage errors in series of adenine nucleotides (A stretches; As) are another 
category of mutations. The main hotspot of these mutations are codon 1191 to 1194 
(9 As), codon 1439 to 1441 (8 As), and 1588 to 1590 (6 As) [25]. Noteworthy, all of 
these mutations occur in exon 14. Furthermore, several deletions and duplications of 
F8 locus have been reported. However, only few cases have been characterized in 
detail [40, 41]. Most of the mutations can be identified using the routine PCR-based 
analysis methods with a mutation detection rate of up to 97% [25]. In addition, mRNA 
analysis of the splicing variants in peripheral blood allows the detection of mutations 
at mRNA levels in patients with splicing defects [42, 43]. Although most of causative 
mutations leading to hemophilia A phenotype are in F8, mutations in interaction 
partners of FVIII considering the transport of the protein including lectin mannose-
binding protein (LMAN1), multiple coagulation factor deficiency 2 protein (MCFD2), 
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and clearance of the protein such as low-density lipoprotein receptor-related protein 
(LRP) should be considered [44-46]. Moreover, mutations in vWF affecting its binding 
to FVIII, the so called vWF type 2N (Normandy) mutations, can reduce the half life of 
FVIII protein dramatically [47]. Interestingly, in about 2% of patients with hemophilia 
A, no mutation can be found at the genomic level [42, 48]. In addition mRNA analysis 
of most of these patients do not reveal any apparent mutation in coding sequences 
as well as promoter and 3´ UTR [42].  
 
2.5 FVIII protein 
 
The main sites of FVIII production in the liver are sinusoidal endothelial cells and 
hepatocytes [49]. Although several tissues express FVIII, the secretion of this protein 
is only limited to a number of cells [50, 51]. Endogenous FVIII is found in relatively 
low levels in blood (100-200 ng/ml corresponding to 0.35-0.7 nM). The primary F8 
cDNA translation product is a polypeptide of 2351 amino acid (aa) residues. The first 
19 amino acids encode a hydrophobic signal peptide, which is removed during 
secretion and transport to endoplasmatic reticulum (ER). Finally, a mature 
glycoprotein of 2332 amino acids with a molecular weight of 267 kDa is synthesized. 
The mature protein consists of several main domains: three A domains, a large B 
domain, and two C domains (Figure 3). The largest domain is the B domain with 908 
aa residues. The sizes of the A1, A2, and A3 domains are 336, 345, and 335 aa 
residues, respectively. The C1 and C2 domain are the smallest domains of FVIII 
protein with 155 and 152 aa residues, respectively. Three short acidic regions (a1 to 
a3) are rich in negatively charged residues. The a1 and a2 domains follow the A1 
and A2 domains, respectively and connect these domains to the amino-terminal of B 
domain. The a3 domain is located before A3 domain and connects this domain to the 
carboxy-terminal end of B domain. Sequence analysis reveals a domain organization 
of A1-a1-A2-a2-B-a3-A3-C1-C2 (reviewed in [52]).  
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Figure 3: Domain structure of FVIII protein showing the major interaction sites. A) The 
precursor FVIII protein is 2351 aa (267 kDa) which is processed to a final product of 2332 aa that 
lacks 19 aa from its N terminus. B) This product will be cleaved by thrombin first at Arg 1689, which is 
the B-A3 junction. This cleavage results in a variably sized heavy chain (92-220 kDa) that consist of 
A1 and A2 domains and the partially proteolysed B domain. C) The A3 domain is as well released 
from the light chain (72 kDa) which consists of A3, C1 and C2. The final cleavage by thrombin results 
in complete removal of the B domain (Arg 740) and cleavage of the protein between A1 and A2 
domains at position (Arg 372). The activated protein is held through a divalent metal ion-dependent 
interaction. 
 
FVIII is highly homologous to FV [53]. Interestingly, the heavily glycosylated B 
domain is not homologous to FV B domain. In contrast, the three A domains share 
about 35 % of homology to each other and also to the A domains of ceruloplasmin 
[54]. Furthermore, the C domains share 35% identity to each other and 55% to the 
discoidin family of proteins, suggesting their interaction with phospholipids. The 
amino acid homology between FV and FVIII suggests that these genes originate from 
a duplication process and exon shuffling [55]. 
 
Prior to secretion into plasma, FVIII is intracellularly cleaved, at Arg1648 and 
Arg1313, within recognition motifs for the subtilisin-like protease PACE/furin [56]. 
FVIII is further cleaved within the B domain. This cleavage results in a heterodimer 
consisting of a heavy chain (a peptide of 92- 220 kDa consisting of A1-a1-A2-a2 
domains with the B domain in variable extensions) and a light chain (a peptide of 72 
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kDa composed of the a3-A3-C1-C2 domains). Both chains are linked through a 
divalent metal ion-dependent interaction (Cu2+ ions, the coordination with further ions 
such as Ca2+ and Mn2+ is also essential for maximal specific activity [57]) via A1 and 
A3 domains.  
 
In plasma, FVIII heterodimers circulate noncovalently bound to vWF via the FVIII a3 
domain. These heterodimers are activated by thrombin (FIIa) and cleaved at 3 
arginine residues: Arg372, Arg740, and Arg1689. The active FVIII protein has a 
domain structure of A1-a1, A2-a2, and A3-C1-C2. This active FVIII is extremely 
unstable [58]. However, within the protein there is a stable metal-ion link within the 
light chain dimer, which is weakly associated with the A2 domain through 
electrostatic interactions. Inactivation of FVIII occurs via cleavage at two other 
arginine residues: Arg336 and Arg1721 by FXa, at Arg336 and Arg1719 by FIXa, or 
by activated protein C (APC) at Arg336 and Arg562. Interestingly, FIX has a dual role 
both in stabilization and inactivation of FVIII: beside its role in protection of FVIII 
against inactivation by APC, it can link the A2 and A3 domains due to its interaction 
with the active protein. On the other hand, FIX can cleave FVIII as well. Noteworthy 
is the protective role of vWF, which not only results in inhibiting phospholipids to 
interact with FVIII, but also helps by occupying the protease binding sites [59].  
 
Two major proteins are known to play a role in clearance of FVIII: the low-density 
lipoprotein receptor (LDLR) and the hepatic low-density lipoprotein receptor-related 
protein (LRP). This clearance process is enhanced by heparan sulfate proteoglycan 
(HSGP) mediating the binding of FVIII to the cell surface [60]. The different sites for 
activation, inactivation and interaction of FVIII, highlights the complexity of regulation 
between hemostasis and thrombosis. 
 
2.6 Determinants of plasma FVIII levels 
 
Plasma FVIII activity (FVIII:C) is a highly variable quantitative trait. In healthy 
individuals several factors have been reported to be associated with elevated FVIII 
levels. While only one gene, the AB0 blood-group locus, has been shown to be 
associated with this broad variability [61-63], also vWF is a main determinant of 
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FVIII:C in plasma [62, 64]. The AB0 blood group account for variations in vWF levels 
as well. Evidence of the supporting role of factors such as age (an increase of 5-6 
IU/dl per decade) [65, 66], body mass index (positively correlated with FVIII:C) [66], 
diabetes mellitus [67], sex ( FVIII:C is higher in women than men) [66, 68], race 
(FVIII:C is higher in blacks than whites) [69] oral contraception [70, 71], smoking [66, 
72], lipid fractions [60, 67] exist. Moreover, several stimuli can cause a transient 
increase of FVIII:C such as exercise (as a possible result of adrenalin and β2-
adrenoreceptor stimulation) and vasopressin that can enhance FVIII levels directly or 
indirectly via the V2 receptor [73]. There are also reports of an increase in FVIII 
levels during pregnancy, surgery, liver disease and chronic inflammation. In most of 
these conditions, there is a simultaneous increase of FVIII and vWF levels [74]. Due 
to the homology between FV and FVIII and the fact that they share common 
biosynthetic pathways, the FV antigen (FV:Ag) levels correlate to some extent with 
FVIII:Ag levels. All in all, due to a multitude of variants that could influence FVIII 
levels in plasma, F8 is not the only determinant that should be considered in cases 
with reduced FVIII:C levels. 
 
2.7 Patients without mutation in F8 gene 
 
In about 98% of all hemophilia A patients, the molecular defect is within the F8 
coding sequence (cDNA). So far, more than 900 causal mutations in F8 cDNA have 
been reported (http://hadb.org.uk). In addition, in about 10% of mild hemophilia A 
cases several point mutations have been described that have an effect on the 
splicing of F8 mRNA. Such mutation could lead to the production of an aberrant 
mRNA, which will produce an abnormal FVIII protein or could reduce the protein 
synthesis. Also an effect on the secretion of the protein due to the production of a 
mis-folded protein can explain the hemophilia A phenotype. Despite tremendous 
improvements in mutation screening methods, in a minority of patients with reduced 
FVIII:C levels no mutation can be found. In such cases, application of more 
excessive methods in addition to the routine mutation screening methods is needed 
to identify the underlying molecular mechanisms. Therefore, mutations in non-coding 
areas of F8 or even in other genes that might interact with FVIII protein should be 
considered to be responsible for the hemophilia A 'like' phenotype. Only few reports 
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have been published so far about these cases. El-Maarri et. al [42] performed 
detailed RNA analysis on a group of such patients, where mutations in the introns 
were excluded due to normal splicing pattern. One year later the same group 
reported absence of F8 mRNA in a severe case, where no DNA change was 
detected [75]. Castaman et. al reported in 2010 several cases of patients where no 
candidate mutations where found after direct sequencing of the cDNA [43]. They 
found several splice site mutations located in or close to exon/intron boundaries. 
These mutations activated new intronic or exonic cryptic splice-sites. The same 
group reported deep intronic variations, which could be responsible for mild 
hemophilia A in patients where no other F8 mutations have been identified. All these 
findings support the importance of further investigation of such cases to find the 
causal mutation responsible for reduced FVIII:C levels. 
  
2.8 Study cohort  
 
Patients referred to the hemophilia center in Bonn with a bleeding tendency and 
FVIII:C levels lower than 35% were diagnosed as hemophiliac. Patients were further 
analyzed using a simple diagnostic flowchart (Figure 4). All patients with FVIII:C less 
than 1% were initially tested for intron 1 and 22 inversions. All severe cases, which 
were negative for inversion PCRs together with mild to moderate patients (FVIII:C 
levels between 1-35%) were screened for mutations in the complete cDNA, 
intron/exon boundaries and promoter region of F8. When direct sequencing did not 
reveal any apparent mutations, these patients were designated as “patients without 
mutation“.  
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Figure 4: Diagnostic workflow. Algorithm of genetic testing approach of patients with reduced or 
no residual FVIII:C. 
 
Our cohort of patient shares some important characteristics: 1) most of them have 
mild to moderate hemophilia A phenotype (FVIII:C levels of 5-35%), 2) none of the 
patients have experienced inhibitor development 3) and, also as reported by 
Castaman et al [76], these patients show a relatively poor response to desmopressin 
suggesting decreased or absent of FVIII protein. Desmopressin is a synthetic 
analogue of the hormone vasopressin that causes release of vWF from Weibel-
Palade bodies in the vascular endothelium with a simultaneous rise in FVIII [77, 78]. 
Desmopressin causes two- to six-fold increase of FVIII in mild or moderate 
hemophilia A patients [79]. In the context of this work, a framework was established 
outlining a systematic approach to identify and characterize genetic determinants of 
FVIII deficiency in patients without mutation. This framework could serve as a rational 
practice guideline to analyze all genetic factors associated with altered FVIII:C levels.  
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2.9 Aim of the study and experimental strategy 
 
The general aim of this study is to investigate new molecular mechanisms of FVIII 
deficiency. Diagnosis of hemophilia A is established on the basis of reduced or lack 
of FVIII:C. In a small group of clinically defined hemophilia A patients, even after 
applying various techniques, a 100% mutation detection rate yield is not achieved. A 
number of mutations are thus being missed, as some of these will involve sequence 
variations in intronic regions that are not being assessed by current techniques. To 
elucidate the molecular mechanism causing the hemophilia A phenotype in such 
patients with no detectable mutation in the F8 cDNA, several mechanisms were 
proposed and investigated. 
 
Therefore, a systematic screening of known genetic and non-genetic parameters 
associated with reduced FVIII:C levels was performed. For all the patients, 
hemophilia A was reconfirmed. This was done based on biochemical measurements 
of FVIII interacting factors in the coagulation cascade and comparing the clinical 
characteristics of the patients to mutation positive hemophilia A patients. Once the 
link between the disease and FVIII was verified, all known defects that mimic the a 
clinical hemophilia A phenotype caused by interacting partners of FVIII protein, 
including mutations in LMAN1 and MCFD2 affecting the transport of FVIII, type 2N 
von Willebrand deficiency (VWD) were excluded. The only factor accounting for the 
bleeding tendency was reduced amount of FVIII.  
 
The analysis was then followed on F8 at DNA and RNA level. Samples were 
analyzed for duplications and deletions in F8 and when necessary for the whole X 
chromosome. Moreover, a targeted next generation sequencing (NGS) approach 
was applied, combining a universal long range PCR (LR-PCR) protocol and massive 
parallel sequencing, to identify sequence variants and rearrangements in the 
genomic region of F8. All variants were characterized. Moreover, qualitative and 
quantitative analysis of F8 mRNA was done to investigate whether reduced 
expression or rapid degradation of mRNA can explain the hemophilia A phenotype. 
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3 Materials and Methods 
 
3.1 Materials 
 
3.1.1 Chemicals and reagents 
 
All the chemicals used were purchased at pro analysis grade. Enzymes used in the 
molecular biology were obtained from Fermentas GmbH (Leon-Rot) or New England 
Biolabs GmbH (Frankfurt am Main). All cell culture media were purchased from Life 
Technologies, Gibco BRL (Eggstein). Primers were designed using the online 
software OlicoCalc and synthesized by Eurofins MWG Operon (Ebersberg) in 
desalted quality (HPSF).  
 
Chemical/ Reagent Provider 
1 kb DNA ladder Fermentas, St. Leon-Rot 
100 bp DNA ladder Fermentas, St. Leon-Rot 
Acetic acid Merck KGaA, Darmstadt 
Agar Sigma-Aldrich Chemie GmbH, Steinheim 
Agarose Biozym Scientific GmbH, Oldendorf 
BigDye terminator Life Technologies, Applied Biosystems, Karlsruhe 
Chloroform Fluka, Neu Ulm 
ddTTP GE Healthcare Europe GmbH, Freiburg 
DMSO Merck KGaA, Darmstadt 
DNA loading dye Fermentas GmbH, Leon-Rot 
dNTPs Fermentas GmbH, Leon-Rot 
DreamTaq DNA polymerase Fermentas GmbH, Leon-Rot 
EDTA Sigma-Aldrich Chemie GmbH, Steinheim 
Ethanol Merck KGaA, Darmstadt 
Ethidium bromide Fluka, Neu Ulm 
Expand long template PCR Roche diagnostics, Mannheim 
FIREPol® DNA polymerase Solis Biodyne, Tartu, Estonia 
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Chemical/ Reagent Provider 
Fluorescein-12-dUTP Roche Diagnostics, Mannheim 
Glycerol Merck KGaA, Darmstadt 
HotStarTaq DNA polymerase Qiagen, Hilden 
HPLC –grade water Merck KGaA, Darmstadt 
Human FVIII-deficient plasma Dade Behring, Marburg 
iProof™ High-Fidelity DNA 
polymerase 
Bio-Rad Laboratories, München 
Isopropanol Merck KGaA, Darmstadt 
Kanamycin Sigma-Aldrich Chemie GmbH, Steinheim 
LGT agarose type VII Sigma-Aldrich Chemie GmbH, Steinheim 
Mineral oil Sigma-Aldrich Chemie GmbH, Steinheim 
Paxgene blood RNA tube PreAnalytiX, Hombrechtikon, Switzerland 
Polyclonal Rabbit anti human 
vWF 
Dako Deutschland GmbH, Hamburg 
Polyclonal goat anti rabbit IgG-
HRP 
Dako Deutschland GmbH, Hamburg 
RediprimeTM II Amersham, GE Healthcare Europe, Munich 
Sodium metabisulfite Merck KGaA, Darmstadt 
SuperScript III™ Life Technologies, Invitrogen, Darmstadt 
T4 DNA Ligase Life Technologies, Invitrogen, Darmstadt 
Tetramethyl-rhodamine-5-dUTP Roche Diagnostics, Mannheim 
Trizol® Life Technologies, Invitrogen, Karlsruhe 
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3.1.2 Labware 
 
Labware Provider 
Centrifuge tubes (15 and 50 ml) Greiner Bio-One GmbH, Solingen 
CryoTube vials VWR International GmbH, Langenfeld 
Filtertips, 10, 200, 1000 µl Sarstedt, Nürbrecht 
Parafilm® Pechiney Plastic Packing, Menasha, USA 
Pasteur pipettes Copan Innovation, Brescia, Italy 
Petri dishes Greiner Bio-One GmbH, Solingen 
PCR 8-stripes Thermo Fischer Scientific, Bonn 
PyroMark Q24 Cartridge Qiagen, Hilden 
PyroMark Q24 Plate  Qiagen, Hilden 
Serological pipettes Sarstedt, Nürbrecht 
Sephadex G-50 Sigma- Aldrich Chemie GmbH, Steinheim 
Reaction tubes (1.5 and 2 ml) Eppendorf, Wesseling-Berzdorf 
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3.1.3 Equipment 
 
Equipment Provider 
3130xl capillary sequencer Life Technologies, Applied Biosystems, Karlsruhe 
7500 Fast Real-Time PCR Life Technologies, Applied Biosystems, Karlsruhe 
Centrifuge (5430R- X) Eppendorf, Wesseling-Berzdorf 
Centrifuge (3-16PK) Sigma Laborzentrifugen GmbH, Osterode am 
Harz 
Chemi doc (Gel Doc XR+) Bio-Rad Laboratories, München 
Fluorskan Ascent Thermo Fisher Science, Bonn 
Fluorochem® Alpha Innotech Corp., San Leandro, USA 
Genome Analyzer II Illumina Inc., San Diego, CA, USA 
Microscope Carl Zeiss Microscopy GmbH, Göttingen 
Mini Rocker Peqlab Biotechnologie GmbH 
Nano-Drop ND 1000 Peqlab Biotechnologie GmbH 
Power supply Biometra, GE healthcare, München 
PyroMark Q24 pyrosequencer Qiagen, Hilden 
PyroMark Q24 Vacuum 
Workstation (220 V) 
Qiagen, Hilden 
Thermomixer  Eppendorf, Wesseling-Berzdorf 
Thermocycler (MJ Research) Bio-Rad Laboratories, München 
Thermocycler (T3000) Biometra, GE healthcare, München 
Vortexer Janke & Kunkel IKA-Labortechnik 
Water bath (Thermostat 2761) Eppendorf, Wesseling-Berzdorf 
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3.1.4 Databases and Programs 
 
CGH array analysis: 
• SignalMap (Roche NimbleGen, Mannheim) 
Dissertation preparation: 
• Office 2008 (Microsoft Corporation, Redmond, USA) 
• Endnote X4 (Thomson Reuters, Carlsbad, CA, USA) 
FISH analysis: 
• FISHView EXPO 2.0 Applied Spectral Imaging, Neckerhausen, DE 
MLPA analysis:  
• Coffalyser (MRC-Holland, Amsterdam, The Netherlands) 
Primer design: 
• Olico calc (www.basci.northwestern.edu/biotools/oligocalc.html) 
Sequence analysis:  
• Geneious (Biomatters Ltd, Auckland, New Zealand) 
• PyroMark Q24 software 2.0 (Qiagen, Hilden) 
• GeneMapper® v.4.1 (Life Technologies, Applied Biosystems) 
• BioEdit (IBIS Bioscience, USA) (http://www.mbio.ncsu.edu/bioedit/bioedit.html) 
MicroRNA analysis:  
• miRBase (http://www.mirbase.org/cgi-bin/blast.pl) 
• RNAfold (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi) 
Sequence search: 
• BLAST (Basic Local Alignment Search Tool) (www.ncbi.nlm.nih.gov/BLAST) 
• BLAT (Basic Local Alignment Tool) (http://genome.ucsc.edu/cgi-bin/hgBlat) 
• dbSNP (http://www.ncbi.nlm.nih.gov/SNP/) 
• HapMap (http://hapmap.ncbi.nlm.nih.gov/) 
• HEMApSTR (www.uenf.br/Uenf/Pages/CBB/LBT/HEMApSTR.html#F8A1) 
Statistical analysis: 
• GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA) 
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3.1.5 Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism software. P values were 
calculated using the Krustal-Wallis test for the autosomal loci and Mann Whitney test 
for the X-lined loci. A p-value below 0.05 shows a significant difference for all tests. 
 
3.1.6 Kits 
 
• BAGene ABO-TYPE, BAG Healthcare, Lich 
• BigDye Terminator v1.1, Life technologies, Applied Biosystems, Karlsruhe  
• Large-Construct Kit, Qiagen, Hilden 
• MLPA F8-P178 kit, MRC-Holland, Amsterdam, The Netherlands 
• Omniscript® Reverse Transcription kit, Qiagen, Hilden 
• PAXgene Blood RNA kit, Qiagen, Hilden 
• PyroMark Gold Q24 Reagents, Qiagen, Hilden 
• QIAGEN Plasmid Mini and Midi Kit, Qiagen, Hilden 
• QIAquick Gel Extraction Kit, Qiagen, Hilden 
• VisuLizeTM FVIII Antigen Kit, Haemochrom Diagnostica GmbH, Essen 
3. Materials and Methods 
 
22 
 
 
3.1.7 Buffers and media 
 
• TAE buffer     40mM Tris base 
 (pH 8.5)     1mM acetic acid 
       1mM EDTA 
 
• SOC medium     2% tryptone 
       0.5% yeast extract 
       10mM sodium chloride 
       2.5 mM potassium chloride 
       10 mM magnesium chloride 
       10 mM magnesium sulfate 
       20 mM glucose 
 
• Luria-Bertani (LB) medium  1% tryptone    
      0.5% yeast extract   
      0.5% NaCl  
 
• SSC solution     0.3 M NaCl 
       30 mM sodium citrate dihydrate 
 
• Church buffer     1 mM EDTA, 
 (pH 7.2)      7% SDS 
       0.5 M Na2HPO4 
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3.1.8 Plasmids 
 
- pCR®-XL-TOPO® vector, Life Technologies, Invitrogen, Karlsruhe (Figure S 1) 
 
3.1.9 Bacterial strains 
 
Table 1: List of bacterial strains used for transformation of plasmids. 
DH5α endA1 hsdR17(rk-mk+) supE44 thi-1 recA1 gyrA relA1 
Δ(lacZYAargF) U169 (φ80lacZΔM15)  
(Hanahan, 1983)  
TOP10 F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(araleu) 7697 galU galK 
rpsL (StrR) endA1 nupG  
Life Technologies, 
Invitrogen  
 
3.1.10 Biological samples 
 
Blood samples from hemophilia A patients and healthy controls were obtained and 
collected in dipotassium EDTA tubes (1.75 mg/ml blood). For FISH analysis and 
karyotyping, heparinized blood was obtained from patients and submitted to the 
Department of Human Genetics of the University of Würzburg. All participants gave 
informed consent to participate in the study in accordance with the Declaration of 
Helsinki. 
 
3.2 General methods 
 
3.2.1 Polymerase chain reaction (PCR) 
 
PCR was performed using FIREPol® DNA polymerase or DreamTaq DNA 
polymerase for DNA fragments up to 6 kb. Both polymerases are suitable for a TA 
cloning strategy. Annealing temperature was 2-6°C lower than primer melting 
temperature and elongation time was 1min/kb. Each PCR product was evaluated on 
1% agarose gel (3.2.3). The PCR reaction mixture was as follows:  
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Reaction mixture Amount (µl) 
10x Buffer  2.5 
dNTP Mix (5mM each) 2.5 
MgCl2 (25mM) 2.5 
Gene-specific reverse primer (20µM) 1 
Gene-specific forward primer (20µM) 1 
Template DNA (100ng/µl) 2 
DNA polymerase (5U/µl) 0.5 
dH2O 13 
Total  25 
 
The cycler conditions for the PCR were as follows: 
 
 Cycler protocol: 94°C  5 min   Initial Denaturation 
   94°C  30-60 s  Denaturation 
   55-65°C  30-60 s  Annealing  
   72°C   1-5 min  Elongation 
   72°C  10 min  Final elongation 
 
3.2.2 Site-directed mutagenesis 
 
To analyze the effect of a mutation in a vector-based system, a site-directed 
mutagenesis approach was applied. Using this approach mutations were introduced 
at a specific residue inducing a desired amino acid substitution [80]. The mutation 
was introduced into the vector via a PCR reaction as described above using partial 
complementary primers incorporating the desired amino acid change and iProof™ 
High-Fidelity DNA Polymerase. 
35 cycles 
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Reaction mixture Amount (µl) 
5x iProofTM HF/GC buffer 10 
dNTP Mix (10 mM each) 1 
Gene-specific reverse primer (20 µM) 1 
Gene-specific forward primer (20 µM) 1 
Template plasmid (100 ng) 1 
iProof™  High-Fidelity DNA Polymerase (5U/µl) 0.5 
dH2O 35.5 
Total  50 
 
PCR program: 98°C  30s  Initial Denaturation 
   98°C  10s  Denaturation 
     x*°C   30s  Annealing 
   72°C   12min  Elongation 
   72°C  10min  Final Extension 
*= Annealing temperature was calculated according to the Tm of the primers used.  
  
After the PCR reaction, a DpnI digestion was done to eliminate the methylated 
template plasmid. The reaction was incubated for 1 h at 37°C and inactivated at 80°C 
for 20 min. The PCR product was subsequently transformed into competent cell as 
described in section 3.2.7 and positive clones were used for expression studies after 
verification of the residue change by sequencing.  
 
3.2.3 Agarose gel electrophoresis 
 
1% (w/v) Agarose gels were prepared by dissolving 5 g agarose in 1x TAE buffer by 
heating. Ethidium bromide was added at a final concentration of 10 µg/ml to detect 
DNA. Samples were mixed with 5x loading dye and separated in 1x TAE at 5-10 
mA/cm. A molecular weight size marker (1 kb or 100 bp ladder) was used depending 
on the size of the products. The gels were visualized and documented under UV light 
on a ChemiDoc system. For TA cloning, crystal violet was used instead of ethidium 
bromide to avoid DNA damage by UV light.  
 
35 cycles 
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3.2.4 Gel extraction 
 
PCR products obtained from different experiments (RT-PCRs (3.3.1.2), Long Range 
PCRs (3.3.3.2)) were gel purified using the QIAquick Gel Extraction Kit. Briefly, the 
products were resolved on agarose gels as described in section 3.2.3 and the 
fragments were excised subsequently. Gel slices were dissolved in a buffer 
containing a pH indicator and incubated for 10 minutes at 55°C. The mixture was 
then applied to the QIAquick spin column, and after several wash steps, the products 
were eluted in an appropriate high-salted buffer provided in kit or water.  
 
3.2.5 Cloning of PCR products 
 
Generally, a TA-cloning strategy was used to sequence low amounts of PCR 
products, multiple fragments obtained from RT-PCR and inverse PCR products. This 
was done using the TOPO® XL PCR cloning kit. The kit uses a linearized and 
topoisomerase I-activated pCR®-XL-TOPO® vector (3.1.8). The PCR products were 
generated using Expand Long Template PCR Enzyme mix, which is a unique 
enzyme mix containing Tgo DNA polymerase [81] a thermostable DNA polymerase 
with proof reading activity and Taq DNA polymerase. The later is essential for the 
cloning to ensure addition of 3´A-overhangs to the PCR products. Amplicons were 
gel purified after agarose gel electrophoresis (3.2.3) to increase the cloning 
efficiency. However, to avoid damage to PCR products by UV light, visualization and 
electrophoresis was done using crystal violet. PCR bands were excised and purified 
using the TOPO® XL Gel purification kit. The DNA was stored at -20°C or processed 
directly to TOPO® Cloning. Four µl of the gel-purified product was mixed with 1 µl of 
the pCR®-XL-TOPO® vector for 5 minutes up to 30 minutes at RT. The reaction was 
stopped by adding 1 µl of the 6x TOPO® Cloning Stop Solution. Subsequently, 2 µl 
of the TOPO® Cloning reaction was used to transform OneShot® TOP10 (Table 1) 
chemically competent cells according to the manufacturer’s instructions as described 
in section 3.2.7. Selection of recombinants was done via disruption of the lethal E.coli 
gene, ccdB [82]. Ligation of a PCR product disrupts expression of the ccdB gene, 
which is fused to the C-terminus of the LacZa fragment, so that cells that contain the 
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non-recombinant vector are killed upon plating. Therefore, no blue/white screening is 
needed. Positive clones were selected and sequenced as described in section 
3.2.6.1 using M13 Forward and M13 Reverse primers (M13F (-20): 5´-
GTAAAACGACGGCCAG-3´; M13R: 5´-CAGGAAACAGCTATGAC-3´) provided from 
the TOPO® cloning kit. Alternatively, candidate clones were first selected on the 
basis of the insert size by direct amplification form bacterial colonies in a PCR 
reaction using the M13F and M13R primers. Bacterial stocks were prepared from 
positive clones as described in section 3.2.8.  
 
3.2.6 Sequencing 
 
Three different sequencing approaches were applied in this work: ABI Sanger 
sequencing, high throughput next generation sequencing and pyrosequencing. 
 
3.2.6.1 ABI Sanger sequencing  
 
Sequencing was performed based on the chain termination method using BigDye 
terminators, which are labeled with dRhodamin acceptor dyes as follows: 
 
Terminator Dye Label 
A Dichloro (R6G) 
C Dichloro (ROX) 
G Dichloro (R110) 
T Dichloro (TAMRA) 
 
BigDye terminator contains a set of dye terminators labeled with novel, high-
sensitivity dyes [83]. Each dye is fluorescenting at a different wavelength. 
Sequencing is based on a mix of these fluorescence-labeled dideoxynucleotides. The 
excitation of dyes is done via a laser beam followed by detection of fluorescence by a 
CCD camera. Approximately 200 ng of plasmid or 2 µl of the enzyme-treated PCR 
products were used in the following sequencing mix:  
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Reaction mixture Amount (µl) 
5x BigDye sequencing buffer 1.5 
Sequencing primer (3.2 pmol) 0.5 
BigDye Terminator sequencing mix 0.5 
Template 0.5-2 
dH2O X 
Total  12 
 
The PCR conditions for the sequencing PCR were as follows: 
 
 Cycler protocol: 96°C  1 min  Initial Denaturation 
   96°C  10 s  Denaturation 
   50°C     5 s  Annealing 
   60°C     4 min Elongation 
 
The products were subsequently purified by EtOH/NaAc precipitation (12 µl of the 
sequencing reaction product, 50 µl 96 % EtOH, 10 µl dH2O and 2 µl of 3M NaAc) 
followed by centrifugation by 4°C at 4000 rpm for 45 minutes. The pellet was washed 
once with 70% EtOH for 10 minutes at the same centrifugation conditions and dried. 
Samples were resuspended in 15 µl HiDi-formaldehyde and loaded on the capillary 
sequencer. 
 
3.2.6.2 Next generation sequencing (NGS) 
 
NGS was performed as a service at GATC Biotech AG (Konstanz, Germany) on the 
Illumina Genome Analyzer II (GA II) platform using the standard protocols and the 
kits provided according to the manufacturers instructions. Briefly, the purified LR-
PCR fragments (3.2.4) were equimolarly mixed and processed after fragmentation 
according to Illumina’s Paired-End Sequencing library kits. The DNA samples are 
sheared to appropriate size (average 800 bp). After library construction each sample 
was tagged with a unique barcode. The tagged libraries were pooled and two unique 
35 cycles 
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adapters were ligated to the fragments. The Paired-End adapter ligated fragments 
(200 bp ±50 bp) were isolated and attached to the flow cell. The flow cell is coated 
with single stranded oligonucleotides that correspond to the sequences of the 
adapters ligated during the library preparation. The adapter-ligated fragments are 
bound to the surface of the flow cell and amplified by bridge amplification via PCR 
(Figure 5). 
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Figure 5: Preparation of samples for NGS. A) Preparing the DNA sample by random fragmentation 
and ligation of adapters to both ends of the fragments. B) Attachment of single-stranded fragments 
randomly to the flow cell channels. C) Bridge amplification on solid-phase after adding nucleotides and 
enzymes. D) Generation of double stranded bridges on the solid-phase. E) Denaturation of double 
stranded templates. F) Generation of several million dense clusters of double-stranded DNA in each 
channel of the flow cell (Pictures are modified based on data available on 
http://www.illumina.com/technology/sequencing_technology.ilmn). 
 
The generated clusters on the flow cell are loaded into the sequencer for sequencing 
by synthesis approach. The sequences were analyzed using Geneious software. The 
reads were aligned onto the reference assembly (Figure 6). 
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Figure 6: Sequencing of clusters on the GAII Illumina sequencer. A) All four labeled reversible 
terminator, primers, and DNA polymerase are added to the flow cell to initiate the first sequencing 
reaction. B) After laser excitation, the image of emitted fluorescence from the first base of each cluster 
is recorded. C) The second base is determined in the next sequencing cycle and the second base is 
recorded for each cluster. D) Cycles of sequencing are repeated to determine the sequence of bases 
in a given fragment. E) Aligning the data to a reference and identifying the differences 
(http://www.illumina.com/technology/sequencing_technology.ilmn). 
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3.2.6.3 Pyrosequencing  
 
Pyrosequencing was carried out according to Tost et al. [84]. PCR fragments were 
generated using the primers listed in Table S 14, whereby either the reverse primer 
or the forward primer was biotin labeled. The sequencing primer was then hybridized 
to the labeled single-stranded PCR product that serves as template, and incubated 
with the enzymes, DNA polymerase, ATP sulfurylase, luciferase, and apyrase as well 
as the substrates, adenosine 5´phosphosulfate (APS) and luciferin. After the addition 
of the first dNTP to the reaction, the DNA polymerase catalyzes the incorporation of 
the dNTP into the DNA strand. If the first dNTP is complementary to the base in the 
DNA strand, pyrophosphate (PPi) is released in a quantity equimolar to the amount 
of the incorporated nucleotide. ATP sulfurylase converts PPi to ATP in the presence 
of APS. ATP drives the luciferase-mediated conversion of luciferin to oxyluciferin that 
generates visible light in amounts proportional to the amount of ATP (Figure 7 A-C). 
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Figure 7: Principle and procedure of pyrosequencing. A) The sequencing primer is hybridized to 
a single-stranded PCR amplicon. B) The first dNTP is added to the reaction. If the dNTP is 
incorporated into the DNA strand, the reaction is accompanied by release of PPi, which is proportional 
to the amount of incorporated nucleotide. C) ATP sulfurylase converts PPi to ATP in the presence of 
APS. ATP drives the luciferase-mediated conversion of luciferin to oxyluciferin that generates light that 
is proportional to the amount of ATP. The light is detected by a CCD camera and is seen as a peak in 
the pyrogram. Unincorporated nucleotides and ATP is continuously degraded and another dNTP is 
added. D) Addition of dNTPs is performed sequentially until the complementary DNA strand is built up 
and the sequence is determined from the signal peaks in the pyrogram. The height of each peak is 
proportional to light signal and to the number of nucleotides incorporated. 
 
The light is detected by a CCD chip and seen as a peak in the raw data output in the 
pyrogram (Figure 7 D). The height of the peak is proportional to the number of 
nucleotides incorporated. A nucleotide-degrading enzyme, apyrase, continuously 
degrades unincorporated nucleotides and ATP. After the degradation is completed, 
the next nucleotide is added. The dNTPs are added sequentially and a special form 
of dATP, the deoxyadenosine alfa-thio triphosphatase (dATP-S) is used in the 
reaction, which will be recognized by the luciferase but not by the DNA polymerase. 
The reactions were prepared using the PyroMark® Gold reagents, applied on a 
PyroMark Q24 system and analyzed subsequently on PyroMark Q24 software 2.0. 
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3.2.7 Transformation of bacteria 
 
Plasmid vectors were introduced into bacterial cells, competent E.coli (DH5α or 
OneShot® TOP10, 3.1.9) according to manufacturer's protocol. Briefly, competent 
cells were thawed on ice.  Five µl of each plasmid was added to the cells, mixed 
gently, and incubated for 30 minutes on ice. Followed by a heat-shock for 30 
seconds in a 42°C water bath, cells were chilled on ice for 5 minutes. Afterwards, 250 
µl SOC medium was added to the cells, followed by an incubation for 1h at 37°C at 
∼200 rpm. Cells were plated on LB-agar plates containing the appropriate antibiotic 
(50 µg/ml end concentration). Plates were incubated in overnight a 37°C incubator.  
 
3.2.8 Isolation and purification of bacterial plasmid DNA 
 
Colonies were picked from LB-Plates and cultured overnight in LB-medium supplied 
with the appropriate antibiotic. Bacterial stocks were prepared from each clone by 
mixing 350 µl glycerol with 650 µl of the overnight LB-culture and stored at -80°C.  
 
For plasmid purification, cells were grown overnight in 5 ml LB-medium. Cells were 
harvested by centrifugation for 15 minutes and subsequently lysed using the lysate 
buffer from Qiagen Plasmid Mini kit. Bacterial lysates were cleared by centrifugation 
and loaded onto the anion-exchange column. Plasmid DNA selectively binds to the 
column and is cleared from impurities. After several wash steps plasmid DNA was 
eluted in high-salt buffer and the DNA was collected by centrifugation. Plasmids were 
subsequently sequenced (3.2.6.1) to verify the insert and/or the mutation introduced 
in the vector. A size validation was done on an agarose gel as described in section 
3.2.3. For plasmid preparation in higher amounts, 50 ml of LB-medium containing the 
appropriate antibiotic was inoculated and grown overnight. Plasmid isolation was 
done using Qiagen Plasmid Midi kit with the same principle as Qiagen Plasmid Mini 
Kit. DNA concentration was assessed (3.2.9) and plasmids were stored at -20°C until 
use. 
 
Purification of bacterial artificial chromosome (BAC) was done using the Qiagen 
Large-Construct Kit. This method ensures DNA of significantly greater purity. The 
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efficient removal of genomic DNA is achieved by an integrated treatment with ATP-
dependent exonucleases performed after the lysis of a 500 ml culture of bacterial 
cells. The sample was then loaded onto the column, where all RNA, protein, 
metabolites, and other low-molecular-weight impurities are removed after a wash 
step. The ultrapure DNA is eluted in high-salt buffer, concentrated and desalted by 
isopropanol precipitation and collected by centrifugation. 
 
3.2.9 Measurements of DNA and RNA concentrations 
 
DNA and RNA concentration was determined by measuring by photometry (1 
OD260nm = 50µg dsDNA/ml, 1 OD260nm = 40µg RNA/ml) on a Nanodrop® machine.  
 
3.3 Mutation analysis 
 
3.3.1 RNA analysis 
 
3.3.1.1 RNA extraction from blood 
 
For RNA analysis, 2.5 ml of human whole blood was collected in a PAXgene Blood 
RNA tube. To ensure complete lysis of blood cells, the tubes were incubated at least 
for 2h at room temperature after blood collection. If the PAXgene tubes were stored 
at -70°C, the samples were equilibrated to RT before starting the RNA extraction 
procedure. The PAXgene Blood RNA tube contains a reagent composition that 
protects RNA from degradation by RNases and minimizes ex vivo changes in gene 
expression.  
 
Total RNA extraction was performed according to the manufacturer's procedure. 
Briefly, the tubes were centrifuged for 10 minutes at 5000 xg. After one wash step 
with RNase-free water (RNFW), the pellet was resuspended in an optimized buffer 
included in the kit supplemented with proteinase K and incubated for 10 minutes at 
55°C. Subsequently, the lysate was applied to a PAXgene Shredder spin column to 
homogenize and remove the cell debris. The supernatant of the flow-through was 
transferred to a microcentrifuge tube and mixed with ethanol to adjust binding 
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conditions. The sample was then applied to a PAXgene RNA spin column, where the 
RNA was selectively bound to the PAXgene silica membrane. The RNA was treated 
with DNase I using the RNase-Free DNase set to remove traces of genomic DNA. 
DNase I was diluted in DNA digestion buffer (RDD buffer) and incubated for 15 
minutes at RT. After several wash steps, RNA was eluted in elution buffer and heat-
denatured at 65°C for 5 minutes. RNA was stored at -70°C until used.  
 
3.3.1.2 Semi-Quantitative analysis of mRNA via Reverse Transcription 
PCR (RT-PCR) 
 
Total RNA was reverse transcribed to complementary DNA (cDNA) using the 
Omniscript® Reverse Transcription kit. Briefly, template RNA was thawed on ice and 
reverse-transcription reaction was prepared as follows and incubated for 60 minutes 
at 37°C. 
 
Reaction mixture Amount (µl) 
10x Buffer RT 2 
dNTP Mix (5 mM each) 2 
Gene-specific primer (10 µM) 2 
RNase inhibitor (10 U/µl) 1 
Omniscript® Reverse Transcriptase 1 
Template RNA (∼ 50 ng) 5 
RNFW 7 
Total  20 
 
The cDNA of F8 was synthesized using 4 different gene-specific primers and 
amplified in eight overlapping fragments using a nested PCR approach as described 
by El-Maarri et al. [42]. RT-PCR products were resolved on a 1% (w/v) agarose gel 
as described in section 3.2.3. Aberrant mRNA products and fragments with low 
amounts of PCR product were cloned using a TA-cloning strategy (3.2.5) and 
subsequently sequenced (3.2.6.1). 
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3.3.1.3 Splice site prediction analysis 
 
Wildtype and mutant sequences were submitted for splice site prediction to the 
Berkeley Drosophila Genome Project (BDGP) (http://fruitfly.org/seqtools/splice.html), 
to the NetGene2 server (http://www.dtu.dk/services/NetGene2/) and to the Human 
Splicing Finder (http://www.umd.be/ HSF/) servers.  
 
3.3.1.4 Quantitative analysis of mRNA expression via real time PCR 
(qRT-PCR) 
 
We performed a one-step qRT-PCR using probes to analyze F8 expression in blood. 
Total RNA was reverse transcribed using SuperScript® III Reverse Transcriptase 
and the cDNA was amplified with HotStarTaq DNA Polymerase using the 
manufacture’s protocol except that the SuperScript® III was diluted 1:10 in the buffer 
supplemented in the kit and mixed with the reaction mixture prepared as follows: 
 
Reaction mixture Amount (µl) 
10x Buffer RT 5 
MgCl (25nM) 5 
dNTP Mix (5mM each) 0.4 
Gene-specific forward primer (10µM) 1 
Gene-specific reverse primer (10µM) 1 
Gene-specific probe (5µM) 1 
Rox 0.03 
SuperScript® III 0.4 
HotStarTaq polymerase 0.25 
Template RNA (∼ 50ng) 2 
RNFW 33.92 
Total  50 
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The PCR conditions for the qRT-PCR were as follows: 
 
 Cycler protocol: 50°C  20 min cDNA synthesis  
   95°C  15 min RTase inactivation/  
       HotStarTaq Polymerase activation 
   94°C     30 s 
   60°C     60 s 
 
The experiment was done on a 7500 Real-Time PCR System. An internal control 
from the human porphobilinogen deaminase gene (PBGD; NM_000190) was 
included and the F8 mRNA levels were normalized to their respective PBGD mRNA 
expression. The sequences of qRT-PCR primers are listed in Table S16. 
 
3.3.2 DNA analysis: general methods 
 
3.3.2.1 DNA extraction from blood 
 
Ten ml of peripheral blood was collected from patients and control groups. 
Additionally, blood samples from extended family members (when available from 
both affected and not affected individuals) were collected. Genomic DNA was 
extracted using a standard salt out precipitation procedure [85].  
 
3.3.2.2 PCR amplification of exons for investigated genes 
 
PCR amplification from genomic DNA for investigated genes: F8 (NG_011403.1); 
vWF (NC_000012); LMAN1 (NG_012097) and MCFD2 (NG_016428.1). The reaction 
was performed using standard PCR conditions (3.2.1). All PCR products were 
resolved on a 1% agarose gel (3.2.3) and were sequenced on an ABI genomic 
analyzer (3.2.6.1). Sequences were analyzed using the Geneious software.  
40 cycles 
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3.3.3 DNA analysis: methods for gross rearrangement analysis 
 
3.3.3.1 Southern blot 
 
Restriction enzymes (100 U each) in combination with the appropriate enzyme 
buffers were used in separate reactions for cleavage of 10 µg genomic DNA. All 
reactions were incubated at 37°C for 2h and subsequently separated on a 0.7% (w/v) 
agarose gel in TAE buffer for 48 hours at low voltage (30 V). After depurination in 
0.25 M HCl solution for 10 minutes and denaturation in 1.5 M NaCl and 0.5 M NaOH 
for additional 10 minutes. DNA fragments were transferred from gel to a positively 
charged nylon membrane overnight by capillary blotting. Subsequently, the 
membrane was neutralized in 2x SSC solution and pre-hybridized in Church buffer at 
65°C while rotating. The probe was amplified by standard PCR conditions using 
healthy control DNA with primers described in Table 2. Later, the probe was labeled 
with α-32P-dCTP using RediprimeTM II (Random Prime Labeling System) according to 
the manufacturer’s recommendation. After incubation at 37°C for 20 minutes, the 
probe was purified by centrifugation through a Sephadex G50 spin-column. The 
probe was denatured at 95°C for 5 minutes and immediately added to the Church 
buffer in which the membrane was pre-incubating. Hybridization of the membrane 
was performed overnight at 65°C in a rotating incubator. The next day, the 
membrane was serially washed three times in washing solutions with different 
concentrations of SSC (2x, 0.5x and 0.1x) supplemented with 0.1% (w/v) SDS in 
order to prevent non-specific binding. Subsequently, the membrane was wrapped in 
plastic wrap and exposed to X-ray film. Band patterns were visualized by 
autoradiography. 
 
Table 2: Primers used for amplification of the southern blot probe. 
Name Sequence (5´-->3´) Tm 
Position on 
chrX: hg18 Length 
Probe-F AAG AAC AGT TCA TGT CAA GGA CAA 153891795 
Probe-R TGG AAG ATC AGA GGG AAC A 
64 
153891293 
502 
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3.3.3.2 Long range (LR)- PCR across the F8 genomic region 
 
LR-PCR was performed on genomic DNA to amplify the complete genomic region of 
F8 by amplification in 28 overlapping fragments using the Expand Long Template 
PCR System according to the manufacturer’s instructions. Briefly, 200 ng DNA was 
used for each reaction. Thermal cycling conditions were as follows: 2 min initial 
denaturation at 92°C, 10 cycles at 92°C for 10 s, 55-65°C (depending on the primers 
used) for 30 s and 68°C for 1 min/kb (depending on the size of the amplicons), 20 
cycles at 92°C for 10 s, 55-65°C for 30 s and 68°C for 1 min/kb + 20 s/cycle, followed 
by 7 min at 68°C. PCR products were analyzed by gel electrophoresis (Figure 16, 
3.2.3). All PCR fragments were purified by gel extraction (3.2.4) and were stored at -
20°C until use. For each patient, the purified LR-PCR fragments were equimolarly 
mixed and were applied to a NGS approach on an Illumina sequencer (3.2.6.2).  
 
3.3.3.3 Inverse PCR 
 
One µg of genomic DNA was digested with 10U of an appropriate restriction enzyme 
for 4 h at 37°C in a reaction volume of 50 µl. After a phenol:chloroform (1:1) 
extraction, DNA was precipitated with 2 volumes of ethanol, 0.1 volume of sodium 
acetate (pH) 4,6 for 30 minutes at -80°C. The precipitate was recovered by 
centrifugation at 14.000 x g for 15 minutes at 4°C, followed by a final wash with 70% 
ethanol (v/v) and a final centrifugation at 14.000 x g for 15 minutes at 4°C. The 
precipitate was resuspended in 50 µl of dH2O. Digested DNA was ligated using 15U 
of T4 DNA Ligase and 120 µl of 5x Ligase buffer and was incubated overnight at 
15°C. After extraction with phenol:chloroform (1:1), the ligated circular products were 
precipitated and resuspended in 30 µl of dH2O. The circular products were used as 
templates for a LR-PCR reaction using the Expand long template PCR System. The 
PCR conditions were as follows: 2 minutes at 92°C, 10 cycles of 92°C for 10 s, 58°C 
for 30 s and 68°C for 5 minutes, followed by 25 cycles of 92°C for 15 s, 58°C for 30 
s, 68°C for 5 minutes plus 20 s for each successive cycle and a final step for 7 
minutes at 68°C. 
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3.3.3.4 Multiple Ligation-Dependent Probe Amplification (MLPA)  
 
MLPA was carried out using F8-P178 kit according to the manufacturer’s instructions. 
The technique comprises 4 steps: denaturation, hybridization, ligation, and 
amplification (Figure 8). Briefly, 250 ng of genomic DNA was denaturized and 
hybridized to the probe mix for 16h at 60°C. The probes were then ligated by 
treatment with ligase65 at 54°C for 15 minutes. Subsequent PCR reactions are 
performed using a 6-carboxyfluorescein (FAM)-labeled primer for each exon. The 
amplification product of each probe has a unique length. PCR products were 
resolved according to the size on an ABI 3130xl capillary sequencer. Results were 
visualized using the GeneMapper® software and analyzed using the Coffalyser™ 
software (MRC-Holland). Samples were compared to a control sample. The 
differences in relative peak height indicate a copy number change of the target exon.  
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Figure 8: Principle and procedure of MLPA. A) Genomic DNA is denaturized and hybridized to 
the probe mix. B) After a ligation step, C) a PCR reaction is performed using universal primers D) and 
the products are resolved on a capillary sequencer. Fragments are visualized using the GeneMapper® 
software. The black arrows indicate the ligation site of the probes to each other 
(http://www.mlpa.com/WebForms/WebFormMain.aspx). 
 
3.3.3.5 Fluorescence in situ hybridization (FISH) analysis 
 
From each index patient, 10 ml blood was taken in heparin-blood collecting tubes. A 
bacterial artificial chromosome (BAC) clone containing genomic region of F8, clone 
number: IMGSB737D062145D (Imagenes GmbH, Berlin, Germany), was isolated as 
described in section 3.2.8 and used as a probe for the hybridization procedure. FISH 
analysis was performed in collaboration with Dr. Indrajit Nanda at the Institute of 
Human Genetics, University of Würzburg. DNA from BAC was directly labeled with 
either fluorescein-12-dUTP or tetramethyl-rhodamine-5-dUTP by standard nick 
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translation. For each FISH experiment approximately 200 ng of labeled DNA was 
hybridized to patient’s metaphase spreads. Hybridization of repetitive sequences 
within the labeled probe was suppressed by adding excess unlabelled human Cot-1 
DNA (10x probe concentration) in the hybridization mixture. Following hybridization, 
chromosomes were counterstained in 1.5 µg/ml DAPI (4',6-diamidino-2-phenylindole) 
in Vectashield anifade. Slides were examined under a Zeiss epifluorescence 
microscope (Imager, A.1) equipped with a CCD camera and appropriate filter sets. 
Selected metaphases displaying DAPI counterstaining and rhodamine fluorescence 
were photographed and images were merged using the software FISHView EXPO 
2.0 (Figure 9). 
 
 
Figure 9: FISH analysis of metaphase cells. A) Schematic representation of the X chromosome. 
The arrow indicates the position of F8 at Xq28 where the probe binds. B) Hybridization of the F8 
specific probe (red signal) and counterstained with DAPI (blue). C) Magnification of X Chromosome 
cut outs with and without hybridization. 
 
3.3.3.6 Comparative Genomic Hybridization (CGH) Array 
 
CGH-Arrays were done as a service at Source BioScience imaGenes GmbH in 
Berlin. Two µg of DNA from the index patient and standard control male DNA was 
labeled with dUTP-coupled cyanine Cy3 and Cy5, respectively. Both samples were 
co-hybridized on a NimbleGen Human CGH 385K chromosome X Tiling Array (Build: 
hg18, NCBI36). Data was analyzed and visualized using the SignalMap software. 
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3.3.3.7  Haplotype analysis  
 
For haplotype analysis, 15 extragenic and intragenic SNPs and Short Tandem 
Repeats (STRs) were analyzed using polymorphic markers selected from HapMap 
and HEMApSR [86] database. For each marker, the PCR reaction mixture consisted 
of 0.2 µM of each primer, 200 µM of each dNTPs, and 50 ng of genomic DNA in a 25 
µl total volume. The amplicons were sequenced as described above. Microsatellite 
repeat analyses were done using a fluorescent-labeled reverse primer in the PCR 
reaction. Subsequently, the amplicons were loaded on an ABI 3100xl capillary 
sequencer and distinguished by size using GeneMapper® software v4.1.  
 
3.3.3.8 Likelihood of carriership  
 
Likelihood of being carrier was determined using FVIII:C values after correction for 
the errors/deviations introduced by age and blood group. Transformed value (TFVIII:C) 
was calculated according to the formula TFVIII:C = ln(FVIII:C)-age2 x 0.00011-bg x 
0.18017-3.61700 as described by Oldenburg et al [87], where bg=0 if the subject has 
blood group 0 or A2 and bg=1 if the subject has blood group A1, B or AB. The T 
values are than used to extrapolate on the density curves of likelihood of being 
carrier or non-carrier. 
 
3.3.3.9 X-Chromosome inactivation 
 
X-chromosome inactivation test was performed using the human androgen receptor 
(HUMARA) assay as described by Allen et al [23]. Two µl of the PCR product was 
mixed with 12 µl of deionized formamide and 2 µl of GeneScan 500 ROX size 
standard. The mixture was denaturized and loaded on an ABI 3130xl capillary 
sequencer. GeneMapper® software v4.1 was used for quantification and 
interpretation of the data. Peak heights of the fluorescence intensity were used to 
calculate ratios. The percentage of inactivation of each X chromosome in the 
possible/obligate carriers was calculated according to the formula: A/(A+1)*100 
where A=((Peak 1 / Peak 2) after digestion) / ((Peak 1 / Peak 2) before digestion).  
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3.3.4 Coagulation assays and biochemical methods 
 
For coagulation factor assays, 5 ml blood was collected in 3.1% sodium citrate blood. 
The plasma was isolated by centrifugation at 2000x g, 4°C for 15 minutes. The 
plasma was used directly or was stored at -80°C until use. 
 
3.3.4.1  FVIII activity assays 
 
FVIII:C was measured using a two-stage chromogenic assay and a one stage 
clotting assay.  
 
3.3.4.1.1 Clotting assay  
 
The clotting assay is an aPTT-based assay [89] done on a Behring Coagulation 
System. The samples were diluted in FVIII deficient plasma. After incubation with 
aPTT reagent, CaCl2 was added to the mixture and the time of the clot formation is 
determined. The machine measures the change in light scattering. The time when 
the maximum scattering is reached reflects aPTT measurement. For each 
measurement, standard plasma and medium from untransfected cells (mock cells) 
were included as positive and negative controls, respectively.  
 
3.3.4.1.2 Chromogenic assay  
 
The chromogenic assay [90] was performed also on a Behring Coagulation System 
using reagents from Siemens Healthcare Diagnostics. It is a two-step test: in the first 
step, FVIII is activated in the plasma with thrombin, in the next step the activated 
FVIII, accelerates the conversion of FX to FXa in the presence of FIXa, 
phospholipids, and Ca2+ ions. The amount of activated FX is measured at 405 nm by 
hydrolysis of a p-nitroanalide substrate. The amount of p-nitroanalide is proportional 
to the generated FXa, which is dependent on the amount of FVIII in the sample. 
Samples are diluted in 0.9% sodium chloride. For each measurement, two control 
plasmas were included: Control N (normal range) and Control Plasma P (pathogenic 
range). 
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3.3.4.2 FVIII antigen assay 
 
FVIII antigen was measured using VisuLize FVIII antigen kit, a commercial 
enzyme-linked immunosorbent assay (ELISA) assay. The wells are pre-coated with 
an anti-human FVIII polyclonal antibody produced in sheep, which can bind to the 
FVIII antigen present in the sample. The samples were diluted 1:8 and 1:16 in 
sample dilution buffer supplied in the kit and the assay was performed according to 
manufacturers instructions. Briefly, the samples were pipetted to the pre-coated 
stripes and incubated for 1h at room temperature. The wells were washed with 
ELISA washing buffer to remove unbound material. The secondary antibody, an anti-
sheep peroxidase-labeled antibody, was applied to the wells and the reaction was 
incubated for 45 minutes at room temperature. The wells were again washed and a 
solution of the peroxidase substrate tetramethylbenzidine (TMB) was applied for 
exactly 10 minutes. During this reaction the wells will develop a blue color. Adding an 
acidic stop solution, which turns the blue color to yellow, stopped the assay. The 
intensity of the formed color, was measured spectrophotometrically in a microplate 
reader at 450 nm. The absorbance is directly proportional to the FVIII antigen amount 
captured in each well. The reference curve was a log-log plot of the mean 
absorbance values versus the FVIII antigen concentration. A dilution factor of 1, 2, or 
4 was calculated for the 1:4 and, 1:8, and 1:16, respectively. 
 
3.3.4.3 vWF activity measurement 
 
VWF activity was measured using an automated latex enhanced immunoassay 
(HemosIL™) on IL Coagulation System. The vWF activity kit is a latex particle 
enhanced immunoturbidimetric assay. The activity of vWF is determined by 
measuring the increase of the turbidity produced by the agglutination of the latex 
reagent. An anti-vWF monoclonal antibody, directed against the platelet-binding site 
of vWF, is adsorbed onto the latex reagent and will react with the vWF of the test 
plasma. The degree of agglutination is directly proportional to the vWF activity in the 
sample and is determined by measuring the decrease of transmitted light caused by 
the aggregates. 
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3.3.4.4 vWF antigen measurement  
 
VWF antigen was measured using an Enzyme-Linked Fluorescent Assay (ELFA). 
VIDAS vWF was applied to perform a quantitative measurement of vWF antigen in 
the plasma samples of patients. The test is a two-step enzyme immunoassay 
sandwich method combined with a fluorescent detection. The samples were diluted 
and cycled in and out of the solid phase receptacle (SPR) to enable the antigen to 
bind to the immunoglobulin adsorbed on the inner side or the SPR. A washing step 
was included to wash the unbound components. The conjugate is then cycled in and 
out of the SPR to bound to the antigen retained during the first step. A second 
washing step is applied to remove unbound material. The substrate, 4-methyl-
umbelliferyl phosphate, is then cycled in and out of the SPR and the conjugate 
enzyme catalyzes the hydrolysis of the substrate into a fluorescent product, which is 
measured at 450 nm. The fluorescence intensity is proportional to the concentration 
of the antigen present in the sample. 
 
3.3.4.5 vWF collagen- and FVIII binding-assay 
 
For both, vWF collagen- and FVIII-binding assays, frozen plasma from the patients 
was measured in collaboration with Prof. Budde at Medilys Laborgesellschaft GmbH 
in Hamburg. The collagen binding assay (vWF:CBA) was essentially done according 
to Thomas et al. [91], while the vWF:FVIII binding assay was done according to 
Schneppenheim et al. [47].  
 
3.3.4.6 vWF multimer analysis 
 
SDS-agarose discontinuous gel electrophoresis was carried out essentially as 
previously described [92, 93] in collaboration with Prof. Budde at Medilys 
Laborgesellschaft GmbH in Hamburg. In brief, low (1.2% w/v) and medium (1.6% 
w/v) resolution gels were prepared. Samples were diluted according to their vWF 
content to approximately 0.5 µg/ml. After electrophoresis, the multimers were 
transferred to a nitrocellulose membrane. The blots were incubated with mouse anti 
human vWF antibody as primary antibody. As secondary antibody, an anti-mouse 
3. Materials and Methods 
 
48 
 
IgG antibody was used. Detection was carried out by luminescence using the video 
detection system Fluorchem™. In addition to visual inspection of the gels, 
quantitative evaluation was performed to improve the reproducibility and 
comparability of multimer analysis. For densitometric evaluation, small, intermediate 
and large multimers were defined as oligomers 1-5, 6-10 and >10, respectively. 
 
3.3.5 AB0 blood group determination 
 
AB0 blood group was determined using the BAGene AB0-TYPE or routine methods 
from genomic DNA or EDTA anticoagulated blood samples, respectively.  
 
3.3.6 C-reactive protein determination  
 
C-reactive protein (CRP) was run on a clinical chemistry analyzer COBAS® 
INTEGRA using the Roche CRP Latex immunoassay.  
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4 Results 
 
All patients with a bleeding tendency were referred to the hemophilia center in Bonn 
and collaborating laboratories. Patients with FVIII:C levels lower than 35% were 
diagnosed as hemophiliacs. The molecular genetic analysis was done to detect the 
causal mutation in F8. Patients were analyzed using a routine diagnostic flowchart 
(Figure 4). Briefly, all severe patients were tested for intron 1 and intron 22 
inversions. All patients who were negative for inversion PCRs together with mild to 
moderate patients (FVIII:C levels between 1-35%) were screened for mutations in the 
complete F8 cDNA as well as the exon/intron boundaries and promoter region of F8. 
A total of 14 patients were included in this study. Among these patients 3 had severe, 
eight had mild and two had moderate phenotype (Table 3). The study was approved 
at the ethic committee of the university of Bonn (approval number 183/07). All 
participants received oral and written information concerning the study and signed 
the informed consent form. All patients were negative for mutations in F8 cDNA 
except patient HA#14, where the amplification of exon 18 failed. The investigation of 
the molecular mechanism behind the severe hemophilia A phenotype in this patient 
was performed as described in section 4.2.6.  
 
4.1 Biochemical and clinical reconfirmation of 
hemophilia A phenotype 
 
The first step was to reconfirm hemophilia A in these patients. This was done based 
on biochemical measurements of all factors in the coagulation cascade associated 
with a bleeding phenotype and later by comparing the clinical characteristics of the 
patients without detectable mutation in F8 to mutation positive hemophilia A patients. 
Table 3 shows the clinical characteristics of the patients included in this study.  
4. Results 
 
50 
 
 
Table 3: Characteristics of the patients included in this study.  
(nd= no data available, Neg.=negative) 
Patient number 
Normal range 
HA 
#1 
HA 
#2 
HA 
#3 
HA 
#4 
HA 
#5 
HA 
#6 
HA 
#7 
HA 
#8 
HA 
#9 
HA 
#10 
HA 
#11 
HA 
#12 
HA 
#13 
Activity 57-245% <1% 21 5.0 5.6 3.0 5.3 <1% 9.9 29 14 35.0 7.4 12.3 
Antigen  50-183% nd 34.0 7.4 7.6 4.0 7.3 nd 14.5 nd nd 9.9 22.1 18.8 
FVIII:C/FVIII:Ag 
activity 
0.67-2.05 nd 0.62 0.70 0.74 0.75 0.73 nd 0.68 nd nd 3.53 0.34 0.65 
FVIII 
mRNA expression 0.029-1.121 nd 0.263 0.067 0.098 0.066 0.063 nd  0.038 0.122 0.038 0.056 0.046 0.033 
Activity  44-276% 76 53 52 96 76 80 nd 168 86 110 60 132 80 
Antigen 40-250% 86 70 66 88 90 108 159 164 79 71 59 170 89 
vWF activity/vWF:Ag 0.406-1.844 0.88  0.76 0.79 1.09 0.84 0.74 nd  1.02 1.09 1.55 1.02 0.78 0.90 
Collagen binding 50-160% 77 63 79 56 61 87 129 97 nd nd 46 118 87 
vWF 
FVIII binding 60-170% 88 103 80 102 95 96 92 100 nd nd 98 126 106 
FII 87-127% 80 101 105 94 105 97 107 88 nd nd nd 95 103 
FV 67-145% 80  134 134 88 86 122 125 119 nd nd nd 111 123 
FVII 77-154% 74  119 134 63 110 115 128 137 nd nd nd 88 55 
FX 80-140% 79 108 99 95 133 125 133 157 nd nd nd 92 nd 
aPTT 25-36 sec.  60.5 34.3 33.7 46.1 46.6 43.6 48.5 42.9 nd nd nd 44.5 32.6 
Antithrombin activity 85-130%  92 99 87 100 98 96 96 92 nd nd nd 99 87 
FVIII-Inhibitor Negative Neg. Neg. Neg. Neg. Neg. Neg. Neg. Neg. Neg. Neg. Neg. Neg. Neg. 
Blood group AB0 A1 0 0 0 A B A B A2 0 0 A1 0 
Clinical severity severe mild moderate mild moderate mild severe mild mild mild mild mild mild 
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The activity levels of investigated factors (FII, FV, FVII, FX, and vWF) were in the 
normal range, thus excluding a quantitative deficiency of these factors. Moreover, the 
only reduced parameters among the patients were FVIII:C and FVIII:Ag levels. The 
clinical phenotype of patients without mutation do not differ from hemophilia A 
patients that harbor known mutations in the F8 cDNA. Both groups receive 
comparable amounts of administrated FVIII concentrate to abolish the bleeding 
symptoms. The residual FVIII:C measured 24h and 48h after infusion is also 
comparable in both groups as well . The bleeding tendency of all patients is efficiently 
corrected with substitution of FVIII concentrates indicating a normal clearance of 
FVIII molecule in these patients (Table 4).  
 
FVIII:Ag levels from 8 patients with mild to moderate hemophilia A phenotype that do 
not undergo a prophylaxis treatment show a very clear and strong linear correlation 
to FVIII:C and the severity of the disease. There is a significant reduction in both 
FVIII:C and FVIII:Ag levels when comparing the patients to a cohort of healthy 
individuals (Table S 9, Figure 10). The ratio of FVIII:C to FVIII:Ag in patients is within 
the normal range (0.74 - 1.55). This result clearly associates the deficiency of FVIII:C 
in these patients to a quantitative deficiency of FVIII protein in blood rather than its 
dysfunction or problems in its structure. 
 
Figure 10: Comparison of FVIII:C and FVIII:Ag levels in normal healthy male individuals and 
patients without mutation. Patients show a significant reduction of FVIII:C and FVIII:Ag levels 
compared to that of healthy controls. FVIII:C and FVIII:Ag levels are shown as % to the normal 
controls. FVIII:Ag levels were not measured for severe patients due to their prophylaxis treatment 
(Mann Whitney test **** = p<0.0001).   
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Table 4: Clinical characteristics of patients without mutation.  
Rec: Recombinant FVIII concentrate, Plasma: Plasma-derived FVIII concentrate, ave.: average, nd= no data available, * vWF containing concentrate, a 
compared to hemophilia A patients with a known mutation and same severity of disease. DDAVP= Desmopressin 
Patient number 
 
HA#1 
 
HA#2 
 
HA#3 
 
HA#4 
 
HA#5 
 
HA#6 
 
HA#7 
 
HA#8 
 
HA#12 
 
HA#13 
Current type of FVIII substitution 
medicament 
Rec. Rec. Rec. Rec. Rec. Rec. Rec. Rec. Plasma* Rec. 
Infusion units nd 3000 4000 nd 2000 3000 nd 3000 3000 3000 
24 h 
FVIII:C nd 24% 16% nd 29% 17% nd 21% 40% 26% 
Infusion units nd 2000 4000 2000 nd nd nd 2000 nd 3000 
FVIII:C after 
48 h 
FVIII:C nd 16.5% 3.0% 7.8% nd nd nd 13.5% nd 18.5% 
Bleeding tendency a nd normal normal normal normal normal nd normal normal normal 
Amount of factors used a 
nd below 
ave. 
above 
ave. 
below 
ave. 
below 
ave. 
below 
ave. 
nd below 
ave. 
above 
ave. 
below 
ave. 
Response to DDAVP: fold increase in 
FVIII:C  after 30 sec.                      
Mild:0.8-16    Mod.:0.8-156 
nd 4.17 10 2.10 nd 0.98 nd   nd nd 6.50 
Clinical severity severe mild moderate moderate moderate mild severe mild mild mild 
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4.1.1 Investigating known determinants of FVIII:C  
 
Once the link between the disease and FVIII was verified, all known defects in 
parameters that mimic a clinical hemophilia A phenotype were analyzed. This 
includes all FVIII interacting proteins, such as: LMAN1 and MCFD2, both affecting 
the intracellular transport of FVIII protein, and vWF causing VWD type 2N that affects 
the stability of FVIII protein. Furthermore the recently described SNPs associated 
with reduced FVIII:C levels were screened for patients without detectable mutation 
[94].  
 
4.1.1.1 Searching for mutations in LMAN1 and MCFD2 
 
Mutations in LMAN1 and MCFD2 cause a combined FV/FVIII deficiency through 
interfering with the intracellular transport of FVIII and FV protein [44, 45]. Although all 
patients have normal FV activity, the possibility of putative rare variations was 
investigated. The hypothesis was that these mutations could result in less optimal 
functionality of these cargo proteins by specifically affecting the trafficking of FVIII 
protein rather than FV. The complete coding regions of both genes were screened for 
mutations (exons 1-13 for LMAN1 and exons 2-4 for MCFD2). No DNA alterations 
were found. Therefore, a link between these proteins and reduced FVIII:C levels in 
patients was excluded.  
 
4.1.1.2 Searching for a qualitative defect in vWF  
 
After the release of FVIII protein in the circulation, vWF plays an important role as 
carrier and protector of FVIII protein [95-98]. For the patients, the FVIII:C/vWF:Ag 
ratio ranged from 0.03-0.58 (mean=0.14) comparing to 0.88-2.44 (mean=1.31) in the 
control group. Such a reduction is similar to what is observed in vWD-2N [99]. Even 
so, not only the FVIII binding domains of vWF protein (which are described to harbor 
mutations causing vWD-2N) but all 52 exons of vWF were analyzed for mutations 
and/or polymorphisms that might affect binding of vWF to FVIII protein. Several 
known SNPs were found but no causal mutations associated with VWD (Table S 1) 
Moreover, to exclude a functional defect in the vWF protein, collagen-binding activity, 
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FVIII binding assay, and multimer pattern of vWF protein were excessively analyzed 
(except for 2 patients -HA#9 and HA#10- where no plasma was available). Our 
vWF:FVIII and vWF:CBA analysis showed normal values in the range of 80-126% 
and 46-129%, respectively (Table 3). In all patients multimer analysis revealed a 
normal pattern of both, high- and low molecular weight multimers (Figure 11). As 
expected, vWF activity levels were largely attributable to vWF:Ag levels and a good 
correlation was observed between vWF activity and antigen levels (Table 3). Based 
on the above analysis, a defect in vWF protein was excluded (whether quantitative or 
qualitative) that could explain reduction of FVIII:C in these patients.  
 
 
Figure 11: Multimer analysis of hemophilia A patients without mutation. All analyzed patients 
show normal vWF multimer patterns (No plasma was available from HA#9 and HA#10 to perform this 
analysis). 
 
4.1.1.3 Searching for associations between FVIII:C and genetic 
polymorphisms  
 
Recently a genome wide association study (GWAS) screening reported five loci 
(STAB2, STXB5, SCARA5, vWF and AB0), to be associated with FVIII:C; these loci 
included one SNP in AB0 (rs687289) and one SNP in vWF (rs1063856). Therefore, 
the possibility was investigated whether these patients harbor several ‘un-favored’ 
polymorphisms that are associated with lower FVIII:C levels. All 5 polymorphisms 
were investigated in patients as well as in controls (Table S 3 and S 5).  
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In addition, three polymorphisms in F8 itself (rs7058826, rs1800291 and rs1800292), 
previously suggested to show association with FVIII activity were also studied [69, 
100]. In healthy controls a significant association was only found between FVIII:C 
levels and the intronic polymorphism in AB0 (Kruskal-Wallis ANOVA test, p=0.0004), 
and 4 out of 9 patients carry the GG genotype, while three are heterozygous. The G 
genotype is reported to be associated with lower FVIII:C levels as also confirmed in 
healthy cohort [100]. The occurrence of the G allele in some of the patients could 
contribute to further lowering the FVIII:C levels. A borderline significance was 
observed with the exonic S1269S (rs1800292) SNP in exon 14 of F8 (Mann Whitney 
test, p=0.0627); however, all the patients carry the AA genotype that is associated 
with higher FVIII:C levels (Figure 12, Table S 5). 
 
 
Figure 12: Association between SNPs and the FVIII:Ag and FVIII:C levels in healthy 
population. Only the data of the SNPs that show significant or borderline association with previously 
known associated SNPs is presented. Graphs that are boxed in green and red correspond to 
statistically borderline significant or significant associations, respectively. FVIII:C and FVIII:Ag levels 
are presented as % to the normal range (P values are calculated using the Krustal-Wallis test for the 
autosomal loci and Mann Whitney test for the X-lined loci, *=p<0.05, **= p<0.01, ***=p<0.001). 
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4.2 Mutation analysis on DNA and RNA level in 
hemophilia A patients 
 
4.2.1 Mutation analysis: DNA level 
 
4.2.1.1 Exclusion of gross chromosomal recombination via FISH 
analysis 
 
Up to this point, all results showed a link of the hemophilia A phenotype to F8 gene 
itself. Therefore cytogenetic analysis was performed to exclude chromosomal 
rearrangements in all patients using a probe for F8 gene. At least chromosomes of 
twenty metaphase nuclei were hybridized with a F8 gene specific probe synthesized 
from a BAC clone (3.3.3.5). The analysis was done for patients where we could 
provide fresh blood material. In 7 patients (for 6 of them the analysis was done in this 
study and for HA#1 it was previously reported) no gross chromosomal 
rearrangements could be found. The probe was hybridized to the tip of the long arm 
of the X chromosome (Xq28) and no translocation of F8 gene was identified (Figure 
13).  
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Figure 13: FISH analysis of metaphase cells for 6 patients. Hybridization of the F8 specific 
probe (red signal) and counterstained with DAPI (blue) is shown for each analyzed patient. The 
magnification of cut outs of X Chromosome with and without hybridization, is shown below. The white 
arrow indicates the site of hybridization. 
 
4.2.1.2 Exclusion of duplications via MLPA analysis 
 
After exclusion of gross chromosomal rearrangements, a copy number variation 
(CNV) in the body of F8 gene was investigated. Owing to limitations in resolution of 
FISH analysis failing to detect small microdeletions and microduplications, it is 
important to perform a complementary method. To detect such variations, MLPA was 
carried out for all patients. Except for patient HA#7 all patients showed normal MLPA 
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pattern (Figure 14). For patient HA#7, MLPA analysis revealed a novel large 
duplication of all exons of F8 except exon 26 and partial triplication of exons 5-22. 
The investigation of the molecular mechanism of the severe hemophilia A phenotype 
was then continued as described in section 4.2.5. 
 
 
Figure 14: Representive picture showing result of MLPA of F8 for the analyzed patients. All 
the patients showed no CNVs in F8 gene expect for patient HA#7. On the X-axis exons of F8 are 
shown. For some exons more than one probe is included. On the Y-axis the copy number of each 
exon is shown as a ratio.  
 
4.2.1.3 Investigation of integrity of F8 locus via LR-PCR 
 
The whole genomic region of F8 (∼190 kb) was analyzed using a LR-PCR approach. 
After excluding the small and large rearrangements at chromosomal and exonic 
level, the intronic regions of F8 were in focus of analysis. Therefore, the complete F8 
locus was analyzed using primers listed in Table S 10 by amplification of 28 
overlapping PCR fragments. In all the patients except for patient HA#1, the 
amplification of all LR-PCRs was successful (Figure 15).  
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Figure 15: Long Range PCRs covering the F8 locus. A schematic diagram of the genomic F8 
locus is shown together with the relative locations of individual LR-PCRs with the gel amplification 
picture and the expected product size. Amplification of all regions was successful for all patients 
except for HA#1 and HA#14. 
 
This data indicates that the F8 locus in all the other patients is intact. For patient 
HA#1 the amplification of region B1 (an amplicon of 5.25 kb region in intron 1 of F8, 
Figure 30 A) failed. The characterization of the molecular mechanism behind the 
hemophilia A phenotype in this patient is described in section 4.2.4. A size based 
analysis of the LR-PCR fragments failed to demonstrate any abnormalities in either 
of the other patients. Thereby, inversions and gross deletions and insertions were 
excluded.  
 
4.2.1.4 Identification of deep intronic mutations using a NGS sequencing 
 
In the next step, all 28 amplicons of each patient were sequenced using a NGS 
approach (3.2.6.2). The first step after the sequencing was to align the NGS reads, 
each with a length of 36 bp, to the reference genome sequence. After analysis of the 
differences between the patient's sequences and the reference sequence a list with 
variants was generated (Table S 2). The significance of these variants was 
determined by sorting out false positive calls. Validation of the variant calls was done 
by verification of each variant with frequency calls above 50%. Five SNPs 
corresponding to frequency of 50% calls and above were sequenced using ABI 
Sanger sequencing. A threshold of 90% call was found to be the false positive border 
and a minimum coverage of 3 reads as a cutoff corresponding to a real variation. 
Forty-four intronic variations were found to fulfill these detection threshold; 36 of them 
were reported in dbSNP database. Nine novel intronic variations were identified that 
are not reported in dbSNP (Table 5).  
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Table 5: List of unique intronic variations found in patients after NGS 
 (c.= coding sequence;*= stop codon; ins= insertion, a= patient HA#4 and HA#5 were not included in the NGS approach because another index patient from 
the same family was included). 
SNP Nr. 1 2 3 4 5 6 7 8 9 
NG_11403.1 g. 88055 94667 123107 124347 124759 130722 138108 160166 190183 
Location in 
 F8 gene Intron 13 Intron 13 Intron 16 Intron 18 Intron 18 Intron 21 Intron 22 Intron 22 UTR 
Nucleotide 
change C>G G_ins C>T C>T G>A A>C G>T A>G G>T 
 
GRCH37.p5 37.3 c.1903+8034 c.1903+11641 c.5586+194 c.5998+530 c.5998+941 c.6273+2864 c.6429+6461 c.6429+28519 c.7055*+56 
HA#1 This patient was not included in the NGS approach (for more details see section 4.2.4). 
HA#2 C G_ins C C G A T A G 
HA#3 C - C C G A T A T 
HA#4a C - C C G A T A T 
HA#5a C - C C G A T A G 
HA#6 C - C C G A T A G 
HA#7 This patient was not included in the NGS approach (for more details see section 4.2.5). 
HA#8 G - C C A A T A G 
HA#9 C G_ins C C G A T G G 
HA#10 C - T C G A T A G 
HA#11 C - T C G A T A G 
HA#12 C - C T G C G A G 
HA#13 C - T C G A T A G 
P
a
t
i
e
n
t
s
 
HA#14 This patient was not included in the NGS approach (for more details see section 4.2.6). 
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4.2.1.5 Association of SNPs found after NGS with F8 mRNA expression, 
FVIII:Ag and FVIII:C levels in patients without mutation and healthy 
controls 
 
In order to investigate, if the detected polymorphisms after NGS in F8 could have an 
effect on the F8 mRNA expression, FVIII:Ag or FVIII:C levels, an association study 
for all 36 detected SNPs was performed (Table S 6). A significant association 
between F8 mRNA expression was found with rs28857481 (Mann Whitney test, 
p=0.0326) and rs6643622 (Mann Whitney test, p=0.0071); however no significant 
association was found between the later two SNPs and FVIII:Ag or FVIII:C levels. 
Among all the 36 SNPs, only rs34552198 was significantly associated with FVIII:C 
(Mann Whitney test, p=0.0490). Two SNPs showed border significance (rs78327897 
(p=0.0611) and rs1050705 (p=0.0535)). From this data, one can conclude that none 
of the SNPs, which are present in healthy individuals alone have an effect on 
reduced FVIII:C levels in these patients (Figure 16 and Table S 7).  
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Figure 16: Association between SNPs and the F8 mRNA expression, FVIII antigen and 
activity levels in healthy population. Only the data of the SNPs that show a significant or borderline 
association is shown. Graphs that are highlighted with red and green transparent boxes correspond to 
statistically significant or borderline significant association, respectively. P values are calculated using 
Mann Whitney test for the X-lined loci. 
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Therefore, all four significant (rs34552198) or border significant SNPs (rs1800292; 
rs78327897; rs1050705), found to be associated with FVIII:C levels, where used to 
construct haplotypes in both healthy controls and patients without mutations. In the 
control group, we could detect 6 haplotypes (Figure 17). When stratified for the AB0 
polymorphisms the group of individuals with AA and AG genotypes at the rs687289 
shows significant differences for the FVIII:C levels among different haplotypes 
(ANOVA Krustal-Wallis test p=0.0048). Two haplotypes, H4 and H5, were associated 
with significantly lower FVIII:C levels in comparison to H1, H2 and H3 haplotypes. 
Interestingly, all patients have haplotypes associated with higher FVIII:C levels 
(HA#2 and HA#3 have H3 haplotype while the rest of the patients have H1 
haplotype). This analysis clearly excludes the effect of common polymorphisms in F8 
on lowering the FVIII:C in the studied patients (Table S 8).  
 
 
Figure 17: Haplotypes analysis based on four SNPs showing the highest significance with 
FVIII:C. FVIII:C is plotted for 6 constructed haplotypes when the haplotypes where A) not stratified 
and B) stratified for the AB0 SNP (rs687289). Significant differences between haplotypes are shown 
with their p-values. P values are calculated using the Krustal-Wallis test for the autosomal loci. 
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4.2.2 Mutation analysis: RNA level 
 
4.2.2.1 In silico analysis predicts new donor and acceptor sites for the 
majority of the unique NGS variants  
 
The next step was to perform in silico analysis for all nine unique variants to study 
the possible effect of these transitions in generation of new donor splice site (dss) 
and acceptor splice site (ass) at mRNA level. Three different algorithms were used 
for this analysis. All SNPs were predicted to create new dss and/or ass sites at least 
by one of the prediction softwares, except SNP1 (c.1903+8034 C>G) and SNP8 
(c.6429+28519 A>G). For two SNPs (SNP5 (c.5998+941 C>T) and SNP6 
(c.6273+2864 A>C)), the softwares predict generation of new ass and dss in intron 
18 and intron 21, respectively. However the predicted strength of the new splice site, 
according to Human Splicing Finder (HSF), were lower than that for the wild type 
sequence (Table 6). 
 
For all the other SNPs, the splice site prediction servers predicted new ass and dss 
sites higher than the wild type sequence. The inconsistencies between different 
algorithms to predict the effect of specific variation on splicing necessitate the 
verification by experimental approaches. Therefore, two independent approaches 
were used to further investigate the effect of these variations on mRNA splicing 
pattern. 
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 Table 6: In silico analysis of novel deep intronic SNPs found in patients after NGS.  
(c.= coding sequence;*= stop codon; ins= insertion; dss= donor splice site; ass= acceptor splice site; mut= mutation; wt= wild type). 
 
 
SNP Patient Position Intron Nucleotide change 
FRUITFLY 
(score 0-1) 
Netgene2 
(score 0-1) 
HSF 
(score 0-100) 
1 HA#8 c.1903+8034 13 C >G not predicted new ass: mut= 0.15 not predicted 
dss: wt= 44.80,   mut= 72.71 2 HA#2 HA#9 c.1903+11641 13 G_ins not predicted not predicted ass: wt= 19.10,   mut= 72.76 
dss: wt= 63.06,   mut= 89.90 3 
HA#10 
HA#11 
HA#13 
c.5586+194 16 C>T new dss: mut= 0.88 new dss: mut= 0.56 
ass: wt= 65.56,   mut= 66.41 
4 HA#12 c.5998+530 18 C>T new dss: mut= 0.99 new dss: mut= 0.35 dss: wt= 59.30,   mut= 86.13 
5 HA#8 c.5998+941 18 G>A not predicted not predicted ass: wt= 75.72,   mut= 46.77 
6 HA#12 c.6273+2864 21 A>C not predicted new dss: mut= 0.45 dss: wt= 65.68,   mut= 60.93 
7 HA#12 c.6429+6461 22 G>T not predicted not predicted ass: wt= 51.30,   mut= 80.25 
8 HA#9 c.6429+28519 22 A>G not predicted not predicted not predicted 
new dss: mut= 0.41 dss: wt= 68.14,   mut= 94.98 9 HA#3 HA#4 c.7055*+56 UTR G>T new ass: mut= 0.14 new dss: mut= 0.96 ass: wt= 89.89,   mut= 90.49 
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4.2.2.2 RT-PCR analysis reveals aberrant splicing associated with two 
deep intronic variations found in two patients 
 
To investigate the association of the identified variations with the hemophilia A 
phenotype, the corresponding molecular alterations were analyzed. To this end, F8 
mRNA was amplified for the patients harboring an intronic variation as previously 
described by El-Maarri et al. [42]. This approach would show the effect of the 
predicted new dss and ass of the variants on mRNA splicing. Indeed, in two of the 
patients with unique variants (SNP4; c.5998+530 in patient HA#12 and SNP5; 
c.5998+941 in patient HA#8; table 4 and 5), in region C2, an aberrant mRNA 
transcript was detected (exons 17-21). Both aberrant mRNA transcripts were bigger 
than normal expected mRNA transcript (Figure 18 C and Figure 19 C). 
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Figure 18: : Identification of a novel intronic mutation in intron 18 in patient HA#12. A) The 
intronic variations was identified in intron 18 using a NGS approach B) and verified using an ABI 
sequencing method. C) An aberrant mRNA band was observed when amplifying fragments spanning 
exons 17-21 (normal mRNA 583 bp; aberrant mRNA 688 bp in patient HA#12). Sequencing of the 
aberrant mRNA transcript revealed the introduction of a 105 of intron 18 into the mRNA sequence. 
The 100 bp ladder is used (C=control, P=patient).  
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Figure 19: : Identification of a novel intronic mutation in intron 18 in patient HA#8. A) The 
intronic variations were identified in intron 18 using a NGS approach B) and verified using an ABI 
sequencing method. C) An aberrant mRNA band was observed when amplifying fragments spanning 
exons 17-21 (normal mRNA 583 bp; aberrant mRNA 709 bp in patient HA#8). Sequencing revealed 
the introduction of a 126 bp of intron 18 into the mRNA sequence. The 100bp ladder is used. 
(C=control, P=patient). 
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The PCR products of aberrant mRNAs were sequenced and the origin of the inserted 
sequences were determined using a Blast analysis (Figure 18 B and Figure 19 B). 
The analysis revealed an alignment with sequences of intron 18 (105 and 126 bp 
sequence insertion for patient HA#12 and HA#8, respectively). Analysis of the 
flanking sequence of these insertions at genomic DNA level revealed and confirmed 
the presence of the previously detected two intronic variations by the NGS analysis, 
the C>T transition at position c.5998 +530 in patient HA#12 and the G>A transition at 
position c.5998 +941 in patient HA#12. The new dss for the intronic mutation for 
patient HA#12 was highly predicted by two of the predictions algorithms.  
 
Interestingly, for patient HA#8, the intronic variant appears to create a false donor 
splice site in intron 18 of F8; AG→AA at –950 bases downstream exon 18, which 
was not predicted using the splice site prediction programs. Sequencing results show 
that this transition activates another splice site in the reference sequence +10 bp 
downstream of the mutation. In accordance with the RT-PCR result and the fact that 
the inserted sequence was absent in controls and other patients, one can consider 
these variations as causal mutation. Both intronic mutations introduce stop codons 
that lead to truncated protein. Therefore, it is expected that the normally spliced 
product of F8 should also be present in order to be compatible with a mild phenotype 
as observed in the patients.  
 
Moreover, an unsteady result in region A2 (exons 4-8) was observed for patients 
HA#5 and HA#6 that belong to the same family. Additional products, smaller and 
larger in size, were amplified along with the normal band in HA#5 and HA#6, 
respectively. However, no intronic variations were found close to the insertion and 
deletion sites. This could result from activation of a pseudo-exon due to a mutational 
event reinforcing the insertion. 
 
In general, the success rate of the RT-PCR was lower for patients than for healthy 
controls. All the other patients showed normal splicing patterns (Figure 20). The PCR 
products of all regions for each patient were sequenced. No alterations were found in 
the sequence of F8 mRNA in the remaining patients.  
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Figure 20: RT-PCR approach of F8 mRNA. A) Schematic diagrams representing different RT-PCR 
fragments (according to [42]) with the B) corresponding experimental gel pictures of analyzed patients. 
The 100bp ladder wasa used. 
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4.2.2.3 Quantitative mRNA analysis reveals reduction of mRNA level in 
exons flanking the intronic mutations 
 
Since the RT-PCR analysis did not reveal aberrant mRNA splicing in all patients with 
unique intronic variations, a Taqman-based real-time PCR assay was designed. 
Using this assay, the amount of F8 mRNA was measured at exon boundaries, where 
an alternative splicing was expected. The amount of F8 mRNA was also measured at 
a region of F8 that is not subject to alternative splicing. As an internal reference 
control, a probe was used, which was designed for exon 1-2 (Hs00240767_m1, 
Applied Biosystems). This probe was upstream to all the variations found after NGS 
approach. The second probe spans the two exons flanking the intronic variations. 
The ratio of the amount of F8 mRNA at internal control was calculated to the second 
probe and compared between a given patient and healthy controls. A reduced ratio in 
comparison to the controls indicates the presence of alternative splicing at the 
investigated region. Primers are listed in Table S 17. 
 
For patients HA#12 and HA#13 with aberrant mRNA splicing in intron 18 (after RT-
PCRs), the amount of normal F8 mRNA was significantly reduced compared to the 
controls (Figure 21). The inserted sequences in both patients led to a frameshift 
generating a premature termination codon. This reduction can explain the mild 
hemophilia A phenotype by decreasing the amount of normal F8 mRNA transcript in 
both patients (Mann Whitney test, p= 0.0005 for c.5998+530 C>T and p=0.0004 for 
c.5998+941 G>A). 
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Figure 21: Quantitative mRNA analysis for two intronic variants in intron 18. The positions of 
the Taq-Man probes are shown on the upper panel. The ratio of control probe to the tested probe is 
shown at the lower panel. A significant reduction of wild type F8 mRNA was observed for both patients 
(p=0.0005 for patient HA#12 and p=0.0004 for patient HA#8). 
 
For patient HA#11 with a unique intronic variation in intron 16 (SNP3 c.5586+194 
C>T), a reduction of F8 mRNA expression was detected in the exons flanking the 
intron 16 (Mann Whitney test p= 0.019). The same SNP was also detected in two 
other patients (HA#10 and HA#13). However, no mRNA was available from these 
patients to perform the qRT-PCR assay. This data suggestive for the presence of an 
aberrant mRNA for patient HA#11. This aberrant transcript is most probably caused 
by the intronic variation. However, this is missed using the nested RT-PCR approach 
applied in this study (Figure 22 A).  
 
On the other hand, for SNP2 (c.1903+11641 (-) > G in intron 13), which is present in 
patients HA#2 and HA#9, quantitative RT-PCR approach did not show a significant 
difference in amount of wild type F8 mRNA level for the patient HA#2 when 
compared to healthy controls (Figure 22 B). No RNA was available from patient 
HA#9 to perform the qRT-PCRs. The later result suggests that even if this variation is 
causative for the disease, it is not through inducing abnormal splicing. But rather 
through another still unexplained mechanism. Interestingly, SNP2 was present in all 
affected members of the index patient and was absent in all healthy individuals 
(Figure 27).  
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Figure 22: Quantitative RNA analysis for two intronic variants. A) The c.5586+194 C>T in 
intron 16 and B) the c.1903+11641 (-)>G in intron 13 were analyzed using a qRT-PCR approach. In 
each case, the tested region is shown for the patient (black) and healthy controls (green). In addition, 
a control region is shown at the right side of each graph. In this region no differences between the 
patient and healthy controls was expected. The upper and lower normal ranges are represented by 
horizontal dashed green lines. Different data points represent independent repetitive measurement for 
the patients, while different data pints of the healthy controls, represent independent measurements of 
different individuals. P-values are based on a non-parametric Mann Whitney t-test. 
 
4.2.2.4  Investigating the effect of SNP9 on F8 mRNA  
 
To evaluate, if SNP9 could have an effect on F8 mRNA, a nested RT-PCR approach 
was designed to amplify the UTR of F8 using the patients mRNA. The cDNA 
synthesis was done using a primer in 3´ UTR (chrX: 154,064,856- 154,064, 877;hg 
19). The nested PCR approach revealed two bands, one having the expected size 
(740 bp) and one smaller in size (581 bp, Figure 23 A). Sequencing of the aberrant 
band revealed a deletion of 159 bp in UTR located 2 bp downstream of SNP9. The 
variation results in alternative splicing that results in an aberrant mRNA with a shorter 
3´ UTR, which could influence the stability of F8 mRNA (Figure 23 B).  
 
 
Figure 23: Nested RT-PCR approach of SNP9 for patient HA#3. A) RT-PCR using a gene 
specific primer in UTR. An aberrant mRNA transcript was detected in patient HA#3. B) Sequencing of 
the aberrant mRNA revealed deletion of 159 bp (boxed) within the UTR of F8 mRNA. The arrow 
indicates the position of the primer used for the reverse transcription. 
4. Results 
 
74 
 
 
Notably, the same variation was found in the obligate carrier, which shows a 
significant reduction of FVIII:C levels (Figure 24).  
 
Figure 24: Haplotype segregation analysis. Both affected family members (HA#3 and HA#4) and 
the obligate carrier with significant reduced FVIII:C levels have SNP9. 
 
This mutation results in changes in alternative splicing of F8 mRNA. The deletion in 
UTR in the aberrant band might affect the structure and accessibility of F8 mRNA to 
its interacting partners. To explore this possibility, the wild type and mutant sequence 
were screened for their microRNA-binding pattern, using the miRBase microRNA 
prediction server. No difference was observed in binding of mature microRNAs. 
However, miRBase results showed differences in 4 stem-loop microRNAs. The 
mutant has lost it ability to bind to three microRNAs (hsa-mir-1470, hsa-mir-493 and 
hsa-mir-607). On the other hand because of the variation a new microRNA can bind 
to UTR (hsa-mir-4754) (Figure 25).  
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Figure 25: Results of microRNA binding prediction using miRBase server. The analysis 
revealed differences between the stem-loop microRNAs binding to the 3´ UTR of F8 mRNA in 
presence and absence of the mutation. The base change is shown in red box. The wild type and 
mutant sequences are shown in positive and negative strands, respectively.  
 
The secondary structure of the RNA was analyzed using the RNAFold program. The 
G>T transition shifts the base pairing in the stem loop. The free energy of the 
thermodynamic ensemble is -4.44 and -1.53 kcal/mol for wild type and mutant 
sequence, respectively. This could be a hint that through the structural change in the 
mRNA the accessibility of mRNA for its interacting protein, which is essential for the 
translation, is disrupted (Figure 27). One guanine–cytosine pair is not present in the 
mutant RNA structure, when compared to the wild type. Longer and stronger paired 
zones are more stable (guanine-cytosine have three hydrogen bonds and adenine-
uracil only two). This could prevent the ribosome from breaking the pairing and 
proceeding translation. The G>T transition is not in disfavor of RNA in regard to 
translation processing.  
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Figure 26: Minimal free energy RNA structure of wild type and mutant RNA predicted with 
the RNAfold program. The structures are colored by base-pairing probabilities. The arrow indicates 
the location of the base change in wild type and mutant sequence. The color indicates the probability 
of being unpaired from 0 to 1. 
 
4.2.3 Within one family the same F8 allele is segregating with all affected 
members  
 
In the remaining patients where the causal mutation was not found, a haplotype 
analysis was done to elucidate if the same allele is shared between the index 
patients and the affected family members in a given family. To address this, 
pedigrees of 2 families were constructed. Fifteen intragenic and extragenic 
polymorphic markers on X chromosome in the F8 locus and its vicinity were selected 
and analyzed using two SNP databases (dbSNP and HapMap) for the most 
informative polymorphic markers. Using these markers it was possible to follow the 
segregation of the F8 allele in the index patient and the family members. Thus, it was 
possible to identify whether all individuals with reduced FVIII:C levels in a family 
share the F8 allele genotype with the index patient.  
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Family 1 (HA#2): This family includes only one patient with mild hemophilia A 
phenotype of about 21% FVIII:C and 34% FVIII:Ag levels (Figure 27). In this pedigree 
the F8 allele of the index patient was also present in 5 potential carriers (I-2, II-4, II-5, 
III-1, III-6) of which only one show significant reduction of FVIII:C (III-6: 35%). In all 
cases the XIR pattern was analyzed to explain the reason for different FVIII:C levels 
despite the presence of the index patient allele. The HUMARA assay in cases with 
normal FVIII:C levels (I-2, II-4, II-5 and III-1) showed inactivation of index patient's 
allele in 82%, 100%, 95% and 69% of the cells, respectively. This could explain their 
relative normal FVIII:C levels.  
 
 
Figure 27: Haplotype segregation analysis in family 1. The X-chromosome inactivation (XIR) 
ratio is shown for the potential carrier females as well as the likelihood of being carrier and non-carrier. 
A horizontal transparent pink box highlights the unique variation of G insertion (SNP2). 
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Moreover, for III-6 about 50% of cells were expressing the patient's allele, explaining 
the reduction of FVIIII:C levels. Based on an informative marker in exon 14 of F8, 
RNA analysis was performed for member III-1 (daughter of the index patient). Using 
this assay we could determine that only the non index-patient allele at RNA level was 
detectable. This result supports the normal FVIII:C levels expected based on the XIR 
pattern (Figure 28). 
 
Figure 28: Allelic analysis of the DNA and RNA of C to A SNP at codon 1269 of F8 in patient 
HA#2 and his daughter. Two alleles are present in the DNA of the daughter, while only the 
maternally inherited allele is present in the RNA, which indicates the skewed inactivation of the 
paternal allele. 
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Family 2 (HA#5 and HA#6): This family includes two patients and three obligate 
carriers. Patient HA#6 has a moderate to mild phenotype with FVIII:C of 5.3% and 
FVIII:Ag level of 7.3%. The second patient (HA#5), appears to be more affected and 
shows a moderate phenotype with FVIII:C of 3%. FVIII:Ag level was also reduced to 
4%. The slight difference in severity of phenotype as well as activity and antigen level 
could be attributed to modifying environmental, genetic or epigenetic factors. Based 
on the haplotype analysis, both patients share the same F8 haplotype. Moreover, all 
three obligate carriers share the same haplotype with the index patients (Figure 29). 
Three of them showed also a decrease in FVIII:C that corresponds quite well to the 
XIR pattern. Markers in exon 14 of F8 were not informative in this family thus it was 
not possible to follow the allelic presence on the mRNA levels. 
 
Figure 29: Haplotype segregation analysis in family 2. The X-chromosome inactivation (XIR) 
ratio is shown for the potential carrier females as well as the likelihood of being carrier and non-carrier.  
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4.2.4 Identification of a rearrangement within the intron 1 of F8 in patient 
HA#1 
 
The index patient (HA#1) is a male hemophilia A patient with severe phenotype 
(FVIII:C<1%) who suffers from no other known health problems. No inhibitors have 
been detected. MLPA analysis showed normal allele copy number for F8. No F8 
mRNA transcript was detectable in his total peripheral blood mononuclear cells [75]. 
Both, intron 1 and 22 inversions, were excluded. Both suggestive carriers of the 
family show reduced levels of FVIII:C (33% and 42% for his mother and sister, 
respectively). Skewed X-chromosome inactivation was excluded in both carriers 
using HUMARA assay. 
 
4.2.4.1 LR-PCRs reveals a breakpoint in F8 gene  
 
To elucidate the molecular mechanism behind the lack of mRNA synthesis for patient 
HA#1, LR-PCRs were performed. This approach was designed to analyze the 
integrity of F8 locus by amplifying 28 overlapping fragments (3.3.3.2). Inability to 
amplify region B1, a 5.25 kb fragment located in intron 1 of F8 from the genomic DNA 
of the index patient indicated the presence of a genomic breakpoint in this region 
(Figure 30 A). Mapping PCRs using 5 different primer pairs were accordingly 
designed to further narrow the borders of the non-amplifiable region (Table S 11). 
Using this approach, the extent of the non-amplifiable region was further localized to 
a 942 bp region (Figure 30 B). The putative break was localized in intron 1 about 1 kb 
upstream of Int1h-1 repeat (Int1h-1 on chrX: 153,887,576- 153,888,616; hg18), which 
is involved in the recurrent intron 1 inversion. 
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Figure 30: Location of the breakpoint in F8 intron 1. A) The relative location of Int1h-1 and the 
Int1R-1 repeat in the non-amplifiable long-range PCR are shown; a schematic presentation of F8 
locus from exon 1 to exon 6 is shown at the upper part and the PCR amplification of the region B1 is 
shown in the box at the upper right. The 1kb ladder was used. B) Detailed localization of the 
breakpoint using overlapping short-range PCRs (C: control non-hemophilic DNA, P: Patient). 
 
4.2.4.2 Sequence analysis near the breakpoint identified the presence of 
inverted repeats  
 
Afterwards, a sequence homology search was performed on the sequence of the 
non-amplifiable region. Since both previously reported inversions in F8 are caused by 
intrachromosomal recombination between highly homologous inverted repeats [23, 
24], the hypothesis was investigated whether a recombination between homologous 
inverted sequences might also be involved in the cause of this breakpoint. A dot plot 
matrix analysis on the sequence of the breakpoint was performed (Figure 31 A). 
Analysis of the entire 5.25 kb intronic sequences flanking the breakpoint (Figure 31 
B) revealed the presence of a 687 bp sequence which is highly homolog to a 
sequence at Xq28 in an inverted orientation, designated as Int1R-1 (chrX: 
153,889,754 -153,890,442; hg18) and Int1R-2 (chrX: 153,433,817 -153,434,506; 
hg18), respectively (Figure 31 B). This result indicated a possible homologous 
recombination between the identified repeat in F8 intron 1 and its highly homologous 
inverted repeat in intron 2 of inhibitor of kappa light polypeptide gene enhancer in B-
cells, kinase gamma (IKBKG).  
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Figure 31: Homology analysis to identify identical repeats within 1Mb (500 kb upstream and 
500 kb downstream of the breakpoint). A) Dot plot of 1 Mb region containing the B1 region at the 
center vs. F8 locus. The identical repeats, Int22h and Int1h, known to be involved in inversions in F8 
and the newly identified Int1R, are labeled. The horizontal red bar at the top left of the figure 
represents the duplicated 94 kb region in the index patient. B) Dot plot of IKBKG vs. the F8 B1 region; 
The Int1h-1 and Int1R repeats are labeled in red and green, respectively. Inverted repeats in dot plot 
are colored purple and direct repeats are blue. The word size and the tile size used for the dot plot are 
50 and 2000, respectively. Geneious software was used for the analysis. 
 
Subsequently, BLAT analysis was done on the sequence of the two repeats. Analysis 
revealed a 98.9% homology between the two repeats (Figure 32). This data 
strengths the possibility of an inversion resulted from a rearrangement between the 
two repeats that are localized on the Xq28 in an inverted manner. 
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Figure 32: Alignment of the two repeats (Int1R-1 in F8 to the Int1R-2 in IKBKG). The sequence 
highlighted in pink represents the consensus sequence. The aligned sequences correspond to F8: 
chrX: 153,889,755- 153,890,460 and IKBKG: chrX: 153,433,810- 153,434,496; hg18. 
 
4.2.4.3 Southern blotting verified the presence of a rearrangement  
 
Southern blot analysis was performed to verify the presence of the rearrangement 
within the intron 1 of F8. The proposed novel DNA rearrangement would result in a 
change in length of restriction fragments surrounding the breakpoint. To detect such 
changes, several restriction enzymes were used whose cleavage sites lie outside or 
within the region of homology. The probe was designed and amplified (Table 2) to 
bind to a sequence upstream of the non-amplifiable region, in a non-repetitive unique 
sequence upstream the Int1R-1 homologous region (Figure 33 B, C). Southern 
blotting verified the presence of a rearrangement in the patient and his mother after 
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digesting with different enzymes (BamHI, EcoRI, HincII or NdeI), whose cutting sites 
lie outside the inverted repeat regions (Int1R-1). Altered band patterns were detected 
in the patient and his mother compared to the wild-type healthy male and female 
controls. The aberrant band sizes from the patient's samples were consistent with a 
rearrangement by which F8 sequence is fused to a sequence in IKBKG with the 
breakpoints in the Int1R-1 repeat (Figure 34 A). 
 
 
Figure 33: Southern blot analysis. A) Radiograms of 4 restriction enzymes used for the patient 
(P), mother (M) and two control (C) samples. The band in the M lane for HincII was weak due to the 
fact that this is a methylation sensitive enzyme and will give several bands when the cutting sites have 
a mosaic methylation pattern on a given allele; thus on the original radiogram several weak bands 
were seen with different sizes ranging from 7.6 up to 20,7 Kb. B) and C) Details of the restriction map 
around the Int1R repeat of the normal and mutant alleles respectively; orange horizontal bar indicates 
the location of the southern blot probe; Int1h-1 and Int1R-1 repeats are represented by red and green 
bars, respectively. Bold horizontal lines indicate the normal wild type (in B) and the mutant (in C) sizes 
of the restriction bands for each restriction enzyme. The horizontal scale at the top of panels B and C 
is in bp. 
 
4.2.4.4 Inverse PCR identified the breakpoint junction F8-IKBKG 
 
An inverse PCR approach was designed and applied in order to amplify the DNA 
fragment containing both breakpoint junctions associated with the rearrangement. 
Primers were designed to allow inverse PCR amplification of regions upstream and 
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downstream of the F8:Int1R-1 repeat (Figure 34). The inverse PCR amplification 
revealed aberrant upstream and downstream PCR products that were generated 
from the patient's DNA and were absent in healthy individuals. The DNA from his 
mother and sister were heterozygous for both PCR amplifications (Figure 34 B, C). 
Subsequently, the inserts were sequenced using a DNA walking strategy after being 
cloned into the pCR-XL-TOPO vector. Sequencing revealed that the sequence 
upstream from F8 intron 1 was joined to intron 2 of IKBKG (Figure 34 B). The 
sequence downstream of F8 intron 1 was joined to a sequence close to IKBKG 
(Figure 34 C) about 65 kb away from the region joined to the upstream breakpoint. 
However a sequence comprising several repetitive elements, with a high homology to 
a region in intron 2 of FUNDC2 (chrX: 153,919,264-153,918,534; hg18), was inserted 
between the sequence downstream of F8 intron 1 repeat (Int1R-1) and the duplicated 
sequences in IKBKG region (Figure 34 C).  
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Figure 34: Inverse PCR analysis. A) Relative positions of the primers in the upstream and 
downstream inverse PCRs together with the surrounding BamHI sites. Pictures of the upstream and 
downstream inverse PCRs are shown in B) and C), respectively; additionally, the map of both the wild-
type and mutant sequenced inverse PCR products is shown; the maps of breakpoints are shown in 
the lower panels. All genomic positions are according to hg18 and based on the coordinates of the 
non-duplicated original sequences on X chromosome. The 1kb ladder is used (P: patient, M: mother, 
S: sister, C: control). 
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4.2.4.5 Multiplex PCR detects the rearrangement  
 
A simple multiplex short PCR was established to provide a straightforward diagnostic 
test for this novel F8-IKBKG inversion in severe hemophilia A cases and/or carrier 
females (Figure 35 A). Primers that bind to the flanking regions of the rearrangement 
junctions would not be expected to amplify products from the wild-type allele. Also, 
primers flanking the Int1R-1 repeat in wild-type F8 intron 1 will yield an amplified 
product for both, a homozygous wild type individual as well as for the patient’s 
heterozygous mother and sister. For these primers, no amplification should take 
place in the patient. Based on this strategy, a multiplex PCR with three primers was 
established: two of them, 3F and 4R, amplify the wild-type F8:Int1R-1 fragment, while 
2R and 4R together are required for amplifying the junction corresponding to the 
region on the recombined mutant allele (Figure 35 B).  
 
Figure 35: Multiplex PCR results identifying the rearrangement. A) PCR picture: the upper and 
lower bands correspond to the mutant and normal products, respectively (P: Patient, M: Mother, S: 
Sister, C: Normal control). B) Schematic diagram showing the relative positions of the primers 4R-3F 
and 4R-2R on both the wild type and mutant chromosomes, respectively. The 1kb ladder was used. 
 
4.2.4.6 Detection of a 94 kb duplication on Xq28 
 
The gene IKBKG, which is involved in the rearrangement reported here, encodes for 
the regulatory subunit of the inhibitor of KappaB kinase (IKK) complex required for 
the activation of the NF-κB pathway. This gene is mapped to a position 386 kb 
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proximal to F8 locus. IKBKG is an essential protein and rearrangements in IKBKG 
that lead to a disrupted gene (equivalent to null mutations) are lethal [101, 102]. 
Therefore, the integrity of this locus in patient was confirmed by LR-PCRs. The 
genomic region involved in the rearrangement was amplified in the patient. PCR 
amplification was successful and a product across the Int1R-2 repeat in intron 2 of 
IKBKG was amplified. However, this result was in contrast to the hypothesized 
recombination event. Therefore, the possibility of a homologous recombination 
between inverted repeat copies of Int1R occurred between the F8 copy and a third 
repeat outside the IKBKG was postulated.  
 
However, the BLAT search revealed the existence of only two copies of the Int1R 
repeat. The next assumption was that of an independent duplication event to be 
responsible for the creation of a third Int1R repeat (designated here as Int1R-2d) in 
the patient’s genome. To prove this, patient's X-chromosome was screened for 
duplications using a CGH-array. The results showed a large duplication of ~94.4 kb 
on the X chromosome where the duplicated region extends from Int1R-2 in the 
IKBKG gene to the IKBKGP (Figure 36). The duplication event provides an intact 
copy of the IKBKG. This data explains well why the patient does not suffer from any 
other health problems than hemophilia A.  
 
4. Results 
 
89 
 
 
Figure 36: Characterization of the duplication. A) Map of the involved region; G6PD, IKBKG, 
CTAG1B, CTAG1A and IKBKGP are shown; the thin arrows above genes indicate direction of 
transcription; the thick pink/transparent horizontal arrows indicate the naturally occurring duplicated 
region; the extent of the duplication in the index patient is indicated by the blue line with arrows below 
the map; orange thin lines represent the detected sequence from the inverse PCRs. B) The CGH 
results of the patient (above) and a pool of male controls (below). All genomic positions are according 
to hg18. 
 
Further analysis of the borders of the duplicated sequence revealed a rich 
occurrence of several repeats mainly of the endogenous retrovirus (ERV) family of 
repeats that could have facilitated the generation of the duplication. However, no 
clear motives could be found at the borders of the duplicated regions or the proposed 
insertion site to explain how the inversion happens (Figurer 37). 
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Figure 37: Search for motives and similarities at duplication (Dup) and insertion borders. 
Schematic presentation of the repeats in the centromeric end (A) and telemetric end (B) of the original 
sequence of the duplicated region and the proposed insertion site (C). Vertical arrows represent the 
start (A), the end (B) and the proposed insertion position. The position of each repeat in the 2 kb 
analyzed sequence is indicated together with the name and class of the repeat as well as similarity 
(Sim) and blast score. (D) Dot plot matrix analysis to identify similarity between sequences; three 
analysis are presented: on the left start of the duplication against the end of duplication, in the middle 
the start sequence of the duplication against the insertion site and on the right the end sequence of 
duplication against the insertion site. 
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4.2.4.7 Proposed mechanism of the complex rearrangement 
 
Based on the inverse PCR sequences of the downstream breakpoint, it appears that 
the 5´ end of the 94.4 kb duplicated region (before the inversion) is connected to a 
repeat sequence with a high homology to a repetitive sequence in intron 2 of 
FUNDC2, followed by a region between CTAG1 and IKBKG. As the later regions are 
found normally duplicated [103]. This gives two possibilities for the position of the 
insertion: the first between CTAG1B and IKBKG, and the second between CTAG1A 
and IKBKGP. The first possibility will lead to an insertion generating Int1R-2d in same 
orientation as the Int1R-1 and thus incompatible with an inversion. Therefore, the 
second insertion position is more likely (Figure 38). 
 
 
Figure 38: Proposed mechanism of the rearrangement. Three steps are schematically 
presented. The first is the duplication, the second is the insertion of the duplication, and the third is the 
intrachromosomal homologous recombination. Part of F8 including exons 1-6 and the IKBKG region 
are shown. 
 
The most clinically obvious effect of the rearrangement is the hemophilia A 
phenotype in the patient that removes the promoter and exon 1 of F8. This is 
sufficient to abolish FVIII synthesis and cause severe hemophilia A. 
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4.2.5  Identification of a novel duplication/ triplication in F8 gene in patient 
HA#7 
 
The index patient (HA#7) is a male hemophilia A patient with a severe phenotype 
(FVIII:C<1%). No inhibitors have been detected. The index patient was negative for 
intron 22 and 1 inversions. Complete sequencing of F8 cDNA revealed no 
deleterious mutations. The vWF 2N mutations were excluded as well. FISH analysis 
revealed normal localization of F8.  
 
4.2.5.1 MLPA analysis revealed a novel triplication/duplication of F8 
 
MLPA analysis for F8 gene was done for the patient and an increased copy number 
of exons 1–25 (duplication of exons 1-4 and 23-25 and triplication of exons 5-22) 
were detected. The CNV pattern does not comprise exon 26 of F8 (Figure 39).  
 
 
Figure 39: MLPA results for patient HA#7. Almost all exons on F8 gene are involved in the 
duplication/ triplication mutation. The arrow indicates exon 26 where no increased probe signal was 
observed. The duplicated and triplicated regions are boxed in red and blue.  
  
After performing MLPA on DNA material of his daughters, we could demonstrate that 
this imbalance is inherited in both obligate carriers.  
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4.2.5.2 The duplication/ triplication event comprises the complete 
intronic regions of F8 
 
To verify the MLPA results and to investigate submicroscopic copy number changes, 
a CGH-array was applied. The results showed that the copy number change at Xq28 
comprises only the genomic region of F8 (Figure 40), and that the span of the 
duplication/ triplication is carried over the intronic regions of F8. These results are in 
agreement with the MLPA findings (Figure 39).  
 
 
Figure 40: Genomic region harboring alterations at Xq28. The upper panel shows the position 
of F8 on X chromosome (hg:18, NCBI build 36). The arrow indicates the direction of F8 transcription. 
Results from CGH array show a large duplication and triplication of genomic region of F8 in patient 
HA#7 (A) comparing to B) DNA from pool of male controls. The duplication/triplication event spans the 
complete genomic region of F8 from exon 1-25 including the intronic regions. 
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4.2.5.3 Absence of FVIII protein despite high F8 mRNA expression levels  
 
When a deletion is found by MLPA, it is recommended to use an independent 
method to confirm the result. In case of duplication, the verification is more laborious. 
To analyze whether despite the duplication/triplication on the genomic level a mRNA 
transcript is generated; the transcription pattern was investigated and RT-PCR was 
performed as described above (3.3.1.2). After performing RT-PCR which is a semi-
quantitative method, a much more intensive PCR band for the patient was observed 
compared to other hemophilia A patients and controls. However since RT-PCR a 
semi quantitative method is, a quantitative mRNA expression analysis was performed 
using a Taqman based assay (3.3.1.4). Quantitative mRNA analysis revealed an 
unexpected high F8 mRNA expression level in comparison to healthy individuals 
(Figure 41). 
 
Figure 41: Relative F8 mRNA expression for 
patient HA#7.  The mRNA expression analysis 
reveals a significant higher mRNA expression of 
F8 compared to healthy male individuals (C1-C7 
are the controls, ttest ****= P<0.0001). 
 
 
 
Despite the high mRNA expression levels, no protein is synthesized (FVIII:Ag<1%, 
Table 3). This could be a hint that no normal mRNA transcript is available, and the 
existing mRNA transcript is not translated into a functionally active FVIII protein. 
4. Results 
 
95 
 
 
4.2.5.4 Genomic gains originate from one chromosome homolog 
 
FISH analysis showed no intra-chromosomal translocation of F8 and all copies of the 
gene were located to Xq28. To test for potential inter-chromosomal exchanges during 
rearrangement product formation, marker haplotypes were evaluated from the 
genomic interval spanning the complex rearrangement. Notably, the patient lacked 
heterozygosity for all SNPs tested using this approach, including SNPs localized to 
both duplicated and triplicated genomic intervals. The lack of heterozygosity 
observed in these regions suggests that these complex genomic rearrangements 
originated from a single chromosome. In addition, linkage analysis showed that the 
haplotype associated with the disease in the index patient is shared between all 
affected members (Figure 42). The analysis revealed to date not described 
duplication/triplication pattern comprising the whole genomic region of F8 locus 
leading to a severe HA phenotype where, despite high F8 mRNA expression levels, 
FVIII protein is lacking.  
 
Figure 42: Haplotype segregation analysis in family of patient HA#7. FVIII:C levels are shown, 
where this information was available. The X-chromosome inactivation (XIR) ratio is shown for the 
potential carrier females. Where no haplotype is constructed no DNA material was available. For III-7 
no haplotype can be constructed, since the allele information from her father is not available.  
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4.2.6 Identification of a novel breakpoint in exon 18 of F8 gene in patient 
HA#14 
 
The index patient (HA#14) is a male hemophilia A patient with a severe phenotype 
(FVIII:C<1%). No inhibitors have been detected. The index patient was negative for 
intron 22 and 1 inversions. Primers used for characterization of this breakpoint are 
listed in Table S12. 
 
4.2.6.1 Discriminative results for exon 18 in patient HA#14 
 
The amplification of exon 18 of F8 failed using the routinely used primers for 
diagnostic (Figure 43). Complete sequencing of all other F8 exons revealed no 
mutations. This result indicates deletion of exon 18, which is consistent with the 
severe hemophilia A phenotype.  
 
 
Figure 43: PCR picture of amplification of exon 18. The 
amplification failed in HA#14 using the primers located in intronic 
regions flanking exon 18 of F8. The 100 bp ladder was used. 
 
 
To verify the deletion, MLPA analysis was carried out. Interestingly, MLPA analysis 
revealed contrary results to the PCR amplification. MLPA approach did not confirm 
the deletion of exon 18 and showed normal copy number for all exons of F8.  
 
4.2.6.2 Identification of a breakpoint in exon 18 of F8 using LR-PCRs 
 
The first assumption was that one of the primers used for the amplification of exon 18 
fails to bind to this region due to a rare polymorphism. To investigate this, primers 
were designed to be amplified with the MLPA probe as forward and reverse primer 
(MLPA18F and MLPA18R). Both amplifications were using these primers (Figure 44). 
Sequencing of the PCR fragments revealed no changes in exon 18.  
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Figure 44: Identification of a breakpoint in exon 18 of F8. PCR amplification using MLPA probe 
as primers to amplify exon 18 for patient HA#14. All PCR fragments show normal amplicon sizes for 
both regions. The red arrows indicate the primers used for the amplification. The 1kb ladder was used 
(P=patient, C=Control).  
 
The next step was to apply LR-PCR using primers of region N (chrX: 154,134,934-
154,124,275; hg19). Inability to amplify region N, a 10.636 bp region located between 
intron 14 and intron 22 of F8 (flanking exon 18) from the genomic DNA of the index 
patient, indicated the presence of a genomic breakpoint in this region (Figure 45).  
 
Figure 45: LR-PCR across exon 18 using the primers in intron 14 and 22 of F8. Schematic 
presentation of the amplified region (left) and LR-PCR picture of region N (left) is shown. LR-PCR 
reveals no amplification for patient and indicates the presence of a breakpoint in this region. The 1kb 
ladder was used (P=patient, C=control). 
 
4.2.6.3 Inverse PCR identifies the junction of the breakpoint 
 
To characterize the breakpoint junctions, an inverse PCR approach was designed to 
amplify the region upstream and downstream of exon 18 of F8 (Figure 47 A). The 
genomic DNA of the index patient was digested using HindIII enzyme. The product 
was ligated and purified as described in section 3.3.3.3 and the ligated product was 
amplified. The PCR fragments, of both upstream and downstream PCRs, were 
sequenced.  
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The upstream inverse PCR revealed a smaller PCR fragment in size (1771 bp 
compared to the 2725 bp of the wild type sequence). Sequencing of the patients 
amplicon revealed a break within exon 18 of F8 (chrX: 154,132,278; hg19). A short 
repetitive element of L1 family of repeats was inserted in the body of F8 gene 
followed by a junction to a sequence at Xq28 from chrX: 154,473,718 to 
154,474,688; hg19 (Figure 47 B). The insertion junction is directly after the binding 
site of the MLPA probe (Figure 46). 
 
 
Figure 46: Sequencing results of upstream inverse PCR product of patient HA#14. The wild 
type sequence (WT-sequence) is aligned to the PCR product of patient. Exon 18 of F8 is boxed grey 
and pink in wild type and patient's sequence, respectively. The breakpoint is located directly after the 
MLPA probe (dark blue box). The inserted regions in patients genomic DNA is boxed in transparent 
blue box. The position of InvF3 primer is shown in green in exon 17 of F8.  
 
The downstream inverse PCR revealed a fragment of 3362 bp, which is bigger in 
size compared to the product obtained from healthy controls (2819 bp). Sequencing 
of the aberrant PCR product revealed an insertion of sequences located at Xq28 
region (chrX: 154,487,749- 154,486,661) in intron 17 of F8 (Figure 47 C). 
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Figure 47: Inverse PCR approach for patient HA#14. A) Relative positions of the primers used for the upstream and downstream inverse PCRs together 
with the surrounding HindIII restriction sites (marked in red). B) Picture and map of the sequence of the upstream C) and downstream inverse PCRs are shown 
for both the wild type and patients inverse PCR product. All genomic positions are according to hg19. The exon 18 junction to the insertion is shown in partial 
exon 18 in pink and the inserted region is shown in yellow. The inserted region before intron 17 is shown in red for the downstream inverse PCR (P: Patient, C: 
Control). Red and purple arrows indicate the location of the primers used for the upstream and downstream PCRs, respectively. The 1kb ladder was used. 
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4.2.6.4 Multiplex PCR detects the rearrangement in HA#14 
 
In order to provide a diagnostic test for detection of this breakpoint in other severe 
hemophilia A cases and/or carriers, a simple multiplex short PCR was established 
(Figure 48). The amplification was done using a forward primer in intron 17 of F8 
(AT-MPX-F8-F: chrX: 154,132,464- 154,132,445; hg19) with two reverse primers, 
one amplifying the wild type F8 sequence located in intron 18 of F8 (AT-MPX-F8-R: 
chrX: 154,132,035- 154,132,015; hg19) and one located in the inserted fragment in 
the genomic region of F8 (AT-MPX-R2: chrX: 154,473,911- 154,473,931; hg19). The 
PCR products of wild type and mutant regions differ in size; 450 bp and 603 bp, 
respectively.   
 
 
Figure 48: Multiplex PCR for detection of the breakpoint in patient HA#14. The PCR 
amplification was carried out using At-MPX-F8-F primer with both reverse primers (The arrows 
indicate the position of the primers used, the insertion is shown as an orange box. The 100 bp ladder 
is used (P: patient, C: control).  
 
4.2.6.5 Proposed arrangement of the genomic region of F8  
 
Based on the results of the inverse PCR and due to the fact that no repetitive 
sequences were found in the border of the rearrangement, an inversion was 
excluded. The possible arrangement of the insertion in the body of F8 gene is shown 
in Figure 49. Genomic region of F8 is disrupted by a large insertion of about 13 kb. 
Interestingly, part of exon 18 (chrX: 154,132,363- 154,132,278; hg19) seems to be 
duplicated which is present in the upstream PCR product.  
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Figure 49: Possible arrangement of the genomic region for patient HA#14. The upstream and 
downstream PCR products with the HindIII cutting site are shown. The insertion is about 13 kb in size 
(orange boxes) and disrupts the genomic region of F8. The grey arrows indicate the transcription 
direction of F8. Exons of F8 are boxed. All coordinates are according to hg 19. 
 
This data clearly shows the presence of a large insertion in body of F8, which leads 
to disruption of F8 genomic region and can explain the severe hemophilia A 
phenotype.  
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4.3 Summary of novel mutations causing hemophilia A 
presented in this work 
 
In the context of this work, several causal mutations were identified in hemophilia A 
patients earlier classified as patients without mutation.  
 
1. Identification and characterization of two breakpoints in genomic region of F8: 
• A novel rearrangement in intron 1 of F8 (patient HA#1) 
• An insertion in intron 18 of F8 (patient HA#14) 
2. Identification of a novel duplication and triplication (patient HA#7) 
3. Identification of deep intronic mutations  
• Characterization and prove of causality of deep intronic mutations (patient 
HA#8, HA#9, HA#10, HA#11, HA#13) 
• Identification of a novel mutation in 3´ UTR of F8 mRNA (patient HA#3 and 
HA#4) 
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5 Discussion 
 
5.1 Key considerations for diagnosis of hemophilia A  
 
Hemophilia A together with VWD, account for the majority of congenital bleeding 
disorders. The main reason for referral of patients to molecular diagnosis is a family 
history of hemophilia A. However, in one third of cases, hemophilia A is a sporadic 
disease [104, 105]. Sporadic cases of severe hemophilia A are often diagnosed in 
about one year of age, after the first unexpected bleeding occurs. Quite contrary to 
severe phenotype, mild and moderate cases may not be diagnosed until adulthood. 
 
Generally, the diagnosis of hemophilia A is based on FVIII:C levels. The severity of 
disease is critical for diagnosis and the choice of the genetic analysis strategy that 
needs to be applied. Two main issues should be considered in order not to 
misdiagnose hemophilia A. The first category is pre analytic considerations which are 
needed to be taken in account to determine the correct severity grade of the disease, 
e.g. correct storage of samples before FVIII:C measurements [106] and amount of 
citrate anticoagulant in blood collection tubes [106, 107]. These variables should be 
considered for mild and moderate phenotypes. The second category is misdiagnosis 
of hemophilia A in patients with VWD or combined FV/FVIII deficiency. For later, 
diagnosis of FV deficiency is essential for the correct treatment regiment. For all 
patients with a bleeding tendency and reduced FVIII:C levels, it is important to 
perform vWF assays to exclude the possibility of VWD, independent of the severity of 
the disease. The role of vWF as carrier and protector of FVIII protein is quite critical. 
A number of patients with a mild phenotype may actually suffer from vWF type 2N. 
Prior to correct diagnosis, all these patients would be treated with FVIII concentrates, 
and would show poor responses to the therapy that might have clinical 
consequences [108-110]. Therefore, mutation analysis in exons comprising the FVIII 
binding domains of vWF [111] and performance of vWF:FVIII binding assays [47, 
112, 113] are necessary. This issue is a very important point in cases, where no 
mutation in F8 is detected.  
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In case of combined FV/FVIII deficiency, the bleeding phenotype is due to disruption 
of cargo specific ER to Golgi transport proteins, LMAN1 and MCFD2. The 
combination of FV and FVIII deficiency does not seem to cause more bleeding. 
Patients usually show a mild phenotype.  Nevertheless, since the causal mutation 
resulting in low amounts of FVIII and FV activity is either in F8 or F5 gene, it is 
important to assay FV levels in patients diagnosed as hemophilia A with a mild 
bleeding tendency as well [44, 45, 114, 115]. 
 
Only a few cases of hemophilia A are reported in females and the molecular 
mechanism in this cases are rarely investigated [21, 22]. On the other hand, the 
correct diagnosis of hemophilia A in carriers should not be neglected. It should be 
taken in consideration that not all carriers are symptomatic [116]. Only about 10% of 
female hemophilia A carriers show bleeding events [117]. Reduced FVIII:C levels in 
these cases may also be due to VWD type 2N or skewed X chromosome inactivation 
[18]. In these cases, vWF:FVIII binding assay and HUMARA test would help to 
achieve a correct diagnosis of hemophilia A carriership.  
 
5.2 Hemophilia A diagnostic- beyond the routine tests 
 
The diagnosis of hemophilia A is mainly done by blood tests on the basis of residual 
FVIII:C levels. The molecular cause of FVIII deficiency can be divided into 3 
categories. The first category is the mutations in F8 causing a structural change in 
FVIII protein, which are the most common reason of FVIII deficiency. The next 
category contains mutations in proteins involved in trafficking and transport of FVIII 
protein such as LMAN1/MCFD2 [44, 45] and vWF [47, 95]. These changes would 
also lead to reduction of FVIII:C levels. The data presented in this work, provide 
insight into the molecular basis of hemophilia A with special focus on the third group, 
consisting mutation negative patients. In a small group of clinically defined 
hemophilia A patients, a 100% mutation detection rate is not achieved [25, 48, 118]. 
For this group of patients, additional experimental protocols should be applied to find 
the causal mutation.  
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The lack or the faulty transcription of F8 might result from a change in genomic 
regions of F8 that are normally not investigated for mutations or it is the result of 
complex rearrangements that are difficult to identify. Current mutation screening 
flowchart applied in most genetic laboratories (Figure 4) includes only screening for 
inversions in intron 1 and 22 [24, 119] as well as sequencing all exons and their 
flanking intron boundaries.  
 
To address the difficulties of finding the molecular mechanisms that can explain the 
clinically defined hemophilia A phenotype in such patients, a 4-step experimental 
protocol was designed. This protocol would serve as a guideline to detect novel 
abnormalities. The first step, after excluding all factors associated with reduced 
FVIII:C levels, is the exclusion of duplications. In step two, the complete F8 locus is 
amplified by overlapping LR-PCRs. In the next step, all LR-PCR products would be 
sequenced using a NGS approach. Finally, mRNA analysis (RT-PCRs and qRT-
PCR) may be applied to detect abnormal splicing across exon-exon boundaries, 
harboring deep intronic variations. Using this protocol several causative mutations 
were found in patients earlier classified as patients without detectable mutations.  
 
The targeted capture NGS approach used in this study combines two techniques; a 
universal LR-PCR protocol and a massive pyrosequencing technology. This 
approach will help to identify sequence variants in regions that are overlooked using 
the conventional screening methods. Although both systematic false positive 
(because of incorrect genome mapping, systematic equipment sequencing errors) 
and false negative variation calls (because of low depth of coverage and difficulty in 
repetitive regions) exist, the clinical application of NGS as a diagnostic tool has 
become increasingly evident [120-122]. 
 
Most of NGS approaches are based on a pyrosequencing principle. Although 
pyrosequencing is widely used in various applications [123-125], it has several 
limitations. Beside its relative short read lengths, it has a limitation when reading a 
strain of more than five or six of the same nucleotides, known as homopolymer. 
These two limitations make NGS less attractive for diagnostic purposes. However, 
although a single read of NGS technology has higher individual-base calling error 
rates compared to Sanger sequencing, the false positive results are significantly 
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reduced by increasing the sequencing coverage [126]. Nevertheless, all variants 
found by NGS should be validated using Sanger sequencing. Moreover, the 
subsequent mRNA analysis performed in this study is a convenient complementary 
approach to the NGS strategy. Though, the limitations of NGS are the reasons why 
its applications in molecular diagnostics are still limited. However, the recent 
improvements in read lengths and coverage make this technology more attractive for 
diagnostic purposes.  
 
The results obtained in this study highlight once more the complexity of mechanisms 
leading to hemophilia A. The presented data shows that CNVs, i.e. duplications and 
triplications and aberrant transcription as well as deep intronic mutations and 
rearrangements contribute to the mutation spectrum of hemophilia A patients 
classified as patients without mutation. These mechanisms can only be determined, 
when diagnosis tests beyond the routine applications are performed. Moreover, it 
should be considered that the large intronic regions of F8 due to their high repetitive 
content [23] are prone to rearrangements. These abnormalities are easily missed 
using the conventional mutation screening methods.  
 
Taken together, application of new mutation screening tools in the routine genetic 
diagnosis of hemophilia A, such as MLPA and CGH for detection of duplications and 
deletions as well as NGS technologies for re-sequencing of the whole genomic 
region of F8 and mRNA analysis, is necessary to reduce the number of cases 
classified as mutation negative hemophilia A patients.  
 
5.3 Disease associated intronic mutations 
 
Quite a number of mutations are being missed, as some of these involve sequence 
variations in intronic regions that are not being assessed by current techniques. Even 
the more recent whole-exome sequencing methods do not cover the intronic regions. 
According to Human Gene Mutation Database (http://www.hgmd.org/), about 10% of 
reported mutations in disease-associated genes are splice site mutations. Most of 
these mutations affect consensus sites. However, the evidence of deeper intronic 
sequence variations affecting splicing process is now becoming more available. 
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Deep intronic sequence exonisation has been reported for several genes: ATM [127], 
CFTR [128], RB1 [129], NF1 [130], CDKN2A [131], BRCA2 [132], HRPT [133], 
USH2A [134], CF [135] and MLC1 [136]. All these reported intronic mutations are 
proved to be associated with diseases. Nevertheless, the importance of screening for 
splicing variations has been underlined in hemophilia A as well [42, 43, 75, 118]. 
Intronic mutations activate a cryptic donor or acceptor splice site and splicing 
between this novel splice site and a pre-existing splice site leads to the inclusion of a 
cryptic exon. These mutations would lead to splice defects that are more commonly 
identified in association with human diseases. For the time being, NGS and mRNA 
analysis are the most suitable approaches to identify and analyze such deep intronic 
mutations.  
 
The results shown in this work highlight the importance of implementation of F8 
mRNA analysis in the clinical practice as well as the relevance of mRNA analysis in 
confirming whether changes found at the DNA level could lead to a disease. 
However, since FVIII is a liver-specific protein, tissue specific splicing should not be 
neglected [137]. The cDNA used in this study was synthesized from RNA obtained 
from blood. So far, there is no assurance that the effect of the variations found here 
will be the same in the liver.  
 
Taken together, the study presented here highlights the necessity of looking beyond 
the coding, exon/intron boundary, and promoter regions, when attempting to find the 
molecular cause of a disease in the absence of pathogenic mutations. There is a 
need to sequence the complete F8 to unveil the underlying mutation in such cases. 
This work clearly shows that targeted capture and NGS are likely to be very useful in 
a diagnostic setting to clarify the genetic basis of patients in which no mutation is 
detectable through conventional Sanger sequencing. Moreover, this data confirms 
that deep intronic mutations in F8, although rare, can cause abnormal splicing that 
leads to hemophilia A.  
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5.4 Heterogeneity of mutational events leading to 
hemophilia A 
 
The majority of hemophilia A cases can be explained by specific defects in F8, but in 
a minority of cases (2%) no genetic F8 variant can be identified [42, 138]. In such 
cases, after excluding large tandem duplications [41, 139] and the two previously 
reported intron 1 and intron 22 inversions [23, 140], a wide spectrum of mutation 
mechanisms have been reported. Among others, mutations in introns [118], 
insertions associated with deletions [141-143] and deletions arisen from both, 
unequal homologous recombination between Alu-derived sequences [144, 145] and 
non-homologous recombination [146], have been reported. Such complex 
rearrangements that evade standard PCR screening strategies need to be 
considered. Both inversions reported in severe hemophilia A cases, are arising from 
rearrangements because of homologous repeats [23, 24]. 
 
Tandem duplication of a genomic segment is one of the possible outcomes of 
unequal crossing over between paralogous sequences. Although genomic 
rearrangements normally do not result in gain or loss of DNA, there are some 
evidences of increase and/or decrease in copy number of genes [147, 148]. Some 
cases of even more complex mutational events have been reported involving 
different mechanisms. Ven der Water et al. reported a 38 bp insertion associated with 
a 20.7 kb deletion within F8 involving LINE-1 retrotransposon-mediated DNA repair 
[141].  Later, a 6 bp insertion in junctions of a 316 bp deletion in F8 was reported that 
resulted from a model of serial replication slippage (SRS) [149]. More recent reports 
demonstrated even a more complex model of break-induced SRS at Xq28 consisting 
of a 15.5 kb deletion/16 bp insertion together with a 28.1 kb deletion/263 kb insertion 
[143]. All these publications show that Xq28 is prone to such rearrangements.  
 
The work here demonstrates techniques to identify and confirms the presence of 
novel rearrangement events as well as deep intronic variations. The severity of the 
disease seems to be well associated with the complexity of the causal mutation. 
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Deep intronic mutations found in this work and other studies [118, 150-152] are 
associated with mild to moderate hemophilia A phenotypes. On the other hand, 
complex rearrangements reported in this study and other studies lead to the severe 
phenotype of hemophilia A [23, 119, 143].  
 
This study presents several novel rearrangements causing severe hemophilia A. 
Using the LR-PCR assay developed for amplification of whole genomic region of F8, 
two breakpoints were identified; one in intron 1 and the other one in intron 18 of F8. 
With the advances in LR-PCR techniques and the sequence information provided by 
the Human Genome Project, gross rearrangements responsible for a number of 
genetic diseases are becoming easier to be identified. Both features helped to 
precisely analyze these rearrangements without the need for laborious genomic 
cloning procedures. In addition to breakpoint characterization, a specific PCR test for 
family carrier detection and prenatal diagnosis of both rearrangements was 
developed, which can easily be implemented in routine genetic diagnosis of 
hemophilia A. 
 
In accordance with the previously characterized inversions (comprising introns 1 and 
22), the novel inversion identified in this work (patient HA#1), was also caused by a 
rearrangement between homologous repeats. This complex novel genomic 
rearrangement causes several changes in gene copy number in the Xq28 region. 
Interestingly, the IKBKG locus at Xq28 involved in the inversion is complex and 
contains an inverted segmental duplication of about 35.4 kb that includes the non-
functional pseudogene, IKBKGP, extending from exons 3 to 10 and a complete 
duplication of the CTAG1 gene. Mutations in IKBKG lead to Incontinentia Pigmenti 
(IP), a dominant neuroectodermal disorder. Null mutations in IKBKG are lethal in 
male fetuses [101]. Inverted orientations and the high homology of the segmental 
duplications at this locus make this region prone to rearrangements [153, 154]. In 
addition, the high frequency of micro/macro homologies and repetitive sequences at 
this locus predispose to pathological genomic rearrangements [103].  
 
However, in contrast to the IKBKG-F8 rearrangement described here, none of the 
previously characterized rearrangements are outside the IKBKG locus and the 
associated inverted segmental duplication. Interestingly, in about 27% of IP patients 
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no genetic defects in IKBKG could be identified [155]. Therefore, based on the 
IKBKG-F8 rearrangement described here, it is questionable if a reciprocal 
phenomenon for which a homologous recombination with a duplicated F8 intron 1 
would also lead to breakage of IKBKG. Such a rearrangement does not lead to gain 
or loss of DNA or change in IKBKG DNA copy numbers and would have escaped the 
traditional screening methods in the IKBKG, which is based on short range PCR 
amplification of the coding sequence [155]. To detect all rearrangements in the 
IKBKG including inversions a long range PCR approach should be implemented. 
Also, a third possibility of recombination between Int1R-1 and Int1R-2 repeats exists. 
Although lethal in males, it would lead in females to two consequences: an IP 
phenotype and a hemophilia A carrier status with considerable reduction in FVIII:C 
levels. 
 
The rearrangement event reported here is the result of two events. The first is the 
duplication of a large 94 kb region that extends from the functional IKBKG to 
IKBKGP. The duplicated region contains the Int1R repeat at one end (designated 
Int1R-2d) and appears to be inserted in the telomeric 35.4 kb segmental duplication. 
This rearrangement leads to the second event wherein an intra-chromosomal 
homologous recombination occurs between F8:Int1R-1 and Int1R-2d in the 
duplicated IKBKG gene. As a result, F8 is split in intron 1 into two oppositely oriented 
fragments for which no functional mRNA is transcribed [75]. On the other hand, the 
essential IKBKG gene is still intact and transcribed, as the homologous 
recombination involves the duplicated copy and not the endogenous IKBKG or 
IKBKGP. This explains the absence of additional clinical symptoms to the hemophilia 
A phenotype for this patient. 
 
For the second severe hemophilia A case characterized in this work (HA#14), first a 
simple deletion of exon 18 was thought to be the causal mutation. However, this case 
shows the importance of implementation of several complementary methods for 
verification of mutations. The discriminative results between the PCR and MLPA 
show the limitations of both applications. Some rare polymorphisms in PCR primers 
can lead to unsuccessful PCR amplifications. In such cases MLPA seems to be an 
efficient method to screen chromosomal abnormalities. Until now, single base 
changes in the probe binding sequence were the major reason of altered results of 
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MLPA analysis. The case studied in this work shows clearly that MLPA can also yield 
false negative results and a disruption of exons can be easily missed depending on 
the position of the probe. MLPA may be a fast and inexpensive method for detection 
of microdeletions and microduplications, but the method should be validated by 
additional methods. However, despite its high sensitivity and accuracy, for application 
of MLPA in a diagnostic setting, different probes for all specific exons should be 
used, to prevent false positive and false negative results. 
 
The practical application of MLPA for diagnostic purposes of hemophilia A is 
demonstrated for patient HA#7. The novel duplication and triplication pattern was 
easily detected by MLPA analysis. Concerning the laborious karyotype analysis for 
patients and the limitations of FISH analysis in detection of microdeletions and micro 
duplications, the MLPA technique serves as a good and fast tool. However, when 
such large duplication and triplication pattern, as in patient HA#7, is observed, it is 
important to exclude extra-chromosomal translocation of the several F8 copies. 
 
Furthermore, to elucidate the extent of duplicated and triplicated segments, either a 
multicolor FISH analysis using several DNA probes or a CGH-array should be 
applied. The later is a less laborious method to identify genomic rearrangement 
complexity. However, this method provides information only about copy number and 
not about the orientation or genomic position of the CNV. Due to experimental 
challenges in determining the breakpoints in case of triplications, it difficult to infer the 
molecular mechanism. Therefore, the molecular mechanism for triplication formation 
in hemophilia A is poorly understood and investigated.  
 
The high expression level of F8 mRNA, in this patient HA#7, is contrary to the severe 
hemophilia A phenotype and can not explain the absence of FVIII protein (based on 
FVIII:Ag measurements). Only a few studies have analyzed the mRNA-protein 
expression correlation in human [156-158]. A recent study showed that gene 
expression at mRNA level is correlated with the protein level [159]. However, in case 
of this patient, despite the duplication/ triplication event, the transcription of F8 mRNA 
is accelerated. However, the translation of this mRNA is failed. 
 
5. Discussion 
 
112 
 
The causal mutation for all severe hemophilia A cases studied in this work was 
detected. In all cases the defect was in F8. This data suggests that further 
characterization of other severe hemophilia A patients without detectable F8 
mutations, may reveal novel complex rearrangements involving either repetitive 
sequence hot spots [23, 160] or micro homology regions [41]. Complex 
recombination mechanisms might be the fundamental cause of a number of severe 
hemophilia A cases that, until now, have evaded specific genetic diagnosis. The 
special features of Xq28 make this region an unstable area of human genome, which 
is exposed to rearrangements [141, 143, 153, 154]. The presence of long, almost 
identical inverted repeats at Xq28 account for the high frequency at which these 
rearrangements occur.  
 
5.5 Role of 5´ - and 3´- untranslated regions of mRNA in 
human diseases 
 
The regulation of protein synthesis is critical for balancing the cellular metabolism. 
Proteins involved in the process of translation play an essential role in the regulation 
machinery of proteins. However, changes in the cis-regulatory elements and trans-
acting factors of UTRs can disturb the protein synthesis, associated with various 
diseases. UTR sequences are highly diverse in sequence but they contain common 
regulatory motifs. The special features of UTRs, such as their GC rich regions and 
internal ribosome entry sites (IRESs), have a significant bearing on translation rate of 
mRNA. Trans-acting factors such as 5´-cap, multiple ORFs, multiple upstream AUG 
(uAUGs), IRESs and polyadenylisation signals, have an effect on the stability of 
mRNA, its accessibility to the ribosome and its general interaction with the other 
proteins involved in the translation machinery [161].  
 
Many important genes encoding proteins that are involved in critical cellular 
processes are regulated at the level of translation, predominately through their UTRs 
[162]. Mutations in these regions can lead to a disease by different mechanisms. So 
far quite a number of mutations are reported in 5´ UTR of mRNAs. These mutations 
could affect the length and the secondary structure of 5´ UTR as in breast cancer 
[163]. A single G>C transition at position -3 downregulates the translation of BRCA1 
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mRNA [164]. Moreover, changes upstream ORFs are reported to be associated with 
Alzheimer [165] and bipolar affective disorder [166]. The X-linked Charcot-Marie-
tooth disease [167], multiple myeloma [168, 169] and fragile X syndrome [170, 171] 
are affected by mutations in IRES elements of 5´ UTR. Additionally, changes in self-
complementary stem-loop structures of 5´ UTR and RNA binding proteins are 
reported to be associated with hereditary hyperferritinemia/cataract syndrome [172].  
 
The number of studies on disease-associated changes in 3´ UTR is much lesser in 
extent. Although, 3´ UTR plays an important role in translocation, localization and 
stability of mRNA, it is often not screened during genetic analysis [173]. MicroRNAs, 
21-24 nt duplex RNAs, are associated with 3´ UTR diseases. They bring the RNA-
induced silencing complex (RISC) to 3´ UTR of mRNAs. Mutations in 3´ UTR can 
lead to gain or loss of microRNA function that results in inhibition or promotion of 
translation [174]. Beside the role of microRNAs on regulation of mRNA translation 
[174, 175], three main mutation mechanisms are reported in this context. Diseases 
associated with mutations in 3´ UTR can be caused by mutations generating stop 
codons (e.g. Epidermolysis bullosa simplex [176], Aniridia [177]). Such mutations 
result in production of a protein that is larger in size. This can interfere with the 
function of the protein or its interaction with associated proteins. Mutations can affect 
the polyadenylation signal causing diseases such as hemoglobin H disease [178-
180] and immune dysfunction polyendocrinopathy enteropathy X-linked [181]. The 
polyadenylation signal is a conserved sequence motif (AAUAAA), which is essential 
for transcriptional termination of mRNA. Furthermore, mutations affecting the 
secondary structure of mRNA have also been reported to be associated with various 
diseases. These mutations effect the interaction with associated proteins. Congenital 
heart disease is caused by mutations in mRNA of GATA4, a sequence motif that 
binds to GATA motif. These mutations alter the secondary structure of mRNA and 
affect the localization and translation of the mRNA [182]. A single transition in the 3´ 
UTR of TGF-β3 is reported to be associated with arrhythmogenic right ventricular 
cardiomayopathy [183].  
 
Several groups have already reported mutations in 5´ UTR of F8 mRNA [184, 185]. 
Figueiredo et al. analyzed the cis-acting elements and transcription factors that are 
involved in the promoter activity of F8. Until recently, no functional assays were 
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performed to characterize these mutations. Recently, Zimmermann et al. analyzed 
the causality of five F8 promoter variants in vitro. All variants led to a decrease in 
promoter activity in accordance to the phenotype of patients [187]. 
So far, no pathogenic changes are reported in 3´ UTR of F8 mRNA. The frequent 
non-pathogenic polymorphism rs1050705 (minor allele frequency G=0.3743), at 
position c.7055*+1223 of F8 mRNA, is the only known variation in this region [69]. A 
unique G>T transition in 3´ UTR of F8 was found in this study (patients HA#3 and 
HA#4).  
 
Results obtained from the miRBase microRNA prediction software showed that no 
differences in binding of mature microRNAs to the wild type and mutant sequence. 
However, miRBase results showed the loss of binding site of three stem loop 
microRNAs (hsa-mir-1470, hsa-mir-493 and hsa-mir-607) and gain of one binding 
site (hsa-mir-4754) in presence of the mutation. However, to assume whether these 
microRNAs could affect the expression of F8 mRNA, two issues should be 
considered. First, it is questionable if these microRNAs are expressed in the liver, 
which is the main site of F8 expression and synthesis [50]. Second, a suitable cellular 
system from the patients is needed to perform functional assays to get conclusive 
results.  
 
Moreover, the wild type mRNA has one more guanidine-cytosine pair than the 
mutant, and the length of the paired zone is one pair longer compared to mutant 
(Figure 27). The loss of the stronger-paired zones (G-C bound is stronger compared 
to the A-U bound) and the shorter paired zones would reduce the melting 
temperature of mRNA. This facilitates the break of the pairing in the mutant by 
ribosome and thereby processing the translation [188]. This could explain the 
reduction of FVIII:C levels due to presence of the alternative spliced mutant mRNA. 
 
The mRNA analysis revealed alternative splicing in UTR of F8 mRNA. The aberrant 
band showed a deletion of 159 bp of 3´ UTR downstream (+2 bp) of this variation. 
This mutation results in a change in length of F8 mRNA. This would affect the 
structure and accessibility of F8 mRNA to its interacting partners. Based on the 
revealed results, the impact of the length of 3´ UTR is more suggestive for the 
instability of F8 mRNA than microRNA and structural changes. The presence of the 
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wild type F8 mRNA in the patient would explain the mild to moderate phenotype 
observed in patient HA#3 and HA#4.  
 
Taken together, mutations in both 5´ and 3´ UTR of mRNA can affect the regulation 
of protein synthesis. These mutations may result in a change in structure, length, and 
interaction of the mRNA. These changes may affect the accessibility of mRNA to 
microRNAs and its interacting proteins, as well as stability of mRNA.  
 
5.6 Reliability and accuracy of splice site prediction 
softwares 
 
When the causality of a DNA change is not clear, there is a need for prediction 
softwares to estimate the impact of these changes on splicing. In eukaryotes, when 
the mRNA is transcribed from DNA the introns are interspersed within the coding 
sequence. This immature mRNA is designated then as precursor mRNA (pre-
mRNA). The mature mRNA is produced during a process known as RNA splicing. In 
most eukaryotes, the 5′ boundary or donor site and the 3′ boundary or acceptor site 
dinucleotides are conserved sequences. The donor site of introns is usually the 
dinucleotide GT (GU in pre-mRNA), while the acceptor site contains the dinucleotide 
AG. A pyrimidine-rich region precedes the AG at the acceptor site, a shorter 
consensus follows the GT at the donor site, and a very weak consensus sequence 
appears at the branch point ~30 nt upstream from the acceptor site (Figure 50). A 
complex of proteins and small nuclear RNAs, known collectively as the spliceosome, 
recognizes these consensus sequences. With the help of spliceosome, the introns 
from pre-mRNA are spliced out and the mature mRNA transcript is produced. In case 
of mutations within the consensus splice site, this site may still be used, although 
less efficient. In case of variations not affecting the consensus splice site, more splice 
sites compete, and alternative splicing generates mRNA variants that produce 
different proteins from the same pre-mRNA (reviewed in [189]). 
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Figure 50: Cis-acting sequences that control splicing. Consensus sequences for the 5′ splice 
site (donor), branch site and 3′ splice site (acceptor). Exon sequences are boxed (modified from 
[190]). 
 
Alternative splicing is a common event [191], which was described for the first time 
1997 in the adenovirus [192] and in 1980 for IgM gene [193]. Splice site prediction 
programs are reliable tools to predict whether a mutation could disturb the correct 
pre-mRNA splicing and result in alternative splicing. 
 
However, several algorithms should be applied to determine if a given variation could 
create a new dss and/or ass site. A number of computational methods have been 
developed to identify these splice sites. The most common resources are: NetGene2 
[194], HSF (based on position weight matrices with position-dependent logic) [195] 
and FRUITFLY (based on neural networks) [196], which are online splice-site 
prediction programs and the program Alamut, which combines several splice site 
prediction tools (SpliceSiteFinder-like, MaxEntScan, NNSPLICE, HSF, GeneSplicer).  
 
Zimmermann et al. analyzed the effect of several intronic variants in F8 close to or 
within splice site consensus sequences. They showed that the majority of results 
obtained from splice prediction tools are in accordance with the experimental F8 
mRNA analysis done. However, a discrepancy was observed between in silico and in 
vitro analysis for some cases [197].  
 
The data presented in this work also strongly suggests that the potential of intronic 
variations on splicing should be determined based on experimental mRNA analysis 
rather than relying on prediction softwares. The two mRNA approaches applied in 
this work investigate F8 mRNA in two aspects. The qualitative nested RT-PCR 
approach reveals alternative splicing of F8 mRNA. Moreover, the quantitative RT-
PCR approach gives insight to the expression amount of normal F8 mRNA transcript 
to the aberrant spliced mRNA. It should be taken into account that incorrect splicing 
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do not affect 100% of the transcripts. The amount of correctly spliced transcripts to 
aberrant transcripts could make a difference between phenotype of the disease. In 
conclusion, the causality of splice site variants needs to be validated by mRNA 
analysis (both, quantitatively and qualitatively).  
 
5.7 Hemophilia A patients without mutation  
 
Still, in some patients, it was not possible to detect a causal mutation explaining the 
hemophilia A phenotype. Here, some possibilities may be considered. The first is 
tissue mosaicism. A point mutation in F8 could be present in the liver among other 
tissues but not in blood. Although mutations causing hemophilia A usually appear to 
have arisen in germ cells, a de novo mutation may also occur during early 
embryogenesis and thus may represent either germline and/or somatic mosaicism 
[198-201]. However, this could be excluded in familial cases as in some of our 
patients.  
 
Another possibility is the rapid degradation of the FVIII protein in blood or its rapid 
uptake. In this respect, the clinical observations from the patients would argue 
against this possibility, as all patients receive similar amount of substitution regimens 
of either plasma-derived or rFVIII concentrates, compared to a hemophilia A patient 
with known mutation and the same severity.  
 
The third possibility is a mutation in another gene encoding a novel interacting or 
modifying protein of FVIII. Other unknown mutations at other loci could affect the 
intracellular trafficking and/or secretion of FVIII molecule. It is possible that not only 
LMAN1 and MCFD2 are responsible for trafficking of FVIII protein. A third protein 
may be involved in VIII/vWF complex and could affect its protection from 
degradation. The last possibility is a still not identified regulatory region in F8.  This 
is, however, in accordance with the observations in pedigrees. The disease seems to 
be caused by a mutation in F8 gene itself or the defect is linked to F8.  
 
To elucidate the molecular mechanism behind hemophilia A in the remaining 
patients, FVIII protein should be investigated at its major site of production, which is 
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the liver. However, taking a liver biopsy from these patients is almost impossible. Not 
only the ethical aspects are important but also the risk of hemorrhage in hemophilia A 
patients is high. Alternatively, a patient specific cellular system should be established 
to monitor the expression and secretion of FVIII in the remaining cases. The recent 
advances in generation of induced pluripotent stem cells (iPS), make them a 
promising tool to establish such patient specific cell lines in the future.  
 
 
5.8 Proposed flowchart for genetic analysis of mutation 
negative patients  
 
Based on this work, the following strategy is proposed to elucidate the molecular 
mechanism in mutation negative hemophilia A patients. In the beginning of the 
analysis, the general algorithm for genetic analysis of patients with bleeding tendency 
and reduced FVIII:C levels should be applied for all patients. Hemophilia A should be 
reconfirmed in all mutation negative patients, on the basis of the flowchart presented 
in Figure 51.  
 
Figure 51: Flowchart for reconfirmation of hemophilia A in patients without mutation.  
 
After performing this analysis, misdiagnosis of hemophilia A is excluded in all 
patients. Up to this point, hemophilia A is confirmed and the only parameter 
associated with the bleeding tendency would be lack or shortage of FVIII protein. The 
next step of analysis would include changes at non-coding region of F8, followed by 
mRNA analysis. 
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In the next step, extensive analysis on DNA level of F8 should be performed to 
exclude CNVs. In case of abnormalities a CGH-array may be applied to verify MLPA 
results. If No CNVs are detected, FISH analysis is needed to exclude translocation of 
F8. The next step of analysis is the amplification of complete genomic region of F8 
using a LR-PCR approach. In cases, where a breakpoint in F8 locus is detected, the 
junctions of the breakpoint can be characterized by an inverse PCR approach. Based 
on sequencing results of inverse PCR products, a multiplex Short-Range PCR can 
be designed. This could be used later for routine diagnostic purposes of mutation 
negative patients. In patients, where the integrity of F8 locus is confirmed, NGS of 
the LR-PCR products could reveal intronic variants (Figure 52). 
 
The analysis will be continued on mRNA level to evaluate the effect of these DNA 
changes on mRNA. Prior to mRNA analysis, all variants should be checked in SNP 
databases to determine the unique intronic variants, which should be analyzed using 
splice site prediction softwares. Irrespective to the in silico results, RT-PCRs of F8 
mRNA should be performed to detect abnormal RNA transcripts resulted from 
alternative splicing. To finalize the analysis, the amount of F8 mRNA should be 
determined in exon-exon boundaries flanking the unique intronic variations. This is 
done by performing qRT-PCR analysis and calculation the ratio of wild type F8 
mRNA to the alternative spliced mRNA (Figure 52). 
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Figure 52: Experimental protocol applied on F8 for identification of novel mechanisms 
leading to hemophilia A.  
 
This proposed experimental protocol would narrow the number of hemophilia A 
patients so far classified as patients without mutation. Moreover, this practical 
approach could serve as a model for genetic analysis of other monogenic diseases, 
where no pathogenic mutation is found.  
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Supplementary tables:  
 
Table S 1: List of polymorphisms found in vWF in hemophilia A patients without detectable mutation.  
nd= no data, Ex= Exon, Int= Intron, W=T/A, R=G/A, M=C/A, Y=C/T, K=G/T, S=C/G 
Nr. Exon/ Intron Nuclotide change rs number aa change HA#2 HA#3 HA#4 HA#5 HA#6 HA#7 HA#8 HA#9 HA#10 HA#11 HA#12 HA#13 
1 Ex 8 T954A 1800387 N318K T T T T T T W T T T T T 
2 Ex 11 A1173T 1800375 T391 W W W A A A A A A A A A 
3 Ex 12 G1411A 1800377 V471I R R R G G R R G G G G G 
4 Ex 13 G1451A 1800378 R484H G G G G G R G R R R G R 
5 Ex 14 T1548C 7312411 P538 T T T T T C T C T C T T 
6 Ex 14 G1626A 35365059 A542 G G G G G G G G G R G G 
7 Int 17 c.2282-42  21693 C>A M C C A A C M C A M A A 
8 Ex 18 A2365G 1063856 T789A R R R A A G A G A R A A 
9 Ex 18 T2385C 1064008 Y795 Y Y Y T T C T C T Y T T 
10 Int18 c.2442+38 77372340 G>T T G G G G K G G K G G G 
11 Int 19 c.2547- 146  12810426 C>T Y C Y T T C Y C T Y T T 
12 Ex 20 A2555G 216321 R852Q G R R G G G R G G G G G 
13 Ex 21 G2771A  33978901 R924Q G G G R R G G G G G G G 
14 Ex 22 G2880A 1800380 R960R R R G G G G G A G R G G 
15 Ex 28 A4141G 216311 A1381T G A A G G A G A A G G nd 
16 Ex 28 G4414C 1800383 D1472H G G G G G G G G S G S G 
17 Ex 28 T4641C 216310 T1547 Y T C C C T Y T Y Y C C 
18 Ex 28 A4665C 1800384 A1555 A A A A M A A A A A A M 
19 Ex 28 G4693T 1800385 V1565L G G G G K G G G G G G K 
20 Ex 39 A6846G 10849371 T2282 A A A A A R A A A A A A 
21 Ex 42 C7239T 216867 T2413 T T Y Y T nd Y C Y nd nd C 
22 Ex 45 T7682A 35335161  F2561 T T T T T W T W T W T W 
23 Int 50 c.8155+50 2270151 C>T C C C C C Y C Y Y Y C T 
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Table S 2: Summary of results obtained after NGS. The number of total reads and the mapped reads are shown. 
The average coverage was between 287-554. The total rate of nucleotide mismatches for all patients was 2%. In total 3.126 variants were identified, from 
which 1510 and 1.616 were SNPs and Indels, respectively (Indel= Insertions and deletions). 
Samples Nr. of reads 
Nr. of  
mapped reads 
Gaps  
(bp) 
Total bases  
(bp) 
Average  
Coverage 
Nucleotide  
mismatches % 
Total  
variants SNPs Indels 
HA#2 2.036.106 1.912.611 3.302 71.263.710 346 0,16 302 141 161 
HA#3 3.391.020 3.066.420 3.787 118.685.700 554 0,19 366 140 226 
HA#6 1.903.566 1.744.525 5.215 66.624.810 315 0,16 323 176 147 
HA#8 4.083.402 3.829.590 4.501 142.919.070 692 0,28 541 328 213 
HA#9 2.681.898 2.490.669 2.473 93.866.430 450 0,15 285 133 152 
HA#10 2.621.230 2.299.893 7.580 91.743.050 416 0,22 407 167 240 
HA#11 1.897.122 1.753.722 5.149 66.399.270 317 0,14 274 116 158 
HA#12 2.294.748 1.849.058 10.329 80.316.180 334 0,21 394 209 185 
HA#13 1.735.616 1.534.895 5.148 60.746.560 278 0,12 234 100 134 
Total 22.644.708 20.481.383 47.484 792.564.780 3.702 2 3.126 1.510 1.616 
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Table S 3: Distribution of known SNPS associated with FVIII:C in healthy controls.  
 MAF= Minor allele frequency, 1C-96C=healthy controls, R=A/G, Y=C/T, K=G/T, nd= no data available 
SNP Nr. 1 2 3 4 5 6 7 8 
Gene F8 F8 F8 STAB2 SCARA5 STBXP5 AB0 vWF 
rs number rs7058826 rs1800291 rs1800292 rs12229292 rs9644133 rs9390459 rs687289 rs1063856 
Chromosome Xq28 Xq28 Xq28 12q23 8p21  6q24  9q34  12p13  
Location  
NM_000132.3 
c.1010-27 
NM_000132.3 
c.3780 
NM_000132.3 
c.3864 
NM_017564.9 
c.7248+582 
NM_173833.5 
c.241+9448 
NM_139244.4 
c.2337 
NM_020469.2 
c.99-329 
NM_000552.3 
c.2365 
MAF A=0.0928 C=0.2459 G=0.1049 T=0.2729 T=0.2418 G=0.4826 A=0.3668 G=0.3429 
(hg:19) 154194989 154158285 154158201 104153633 27814483 147680359 136137106 6153534 
1C A G A nd C R R R 
2C G C A G Y A G R 
3C G C A G C G A R 
4C G C A G C R R G 
5C G G A G Y A G R 
6C A G A G Y G R A 
7C G C C G C R R A 
8C G C C nd C A R A 
9C G C A nd C R R R 
10C G C A K C R R A 
11C G C C G C A R A 
12C G C A G Y R R A 
13C A G A K C R G A 
14C G C A G Y R G A 
15C G C A K Y R A nd 
16C G C C nd C R G R 
17C G C A T T R nd A 
18C A G A K Y R R G 
19C G C A nd C R A R 
20C G C A nd Y R R R 
21C G C A K C A A R 
22C G C A K C A R A 
24C G C A G C R G A 
25C G C A nd nd nd nd nd 
26C G C A nd nd nd nd nd 
SNP Nr. 1 2 3 4 5 6 7 8 
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27C G C A K C A R A 
28C G C A K Y R R A 
29C A G A nd nd nd nd nd 
30C A G A K C R R R 
31C G C A nd C R R nd 
32C G C C K nd R G A 
33C G C C K nd R R A 
34C G C A G nd R G G 
35C G C A K C R A R 
36C A G A K C G G A 
37C G C A K Y G G A 
38C G C A G Y G G G 
39C G C A K nd G R R 
40C G C A K T R R R 
41C G C A K C nd R R 
42C G C A T C nd A A 
43C G C A K Y R R A 
44C G C A G Y nd G A 
45C G C A nd C A G A 
46C G C A K T A R G 
47C G C A G C G R A 
48C G C A G Y G A R 
49C G C A K Y G G R 
50C G C A G C G A A 
51C A G A G C R G R 
52C A G A nd Y G R R 
53C A G A G C G R A 
54C G C A G Y G R A 
55C G C A nd Y A G A 
56C A G A T Y A A A 
57C G C C K Y A G R 
58C G G A G C R R R 
59C A G A T C A R G 
60C G G A K C G R A 
61C G C C T Y G R A 
62C G C A G Y G G R 
63C G C A G C G R A 
64C G C C G Y R R nd 
SNP Nr. 1 2 3 4 5 6 7 8 
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65C G C C K C A A A 
66C A G A K Y G R R 
67C G C A G Y R R nd 
68C G C A G C R R R 
69C A G A G C A R R 
70C G C A nd C G R A 
71C G C A G C nd A A 
72C G C A K Y A R A 
73C A G A G C R R R 
74C G C A G C R A A 
75C G C A G C R nd R 
76C A G A G C A R R 
77C A G A G C R G nd 
78C A G A K C A R R 
79C G C A G T G G A 
80C G C A K Y G G A 
81C G C A K C G G R 
82C G C A K C R R A 
83C G C A T C A R R 
84C G C A G Y R R A 
85C G G A K C R G A 
86C G C A K Y G G A 
87C G C A K C R G R 
88C G C A K C G G A 
89C G C A nd Y R R A 
90C G C C G C R G nd 
91C G C A nd Y G G R 
92C G C A G C A A A 
93C G C A nd C R R A 
94C G G A K C R R R 
95C A G A G C G A G 
96C G C A nd C  A  R R 
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Table S 4: Association of studied SNPs of Table S 3 with FVIII:C, FVIII:Ag, F8 mRNA expression, vWF activity and vWF:Ag 
levels in healthy individuals. 
 P values are calculated using the Krustal-Wallis test for the autosomal loci and Mann Whitney test for the X-lined loci, exp.=expression. 
SNP Nr. 1 2 3 4 5 6 7 8 
Gene F8 F8 F8 STAB2 SCARA5 STBXP5 AB0 vWF 
rs number rs7058826 rs1800291 rs1800292 rs12229292 rs9644133 rs9390459 rs687289 rs1063856 
Chromosome Xq28 Xq28 Xq28 12q23 8p21  6q24  9q34  12p13  
Location  
NM_000132.3 
c.1010-27 
NM_000132.3 
c.3780 
NM_000132.3 
c.3864 
NM_017564.9 
c.7248+582 
NM_173833.5 
c.241+9448 
NM_139244.4 
c.2337 
NM_020469.2 
c.99-329 
NM_000552.3 
c.2365 
MAF A=0.0928 C=0.2459 G=0.1049 T=0.2729 T=0.2418 G=0.4826 A=0.3668 G=0.3429 
(hg:19) 154194989 154158285 154158201 104153633 27814483 147680359 136137106 6153534 
F8 mRNA exp. 0,5954 0,4079 0,6289 - - - - - 
FVIII:C 0,293 0,703 0,0627 0,6593 0,4005 0,5736 0,0004 0,4498 
FVIII:Ag 0,3996 0,8572 0,5765 0,0592 0,2352 0,4553 0,0022 0,4724 
vWF activity 0,6754 0,7063 0,058 0,7571 0,7987 0,4292 < 0,0001 0,3582 
vWF:Ag 0,9148 0,5458 0,1097 0,948 0,9116 0,4624 0,0002 0,2441 
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Table S 5: Association of known SNPs associated with FVIII:C levels in patients without mutation.  
MAF= Minor allele frequency, 1C-96C=healthy controls, R=A/G, Y=C/T, K=G/T 
SNP Nr. 1 2 3 4 5 6 7 8 
Gene F8 F8 F8 STAB2 SCARA5 STBXP5 AB0 vWF 
rs number rs7058826 rs1800291 rs1800292 rs12229292 rs9644133 rs9390459 rs687289 rs1063856 
Chromosome Xq28 Xq28 Xq28 12q23 8p21  6q24  9q34  12p13  
Location  
NM_000132.3 
c.1010-27 
NM_000132.3 
c.3780 
NM_000132.3 
c.3864 
NM_017564.9 
c.7248+582 
NM_173833.5 
c.241+9448 
NM_139244.4 
c.2337 
NM_020469.2 
c.99-329 
NM_000552.3 
c.2365 
MAF A=0.0928 C=0.2459 G=0.1049 T=0.2729 T=0.2418 G=0.4826 A=0.3668 G=0.3429 
(hg:19) 154194989 154158285 154158201 104153633 27814483 147680359 136137106 6153534 
HA#2 G C A nd C R G A 
HA#5 G C A G C nd nd A 
HA#6 G C A G Y R R A 
HA#8 G C A K Y R R A 
HA#9 G C A G T nd R G 
HA#10 G C A G C R G R 
HA#11 G C A K C R G R 
HA#12 G C A G C G A A 
HA#13 G C A K Y R G  A 
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Table S 6: Analyzing the distribution of SNPs found in patients after NGS in healthy controls 
SNP 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 
Intron 
5´U
TR
 1 1 I1 4 4 4 I6 6 6 6 6 I7 10 10 12 13 13 13 14 14 I14 14 22 22 22 22 22 22 22 25 25 25 25 25 
3Ú
TR
 
rs Nr. 
rs6649625 
rs55807428 
rs1470586 
rs141897310 
rs5945269 
rs73641115 
rs144231135 
rs5945128 
rs28857481 
rs3861554 
rs201280173 
rs59835535 
rs148954517 
rs76063559 
rs190639729 
rs150203712 
rs6643622 
rs34552198 
rs78362479 
rs113224419 
rs6643714 
rs28845018 
rs147346816 
rs9305 
rs113683431 
rs11152585 
rs2292089 
rs28810103 
rs78327897 
rs28835013 
rs112922881 
rs28536050 
rs6643711 
rs3076842 
rs1509787 
rs1050705 
N
G
_11403.1 
g. 
7716 
15614 
17323 
25961 
36681 
37752 
37942 
45117 
45260 
46841 
49012:49014 
55023 
60195 
68425 
69579 
74668 
82469 
88822:88823 
90648 
103221 
106551 
113955 
117255 
140194 
142941 
141745 
142472 
148356 
161095 
161935 
168273 
174645 
177957 
186709D
del TT 
187365 
191799 
MAF 
T=0,247 
C
=0,084 
A
=0,210 
C
=0.021 
C
=0.1802 
C
=0.1519 
T=0.0084 
C
=0.223 
T=0.3924 
G
=0.4696 
-=0.024 
A
=0.0476 
A
=0.0072 
G
=0.0874 
C
=0.0018 
G
=0.0205 
C
=0.4063 
rare 
G
=0.0886 
G
=0.0995 
A
=0.4907 
A
=0.4756 
A
=0.0241 
rare 
rare 
rare 
rare 
A
=0.4834 
A
=0.088 
C
=0.4943 
A
=0.0928 
T=0.495 
A
=0.4623 
-=0.0187 
T=0.1248 
G
=0.3743 
C
hrom
osom
al 
location  
(hg:19) 
154248283 
154240385 
154238676 
154230038 
154219318 
154218247 
154218057 
154210882 
154210739 
154209158 
154211329 
154200976 
154195804 
154187574 
154186420 
154181331 
154173530 
154167176:77 
154165351 
154152778 
154149448 
154142044 
154138744 
154115804 
154114300 
154114508 
154113527 
154107643 
154094904 
154094064 
154087726 
154081354 
154078042 
154069291 
154068634 
154064200 
1C C A A A T T G T T G - A G nd A T nd TA A A G G G C G C A G G T G C A nd T G 
2C C A G A T T nd T T A - A G A A nd A - A A A A G nd G T A A G C G T G T C A 
3C C A G A T T G T A A - A G nd A T C - A A A A G nd G C A A G C G T G T C A 
4C C A G A T T G T A A - A G A A T C - A A A A G nd G T A A G C G T G T C A 
5C C A G A C T G T T G - A G A A T C TA A A G G G C G C A G G T G C A T C G 
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SNP 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 
6C C A A A T T G T T G - A G A A T C TA A A nd G G C G C A G G T G C A nd T nd 
7C C A A A T T G C T G - A G A A T C - A A G G G nd G T A G G T G C A nd C G 
8C C A A A C C G C nd G - A G A A T C - A A G G nd nd G T A G nd T G C A T C G 
9C C nd G A T T G C A A - A G A A T A - A A G G G C C C A G G T G C G T C nd 
10C C C G A C C G C T G - A G G A T A TA G G G G G nd G C A G G T A C A T C A 
11C nd A A A T T G T T G - A G A A T C - A nd G G G C G C A G G T G C A T C nd 
12C C A G A T T G C A A - A G A A T A - A A G G G C C C A G G T G C G T C A 
13C C A A A T T G T nd G - A G A A T C TA A A G G G C G C A G G T G C A T T G 
14C T A G A T T G T A A - A G A A T A - A nd A A G  A G C G A G C G T G T C A 
15C T A G A T T G T A A - A G A A T A - A A A A nd A G C A A G C G T G - C A 
16C C A A A C C G C T G - A G A A T C - A A G G G C nd C A G G T G C A T C G 
17C T A G A T T G T A A - A G A A T A - A A A A G A G C A A G C G T G T C A 
18C C A A A T T G T T G - A G A A T C TA A A G G G C G C A G G T G C A T T G 
19C T A G A T T T T A A - A G A A T A - A A A A G A G C A A G C G T G T C A 
20C T A G A T T G T A A - A G A A T A - A A A A G A G T A A G C G T G T C A 
21C T A G A T T G T A A - A G A A T A - A A A A G A G C A A G C G T G T C A 
22C C A G A T T G T A A - A G A A T C - A A A A nd nd G T A A G C G T G T C A 
24C T A nd A nd T T T A A - A G A A T A - A A A A nd C G C A A G C G T G T C A 
25C C C G A C C G T T G - A G nd A G A TA nd nd G G G nd G nd G G A nd G C A T C nd 
26C nd A A A T T G T T G - A G nd A nd C - A nd G G G nd G nd A G G T G C A T C G 
27C T A G A T T G T nd A - A G A A nd A - A A A A G A G C A A G C G T G T C A 
28C T A G A T T G T A A - A G nd A nd A - A A A A G A G T A A G C G T G T C A 
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29C T nd nd A T T G T T G - A G nd nd nd C TA A nd G G G nd G nd A G nd T G C A nd T G 
30C T A A A T T G T T G - A G A A T C TA A A G G G C G C A G G nd G C A T T G 
31C C nd nd A C C G T T G - A G A A T A TA G A G G G A G C A G nd T A nd A T C A 
32C C A A A T T G T T G - A G A A nd C - A A G G G C G C A G G T G C A T C G 
33C C A A A T T G T T G - A G A A T C - nd A G G nd A G nd nd G G T G C A T C G 
34C C A G A T T G T A A - A G A A T C - A A A A G A G C A A G C G T G T C A 
35C C C G G C C G C T G - A G G A G A TA G G G G nd C G T A G A T A C A T C A 
36C C C G G C C G C T G - A G A A T C TA A A G G G C G C A G G T G C A T T G 
37C T A G A T T G T A A - A G A A T A - A A A A G A G T A A G C G T G T C A 
38C C A G A T T G T A A - A G A A T C - A A A A G nd G T A A G C G T G T C A 
39C C A G A T T G C A A - A G A A T A - A A G G G C C C A G G T G C G nd C A 
40C C C G A C nd G C A G - A G G A T A TA G G G G G A G C A G A T A C A T C A 
41C T A G A T T G T A A - A G A A nd A - A A A A G A G C A A G C G T G T C A 
42C T A G A T T G T A A - A G A A T A - A A A A G A G C A A G C G T G T C A 
43C T A G A T T G T A A - A G A A nd A - A A A A G A G nd A A G C G T G nd C A 
44C C A G A T T G T A A - A G A A nd A - A A A A G A G T G A G C G T G T C A 
45C C A G A T T G T A A - A G A A T A - A A A G G A G nd nd A G C G T G T C A 
46C C A G A T T G T T A - A G A A T A - A A G G G C C C A G G T G C G T C A 
47C nd C G G C C G C nd G - A G A A nd A TA G G G G A C C T A G A T A C A T C A 
48C C A G A T T G T nd A - A G A A T A - A A A A G A G C A A G C G T G T C A 
49C C A G A T T G T T A - A G A A T A - A A A A G A G nd A A G C A T G T C nd 
50C C C G A C C G C T G - A G G A T A TA G G G G G A G C A G A nd G C A T C nd 
51C T A A A T T G T T G - A G A A T C TA A A G G G C G C G G G T G C A T T G 
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52C C A A A T T G T T G - A G A nd T C TA A A G G G C G C G G G T G C A T T G 
53C C A A A T T G T T G - A G A A T C TA A A G G G C G C A G G T G C A T T G 
54C T A A A T T G T A G - A G G nd G A TA G G G G A A G T A G A T A C A T C A 
55C C C G G C C G C T G - A G G A G A TA G G G G A C G T A G A T A C A T C A 
56C C A A A T T G T nd G - A G A A T C TA A A G G G C G C G G G T G C A T nd G 
57C C A A A T T G T nd G - A G A A T C - A A G G G C G C G G G T G C A T C G 
58C C A G A T T G T A G - A G A A T C - A A G G G A G T A G G T G C A T C G 
59C C A A A T T G T T G - A G A A T C TA A A G G G C G C A G G T G C A T T nd 
60C C A G A T T G T A G - A G A A T C - A A G G G A G C A G G T G C A T C G 
61C C A G A T T G T T G - A G A A T C - A A G G G A G C G G G T G C A T C nd 
62C T A G A T T G T A A - A G A A T A - A A A A G A G C G A G C G T G T C A 
63C T A G A T T G T nd R - A G A A T nd - A A A G G A G T G nd G nd G nd nd T C nd 
64C C A G A C C G C nd G - A G A A T C - A A G G G A G T G G G T G C A T C nd 
65C C A A A C C G T T G - A G A A T C - A A G G G C G C A G G nd G C A T C nd 
66C C A A A T T G T nd G - A G A A nd C TA A A G G G C G C A G G T G C A T T nd 
67C T A G A T T G T A A - A G A A T A - A A A A G A G nd A A G C G T G T C A 
68C T A G A T T G T A A - A G A A T A - A A A A G A G C A A G C G T G T C A 
69C C A A A T T G T T G - A G A A nd C TA A A G G G C G C A G G T G C A T T nd 
70C T A G A T T G T A A delTAA A G A A T A - A A A A G A G C G A G C G T G T C A 
55C C C G G C C G C T G - A G G A G A TA G G G G A C G T A G A T A C A T C A 
56C C A A A T T G T nd G - A G A A T C TA A A G G G C G C G G G T G C A T nd G 
57C C A A A T T G T nd G - A G A A T C - A A G G G C G C G G G T G C A T C G 
58C C A G A T T G T A G - A G A A T C - A A G G G A G T A G G T G C A T C G 
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59C C A A A T T G T T G - A G A A T C TA A A G G G C G C A G G T G C A T T nd 
60C C A G A T T G T A G - A G A A T C - A A G G G A G C A G G T G C A T C G 
61C C A G A T T G T T G - A G A A T C - A A G G G A G C G G G T G C A T C nd 
62C T A G A T T G T A A - A G A A T A - A A A A G A G C G A G C G T G T C A 
63C T A G A T T G T nd R - A G A A T nd - A A A G G A G T G nd G nd G nd nd T C nd 
64C C A G A C C G C nd G - A G A A T C - A A G G G A G T G G G T G C A T C nd 
65C C A A A C C G T T G - A G A A T C - A A G G G C G C A G G nd G C A T C nd 
66C C A A A T T G T nd G - A G A A nd C TA A A G G G C G C A G G T G C A T T nd 
67C T A G A T T G T A A - A G A A T A - A A A A G A G nd A A G C G T G T C A 
68C T A G A T T G T A A - A G A A T A - A A A A G A G C A A G C G T G T C A 
69C C A A A T T G T T G - A G A A nd C TA A A G G G C G C A G G T G C A T T nd 
70C T A G A T T G T A A delTAA A G A A T A - A A A A G A G C G A G C G T G T C A 
71C T A G A T T G T A A - A G A A T A - A A A A G A G nd A A G nd G T G T C A 
72C T A G A nd T G T A A - A G A A T A - A A A A G A G C A A G C G T G T C A 
73C C A A A T T G T nd G - A G A A nd C TA A A G G G C G C A G G T G C A T T nd 
74C nd A G A T T G T A A - A G A A T A - A A A A G A C C A A G C G T G T C A 
75C nd A G A T T G T T G - A G A A T C TA A A G G G C G C A G G T G C A T C nd 
76C nd A A A T T G T T G - A G A A nd C TA A A G G G C G nd A G G T G C A T T nd 
77C nd A A A T T G T T G - A G A A T C TA A A G G G C G C A G G T G C A T T nd 
78C nd A A A T T G T T G - A G A A T C TA A A G G G C G C A G G T G C nd T T nd 
79C nd A G A T T G T A A - A G A A T A - A A G G G A G C A G G T G C A T C nd 
80C C C G A C C G C A G - A G G nd T A TA G G G G G A G C A G A T G C nd T C A 
81C T A G A T T G T A A - A G A A T A - A A A G G A G nd A A G C G T G T C A 
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82C nd C G A C C G C A G - A G G A T A TA G G G G G A G nd A G A T A C A T C A 
83C nd A G A T T G T T A - A G A A nd A - A A A A G A G C A A G C G T G T C nd 
84C T A G A T T G T A A - A G A A T A - A A A A G A G nd A A G C G T G T C nd 
85C T A G A T T G T nd nd - A G A A T C - A A G G G A G T A G G T G C A T C G 
86C T A G A T T G T T A - A G A A T A - A A A A G A G C A A G C G T G T C A 
87C T C G A C C G C T G - A G G A T A TA G G G G G A G C A G A T A C A T C nd 
88C nd C G G C C G C nd G - A G G A G A TA G G G G A C G T A G A T A C A T C nd 
89C C  G A T T G T T A - A G A A nd C - A A A A G A G nd A A G C G T G T C A 
90C T A A A C C G C T G - A G A A T C - A A G G G A G nd nd G G T G C A T C nd 
91C nd A G A T T G T A A - A G A A T A - A A A A G A G nd nd A G C G T G T C A 
92C nd A G A T T G T A A - A G A A T A - A A A A G A G C nd A G C G T G T C A 
93C T A G A T T G T A A - A G A A T A - A A A A nd A G C nd A G C G T G T C A 
94C nd A G A T T G T A G - A G A A T C - A A G G G A G C nd G G T G C A T C nd 
95C nd A A A T T G T nd G - A G A A T C TA A A G G G C G C A G G T G C A T T nd 
96C T A G A T nd G T A nd - A G A A T A - A A nd A G A G T A A G C G T nd T C A 
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Table S 7: Association of studied SNPs of Table S 6 with FVIII:C, FVIII:Ag, F8 mRNA expression in healthy individuals. 
 *P values are shown calculated according to Mann Whitney test for X-lined loci 
SNP 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 
F8 m
R
N
A
 exp. 
0.3845 
0,6012 
0.3181 
0,8872 
0.8449 
0.8383 
- 
0.2331 
0.0326 
0.4062 
- - - 
0.1296 
- 
0.6142 
0.0071 
0.9349 
0.12 
0.0617 
0.717 
0.8187 
0.1131 
0.1859 
0.0856 
0.3401 
0.4614 
0.5099 
0.2236 
0.4751 
0.2372 
0.6568 
0.3191 
- 
0.5037 
0.1624 
FV
III:C
 
0.4359 
0.773 
0.6651 
0.8349 
0.2773 
0.5541 
- 
0.3378 
0.1045 
0.7632 
- - - 
0.6353 
- 
0.1646 
0.3364 
0.049 
0.2115 
0.3491 
0.8824 
0.8367 
0.1355 
0.8056 
0.3109 
0.6039 
0.6571 
0.9367 
0.0611 
0.924 
0.7846 
0.8609 
0.8516 
- 
0.3038 
0.0535 
FV
III:A
g 
0.3375 
0.3008 
0.2044 
0.4631 
0.1669 
0.3524 
- 
0.3448 
0.1487 
0.7871 
- - - 
0.8966 
- 
0.4683 
0.519 
0.2503 
0.586 
0.744 
0.8731 
0.76 
0.3944 
0.3619 
0.3071 
0.6237 
0.3245 
0.8886 
0.3283 
0.8747 
0.9629 
0.9039 
0.9239 
- 
0.5164 
0.4036 
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Table S 8: Distribution of SNPs found after NGS in patients without mutation.  
SNP numbering is according to Table S 6, del= deletion, nd=not data avaliable 
 
SNP 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 
HA#2 C C G G C C G C T G - A A G A G nd TA G G G G A C C T A G A T A C A - C A 
HA#5 T A G A T T G T A A - G G A A T A - A A A A G A G C G A G C G T G T C A 
HA#6 T A G A T T G T A A - G G A A T A - A A A A G A G C G A G C G T G T C A 
HA#8 T A G A T T G T A A delTAA G G A C T A - A A A A G A G C G A G C G T G - C A 
HA#9 C C A G T T G C T G - G A G A G A TA G G G G A C C T A G A T A C A - C A 
HA#10 T A G A T T T T nd A - G G A A T A - A A A A G A G C G nd G C G T G - C A 
HA#11 T A G A nd T T T A A - G G A A T A - A A A A G A G C G A G C G T G - C A 
HA#12 T A G A T T G T nd A delTAA A G A A T nd - A A A A G A G C G A G C G T nd - C A 
HA#13 T A G A T T T T nd A - G G A A T A - A A A A G A G C G A G C G T G - C A 
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Table S 9: Characteristics of healthy individual controls included in this study. 
Sample Age FVIII:C vWF activity FVIII:Ag vWF:Ag F8 mRNA exp. ABO Rhesus 
1C 36 105 97.5 103 109 0.09 A1 Pos 
2C 31 91 45.3 90 55 0.06 O Pos 
3C 28 102 94.5 89 102 0.09 A pos 
4C 27 159 151.8 140 198 0.08 B Pos 
: 5C 37 57 35.9 55 40 0.06 O pos 
6C 57 129 119 116 133 0.07 A1 Pos 
7C 44 126 66.2 95 94 0.10 B Pos 
8C 56 89 80.6 85 95 0.10 A2 Pos 
9C 62 85 43.7 83 97 0.16 A2 Pos 
10C 40 91 75.5 81 87 0.26 A1 Pos 
11C 28 111 79 93 85 0.07 A Pos 
12C 35 139 106.3 121 133 0.06 A1 Pos 
13C 32 67 44.4 59 83 0.21 O Pos 
14C 54 113 90.9 96 152 0.05 O Pos 
15C 22 114 95.4 96 235 0.12 A Pos 
16C 50 129 88.3 96 94 0.05 O Neg 
17C 40 119 98.8 89 103 0.11 AB Pos 
18C 40 159 121.7 112 139 0.16 B Pos 
19C 49 118 82.7 90 79 0.24 A1B Pos 
20C 56 164 75.9 141 86 0.24 A1 Pos 
21C 48 193 185 163 197 0.19 B Pos 
22C 57 139 114.2 85 139 0.07 A Pos 
24C 51 118 76.1 97 85 0.18 O pos 
25C 50 168 144.5 119 168 0.05 A1 Pos 
26C 39 98 78.1 78 84 0.06 B Pos 
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Sample Age FVIII:C vWF activity FVIII:Ag vWF:Ag F8 mRNA exp. ABO Rhesus 
27C 50 107 85.5 76 84 0.08 A2 Neg 
28C 29 118 90.9 88 106 0.09 B Neg 
29C 42 123 82 67 81 0.13 O Pos 
30C 33 117 70.9 81 72 0.11 A2 Pos 
31C 41 147 112.6 97 118 0.07 A1 Pos 
32C 28 106 76.9 81 84 0.12 O Pos 
33C 48 114 78.7 86 88 0.05 A1 Pos 
34C 48 128 93.1 100 108 0.04 O Pos 
35C 27 119 92.3 89 103 0.04 A1 Pos 
36C 48 85 54.6 50 55 0.10 O pos 
37C 54 93 58.6 70 70 0.49 O Pos 
38C 36 109 77.1 69 75 0.07 O Pos 
39C 59 149 98.6 91 99 0.47 A Pos 
40C 30 117 111.4 83 114 0.31 A1 Pos 
41C 29 155 118.8 135 122 0.15 A1 Pos 
42C 57 129 103.2 85 113 0.13 A1B Pos 
43C 48 169 136.9 125 147 0.75 B Pos 
44C 46 100 63.4 149 70 0.32 O Neg 
45C 46 110 86.2 89 95 0.26 O Pos 
46C 34 109 88.2 74 103 0.33 A1 Pos 
47C 33 163 147.7 132 138 0.29 B Pos 
48C 38 147 114.2 119 119 0.52 A1 Pos 
49C 41 96 63.9 80 70 0.16 O neg 
50C 55 144 97.7 102 111 0.28 A1B Pos 
51C 46 111 63 90 72 0.43 O pos 
52C 44 144 120.1 183 139 0.19 A1 Pos 
53C 57 161 123 173 141 0.16 A1 Pos 
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Sample Age FVIII:C vWF activity FVIII:Ag vWF:Ag F8 mRNA exp. ABO Rhesus 
54C 50 245 275.7 143 250 0.41 B Neg 
55C 28 95 47.3 64 54 0.26 O Pos 
56C 30 125 75.2 115 88 0.23 A1B Pos 
57C 39 138 88.1 120 107 0.32 O Pos 
58C 41 118 84.6 96 94 0.05 A1 Pos 
59C 27 131 94.7 96 108 0.29 A2 Pos 
60C 51 101 68.8 85 75 0.43 O Pos 
61C 36 123 93.7 106 97 0.15 A2 Pos 
62C 31 90 45.6 75 57 0.16 O Pos 
63C 28 121 88.3 80 94 0.05 A1 Pos 
64C 29 96 62.9 74 85 0.32 A2 Neg 
65C 42 102 109.9 83 107 0.12 A1B Pos 
66C 44 126 124.7 79 133 0.12 A1 Pos 
67C 26 144 119 118 123 0.22 A1 Pos 
68C 37 108 65 116 70 0.17 A2 Pos 
69C 41 142 111 108 126 0.10 A1 Pos 
70C 53 134 112 65 136 0.08 B Neg 
71C 29 139 103.3 88 118 0.03 B Pos 
72C 35 121 86.5 82 102 0.13 A1 Pos 
73C 28 159 145.3 106 144 0.04 A1 Pos 
74C 32 191 159.1 119 103 0.24 A1B Pos 
75C 48 161 146.8 107 87 0.07 A1 Pos 
76C 58 189 134.6 112 73 0.07 A1B Neg 
77C 40 106 53.9 73 81 0.10 O Pos 
78C 55 146 59.8 86 87 0.05 A2 Pos 
79C 26 100 59 72 65 0.10 O Pos 
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Sample Age FVIII:C vWF activity FVIII:Ag vWF:Ag F8 mRNA exp. ABO Rhesus 
80C 27 146 96 89 102 0.23 O Pos 
81C 53 124 103.1 81 108 0.26 O Neg 
82C 35 161 131.8 112 130 0.18 A1 Pos 
83C 45 128 96.1 74 97 0.05 A2 Pos 
84C 47 133 117.2 84 148 0.38 A2 Pos 
85C 28 111 70.7 74 89 0.06 O Neg 
86C 39 123 92.1 75 105 0.26 O Pos 
87C 50 96 82.3 80 84 0.13 O Pos 
88C 48 158 88 95 158 0.10 O Pos 
89C 38 88 59.3 70 65 0.11 A2 Pos 
90C 31 97 57.7 55 61 0.23 O Pos 
91C 52 143 131.1 89 138 0.26 O Pos 
92C 26 124 115.9 81 113 0.23 A1B Neg 
93C 28 134 111.7 98 135 0.11 A1 Pos 
94C 47 156 113.1 95 118 0.24 B Neg 
95C 56 154 125.4 112 126 0.16 A1 Neg 
96C 44 114 82.3 78 95 0.08 A1 Pos 
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Table S 10: List of primers used for LR-PCR amplification of genomic region of F8. 
Name Sequence 5´-->3´ Tm 
X:Chr 
(hg18) 
length 
(bp) 
5´-F TAC ATC ACA GAG CTC AGC GTG  153908320 
5´-R CTC ACT CTG GTT ATA CTG GTC 
64 
153904797 
5323 
A-F ATG CCA GGT GGT TAT GAG TGC 153905062 
A-R ACC TGG GCC TCT ACT TTC AAG 
60 
153892266 
12796 
B1-F AGT TCG TTC TAC AGC CTA TAT AGC 153892311 
B1-R GGA ACC ATT CCA GAA CTT ATG AAG 
60 
153887061 
5250 
B2-F GTG TGC TAA GAT TGT GTG GCA G 153887666 
B2-R ACT TAG ATG TGA AGC AGT TGT TCG 
60 
153882216 
5450 
C-F ATC CTG GTA ATC TGA GGC ATG G 153882470 
C-R TCA GGT ATT AAC CAA CAG TAT CAC TC 
60 
153879609 
2861 
D-F ATG CAG TGT ATG GTT ATT GAT TTT ATG ATT CTT A 153881259 
D-R CTG ATG ATA GAG AGG AAG ATA CAG 
60 
153867207 
14052 
E-F AAG TAA CTG ATG AAG AAC TGT CTC 153868842 
E-R CAG CAT GCA CTA CTT AAT CAC AAG 
60 
153862849 
5993 
F-F ATA AGG TCA AAC AAA ATG TGG TTG AG 153864554 
F-R AAT CTG TCC CTC CAC TAT AAG G 
55 
153852356 
12198 
G-F AGC AAC CCA AGA GAA TAA TGA AG 153852504 
G-R AGG GTA GAT GTT ATA TGG TCT GC 
60 
153842593 
9911 
H-F AGT AAG AGA CTT GAG CAT CAC AGA TTG 153842844 
H-R GAT TAC ATC AAT TTT TCT TTA TTC ACC ACC 
60 
153835303 
7541 
I-F ATG AAG AGA ATA AGG CTA CAG ACT G 153835798 
I-R AGT CTA TGA AGG GAA TTG TTT CTG 
60 
153830143 
5655 
J-F ACA CAG TAC CTA GTA ACA GAG TAG 153830215 
J-R AGA CAT CAG TAC AGA CAT TAT AAG G 
60 
153819013 
11202 
K-F ACT GTT GTC TTT GCC ATG AAT CTG 153819771 
K-R AGC AAT AAG GGC TTA CTT GAG C 
60 
153809157 
10614 
L-F AGT TGA GAC CTA AAT GAT GAT AAC AG 153809322 
L-R ATG ACC AGT AGT GTT GAA CTT TCC 
60 
153800492 
8830 
M1-F ATG AAG AAC AAT GCC ACC AAG C 153801065 
M1-R AGG TGG CAG TGG GAA TAA GTG  
60 
153796561 
4504 
M2-F ATC TAG GAA CAA ATT TAA CCA AAG AGG 153797003 
M2-R AAT TCC ACT GTC CTT AAC TCA CC 
60 
153787867 
9136 
N-F CAG GCA CCT AGG AAA ATG AGG ATG 153788105 
N-R GTG TTT GTC CAA TAT CTG AAA TCT GCC 
60 
153777469 
10636 
O-F AGG TGT AGC AGT TCA TCA CTG A 153778148 
O-R CTG CGT TTT GTT ATT CCT ACT GC 
60 
153769105 
9043 
P1-F AGT ACA AGA GTA GCT TTA TCA TGG ATT TAG GGC  153769493 
P1-R ACT CTC ATG CAC TAC TGT TGG GAA TGC GA  
60 
153765453 
4040 
P2-F GAG GCC GTG TGT GTC TGG CTG CTT TCA  153765806 
P2-R AGC CAC ATC AAC CAC TAC TGC  
60 
153762756 
3050 
Q-F AAG TGG CAT TCC TGA TCT TAG G  153763253 
Q-R AGA GGA CAC AGT CAG CTG TG 
57 
153757121 
6132 
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R-F ATG TTA TGT AAT TTT GTC CAG AAC CCA G 153757348 
R-R ATG TGT CCA TGT GCA TTT AAT GTT TAG 
60 
153744055 
13293 
S1-F ACA ATA GCA AAG GCA TGG AGT C 153744273 
S1-R CCA TGG TGG CAG GGA TAG AG  
64 
153739706 
4567 
S2-F GGT GAC CCA AAC CTT TAT TCC TG  153740100 
S2-R ATC AAT TGA CCA TAG ATG TAT AGG C 
58 
153733971 
6129 
T1-F ACA GAC ATA GAT CAG CAA ACA TGC 153734957 
T1-R ACA TTC TTA ATC TTC AGC AAT ACT TTC  
60 
153730753 
4204 
T2-F ACC TAA ATG AAA GCA AGC AAA GAG AG  153731207 
T2-R CTC AAG AAC ATT AAT ACC ATC TGC 
60 
153722403 
8804 
U-F ATG ACT AAA ACC ACC CAT AAC CC 153722807 
U-R AGA GTG TCC ATC TTG CTA TTC AG  
60 
153717163 
5644 
3´-F GGC AAA TG G AAA ACA GGA GA  153717702 
3´-R GAA CTT CCA CAC AGC AGC AA 
64 
153712952 
4750 
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Table S 11: Primers used for characterization of the rearrangement (Patient HA#1) 
 
List of primers used for mapping PCRs in intron 1 of F8. 
X:Chr Length Name Sequence 5´-->3´ Tm (hg18) bp 
B1-F1 AGT TCG TTC TAC AGC CTA TAT AGC 153892311 
B1-R1 CAT ATC CTT GGT TCC ACT ACG T 59 153890807 1505 
B1-F2 TGT TGG CCC GGC TGG TGT 153891024 
B1-R2 GAA CTC CCC AGT CCC AGC 59 153890063 959 
B1-F3 GTC TTG GGA AGG AAG GTG C 153890164 
B1-R3 GCG GAC AGT TTC ATG CCG TA 59 153889223 938 
B1-F4 CCA CCG AGA AGC TGG TTT G 153889353 
B1-R4 CCT TGA AAC TGC AGA CCT CTC T 59 153888392 983 
B1-F5 GAA ATG CAG GGC TAC GTG G 153888454 
B1-R5 ATG ATG AGT ACC AGT TGC AGA 59 153886954 1500 
 
List of primers used for inverse PCRs. 
Name Sequence 5´-->3´ Tm X:Chr hg 18 
Up-F CTG GGG AGC TGG ATA TTG TC 153891540 
Up-R ATT TGG CAA CCA TTG TCC TT 60 153891779 
Down-F CCT GAA GGG AGG AAA GGC TA 153889443 
Down-R TGG TAT TGT CCA TCA CAG AGA C 60 153889353 
 
List of primers used for multiplex PCR  
Name Sequence 5´-->3´ Tm X:Chr hg18 
3F TGG GGA ATC ATT GTA CAG CA 153890934 
4R TGG GTC TGG CCT TTA ATC AG 153889544 
2R GGA CTC TGC TCC ACA CCC TA 
62 
153435095 
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Table S 12: Primers used for characterization of the breakpoint (Patient HA#14) 
 
List of primers used for identification of breakpoint. MLPA specific adapters are 
underlined. F8 specific sequences are in capital. 
Name Sequence 5´-->3 Tm Length 
(bp) 
MLPA18F gtagcgcgacggccagtAGCATGGGCAGCAATGAAAA 
19R cagggcgcagcgatgacGGAAGAAAGCTGTAAAGAAGTAGGC 
58 2057 
17F gtagcgcgacggccagtCAGGTTGGACTGGCATAAAAA 
MLPA18R cagggcgcagcgatgacTTTTCATTGCTGCCCATGCT 
58 539 
 
List of primers used for inverse PCRs.  
Name Sequence 5´-->3 Tm Length 
(bp) 
InvR3 CTA GGG AGG GAA GAC ATC AAT C 
InvF3 ATG AGA CCA AAA GCT GGT ACT 
55 2725 
Inv-D-F1 CAA TAG TGA GTA GCA ATG TG 
Inv-D-R1 CAT GTA GAT GCT CGC CAA TA 
55 2819 
 
 Supplementary tables 
 
XXIV 
 
 
Table S 13: Primers used for haplotype analysis. 
Marker Polymorphism rs number Genotype c Position Name Sequence 5' to 3' Position (hg 19) Tm Length 
HEMA154507.3 GGG ATT CAT CTG GCA TTT ATT T 154853916 
1 ATCT a rs71969354 Indel 154854179 
HEMA154507.3 GGG ATT TTG TAG TGT TGC TAT GG 154854271 
57 356-364 
TMLHEInt5 CCA AAA CTA ATG GTT AGG CAA T 154739770 
2 TTTTA a rs34754890 Indel 154739902 
TMLHEInt5 GAG GGA TAG CAT CGG GAG AT 154740055 
57 276-286 
F8Int1SNP-F ATC TAC TAT TAT CTT GCT ATG CCA 154248447 
3 C/T rs6649625 CC: 0.345; CT: 0.195; TT: 0.460 154248283 
F8Int1SNP-R ATA GCA TCA CAC TTA TAA AAT ACA C 154248190 
57 258 
F8Int1-F CTG CCC TTG GAC ATA AGC AT 154230814 
4 CA repeat b rs72130835 Indel 154230888 
F8Int1-R Fam-CCA TAT GAT CCA GCA ACT CG 154231033 
59 218-220 
F8-Ex 8-F CCC ATA TAG TAG CCT GCA GAA ACA TGA 154195086 
5 G/A rs7058826 GG: 0.867;  GA: 0.080;  AA: 0.053 154194989 
F8-Ex 8-R TGG CTT CAG GAT TTG TTG GT 154194633 
57 454 
F8Int13.2-F GCC TAG AGA ATG CCA AAG TAA CA 154164237 
6 CA (STR) a rs10626536 Indel 154164258 
F8Int13.2-R Fam-TTG TTG TAA TTC CCA TTT GCA T 154164386 
61 150 
C/G rs1800291 GG: 0.797; GC: 0.102; CC: 0.102 154158285 F8-Ex14-5-F AAA GAG ATG GTT TTT CCA AGC A 154158497 
7-8 
C/A rs1800292 AA:  0.833; AC: 0.083; CC: 0.083 154158201 F8-Ex14-5-R CTC GGG GTC AAA TGT TTC AT 154157978 
57 520 
F8Int14SNP-F CCT GAC TTT TTA ATG ATC GCC A 154149540 
9 G/A rs6643714 AA: 0.522; GA: 0.221; GG: 0.257 154149448 
F8Int14SNP-R AGA TCT AGC TTT TGT CTT TCT GAG 154149332 
59 209 
F8Int18SNP-F ATG TGT TCA CTG TAC GA 154131971 
10 T/A rs4898352 AA: 0.688; AT: 0.152; TT: 0.161 154132090 
F8Int18SNP-R AAT ATC TTG GGA TGG AC 154131605 
50 367 
F8Int19SNP-F GTG AGT AGC AAT GTG GGC AG 154130306 
11 T/C rs4074307 AA: 0.696; AG: 0.152; GG: 0.152 154130223 
F8Int19SNP-R ATC TTC GAG CTT TAC CAA GTT G 154130078 
59 229 
LR-F8B-F ATG TTA TGT AAT TTT GTC CAG 154104162 
12 CA repeat a rs5818972 Indel 154104012 
LR-F8B-R Fam-AGA GGA CAC AGT CAG CTG TG 154103946 
57 217 
F8Int25.1-F CTG CCT TTG GAC TGG AAC AT 154087369 
13 GA repeat b REN90957 Indel 154087437 
F8Int25.1-R TGT GTT AGT CAG GGA TAT CCA AA 154087513 
57 145 
F8Int25.2-F CTC TAG GCT GCC AAC TCA CC 154082796 
14 ./CA a REN90841 Indel 154082866 
F8Int25.2-R Fam-TCA TGG TTC CCA AAG AAA CA 154082939 
59 144 
F8Int25SNP-F GAT TAA TGT TGT AGT TTA TAG GAT AG 154078123 
15 G/A rs 6643711 AA: 0.25;  GA: 0.222;  GG: 0.528 154078042 
F8Int25SNP-R GCC ATC ACA CCC AGC TAC 154078464 
57 342 
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Table S 14: Primers used for analyis of SNPs found after NGS.  
*Some SNPs were amplified using biotin labeled primers and were subsequently applied on a Pyrosequencer. The rest of the SNPs were amlified ans sequenced on an ABI 
capillary sequencer. 
SNP Nr. Ref Base->SNP  F8 Position SNP coordinates  NG_0014031:g. X-Chr / F8 Position Primer name Sequence 5' to 3' Position on  
X Chr hg19 
Length (bp) 
154210739-F GAC ACT TTA TTC TTC CAC ATA AAA CTG 154248343 
154210739-R Bio-GCA CTC ATA AAT GGA AAT AGG AGA 154248125 
1 C>T 5´UTR rs6649625 7716 154210739 
154210739-SQ TTA AAA AGA TCC AAG C     
219 
154240385-F TAG GCA AAA CCA CAG TGA CG 154240212 
2 A>C Intron 1 rs55807428 15614 154240385 
154240385-R ATC AGC CTG GGC AAC ATA AC 154240802 
591 
154238676-F TCT GGA CAC ATC CTG ACA GC 154238754 
3 G>A Intron 1 rs1470586 17323 154238676 
154238676-R TGG AGA AAC AAG ATT GTG AGA CA 154238183 
572 
154230038-F ACT GGA GGA GGT GAG AGT TAT TGT 154230267 
154230038-R Bio-TGG GCA ACA CAG CAG TAC CT 154230016 
4 A>C intron 1 rs141897310 25961 154230038 
154230038-SQ ACC ACC ACG CCT GGC        
252 
154219318-F GGA GGG GAA CAT TAT TCT TCA TT 154219366 
154219318-R Bio-CCA GTT CTG TGA GCT CCC TTT 154219214 
5 T>C Intron 4 rs5945269 36681 154219318 
154219318-SQ AGA TCT AAG ACA T   
153 
154218247-F TGA TGC AAA CAT GAA TAT GAA GAA 154218280 
154218247-R Bio-TGG TTC CAA GCA TTT CAG GT 154218133 
6 T>C Intron 4 rs73641115 37752 154218247 
154218247-SQ CAA ATC TGT AAT CAC AAC     
148 
154218057-F AAC GTT TCA GAT TTC AGA TAC TGG 154218088 
154218057-R Bio-TGG TGT CTT TTA TAA AGC ATA TGG A 154217943 
7 G>T Intron 4 rs144231135 37942 154218057 
154218057-SQ CAT ATA TAA TGA GAT AG    
146 
154210882-F CAC AAT GAA ACC CCG TCT CT 154210536 
8 T>C Intron 6 rs 5945128 45117 154210882 
154210882-R GGG TCC CAA GTA TCC TTC AA 154211091 
556 
154210739-F CGT TTG TTT ACA TTT GTC CCA AC 154210919 
154210739-R Bio-CTG GGC GAC AGC AAG ACT          154210696 
9 A>T Intron 6 rs28857481 45260 154210739 
154210739-SQ GTG TAT ACA TAT ATA TAT A     
223 
154209158-F GAG TGC CCT CTG TGG ATC TC 154209346 
154209158-R Bio-CAG CCT GAG CAA CAT AGC AA       154209146 
10 A>G Intron 6 rs3861554 46841 154209158 
154209158-SQ CCT GGC TGG GCT CAC    
201 
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154211329-F TAC CCA AGC AAC ACC ACA GA 154207051 
154211329-R Bio-CCC TCA AGC ACT TAT CCT TTG   154206740 
11 TTA-del Intron 6 rs201280173 49012:49014 154211329 
154211329-SQ AAA TTG GAA AAA GTG A   
312 
154200976-F ACC TGT TGG CCA TTT GTA GG 154200571 
12 C>A Intron 6 rs59835535 55023 154200976 
154200976-R TGT GGT GGC ACA CCT GTA GT 154201146 
576 
154195804-F TTT TTC GAT GCA GAC TGA GTT 154195829 
154195804-R Bio-TTA TAC CAC AGG GCA ATT TTG A   154195721 
13 G>A Intron 7 rs148954517 60195 154195804 
154195804-SQ AAG GCT ACA TGA ACC CC   
109 
154187574-F Bio-GAT GCA AAA TTC CAG CTA GAT AGG 154187904 
154187574-R ATG GTA GTG TGC GTC TGT GGT C 154187543 
14 A>G Intron 10 rs76063559 68425 154187574 
154187574-SQ GCT GAA GTG GGA GGA  
362 
154186420-F GGG TGA GGG AGG GTA GGT AA 154186252 
15 G>T Intron 10 rs190639729 69579 154186420 
154186420-R CTG AGG GGA TAG CAG AAC CA 154186558 
307 
154181331-F TCC TAC AGG GAA ATG CGA AA 154181343 
154181331-R Bio-CAG AAT TTC AAA AGG CAT ATA TTG G 154181217 
16 T>G Intron 12 rs150203712 74668 154181331 
154181331-SQ CGA AAT AGA ATA ACA A    
127 
154173530-F TTT GCA TCA ATG TTC ATC AGA GA 154173599 
154173530-R Bio-CAA GGG GGA AAA ATA CTT CCA A 154173515 
17 C>A Inron 13 rs6643622 82469 154173530 
154173530-SQ TTG GTT TCA GGG TAA TAC T  
85 
154167176-F Bio-CAT ATA TTT TAA ACC CCA TAA GAC ATT 154167205 
154167176-R GCC AAC ACA CAC TGA AGG AA 154167070 
18 TA-del Inron 13 rs34552198 88822:88823 154167176:77 
154167176-SQ AAA GAA ATG AAA GG  
136 
154165351-F GTT TGT CGC CTT TGT TAT AGG TTC 154165631 
154165351-R Bio-TTG TGA TAT GGG GTT AAA GCA GT 154165349 
19 A>G Inron 13 rs78362479 90648 154165351 
154165351-SQ AGC ATA AAT TTC CCT T  
283 
154152778-F ATG GCT GAA AGG GGT CAA TGT A 154153130 
154152778-R Bio-TGG CAT TTT GCT CCT GTC CTA 154152773 
20 A>G Intron 14 rs113224419 103221 154152778 
154152778-SQ AAT TCG AAG TTC CAC AA  
358 
154149448-F TTT TGA GAA GTG TCT GTT CAT ATC C 154149517 
154149448-R Bio-TTT ATC ACC CCT TCA TTT CTG A 154149360 
21 G>A Intron 14 rs6643714 106551 154149448 
154149448-SQ TTT CTC AGA AGA AAT ATT GT  
158 
154142044-F CTC TGG ATA GGC AGG AAT TTT TAC 154141549 
22 T>C Intron 14 28845018 113955 154142044 
154142044-R CGT GGA GAA CCT CTG CTA GG 154142273 
725 
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154138744-F CGG CCT TCC GCA GTG TAT 154138911 
154138744-R Bio-CAC AGG AGG GGG AAC ATC A 154138660 
23 G>A Intron 14 rs147346816 117255 154138744 
154138744-SQ GCT GCA CCC ACT AAC TC  
252 
154115804-F AAA TAA TTC CTA TGG CGG CAG T 154115929 
154115804-R Bio-AAG GAC ACG GAA GCC ATC AA 154115662 
24 C>A Intron 22 rs9305 140194 154115804 
154115804-SQ ACT GAT GCA AAA AGT CC  
268 
154114253F Bio-GCT GCA ATG CAA GTG GTC TA 154114349 
154114253-R ATG GCA CAG AGG AGC AGT CT 154113988 
25 C>T Intron 22 rs11152585 141745 154114253 
154114253-SQ  GGG GAC AAC AGT  
362 
154113527-F Bio-TTC CGC TCT CCG CTG TTC T 154113550 
154113527-R GTC TAC CTC GCT GCG GTT ATT G 154113505 
46 
26 A>G Intron 22 rs2292089 142472 154113527 
154113527-SQ CCT GAC GGC CAA GGT   
154114301-F GCC TGC CCG GGA AAG TCC TC 154114061 
27 G>C Intron 22 rs113683431 142941 154114301 
154114301-R TGA TGA GGT GCA AAG AGC GG 154114511 
451 
154107643-F Bio-TGA AAG TGA AAG GCA GAA TGG 154107761 
154107643-R GTT ATC AAT GCT TTG TGG TAC TGG 154107554 
28 G>A Intron 22 rs28810103 148356 154107643 
154107643-SQ ATG GGT ATG TAC CTC AAA  
208 
154094904-F Bio-CCT GGA GGT GAT AAG TTG GG 154095041 
154094904-R CCC AAC AGT AGA ATT ATC AAG C 154094718 
29 G>A Intron 22 rs78327897 161095 154094904 
154094904-SQ ACT GGG TTA CCA G    
324 
154094064-F GAC TTT CTG TTG CCA TTC TGT TAA 154094099 
154094064-R Bio-TTC AAT TTG ATC CCT GTG GTA A 154093960 
30 T>C Intron 22 rs28835013 161935 154094064 
154094064-SQ TTG TAG TTT TCT TGT TCC TT  
140 
154087726-F CAC AGT GAA ACC CCA TCT CT 154087781 
31 G>A Intron 25 rs112922881 168273 154087726 
154087726-R CTC ACT CTG TTG CCC AGG TT 154087606 
176 
  
154081354-F GAG GTG CAA GTC TTG TCC ACT AAA 154081404 
154081354-R Bio-ACC CAG AAT GCT TGC TTT GAA 154081199 
32 C>T Intron 25 rs28536050 174645 154081354 
154081354-SQ AAG AAC TGT CTG GTC TGA  
206 
154078042-F Bio-ACA ATG TAA GAC TCC CAA AAT GGT 154078077 
154078042-R TCT CTT TGC TTG CTT TCA TTT AGG 154078037 
33 G>A Intron 25 rs6643711 177957 154078042 
154078042-SQ GCT TGC TTT CAT TTA GGT  
41 
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154069291-F CCT CAT GTC TGC CTG CAT AA 154069300 
154069291-R Bio-GGC CAT GCC TAA AGT TGA TG 154069180 
34 TT_del Intron 25 rs3076842 186708;09 154069291 
154069291-SQ CTG GCA TAA ATC ACC T   
121 
154068634-F GCC AGA AGA TTA ATG GGA TCA 154068658 
154068634-R Bio-TCC AAT GGT ATT AGC AAC CCT TA 154068501 
158 
35 C>T Intron 25 rs1509787 187365 154068634 
154068634-SQ CAC AGA AAC TGG    
154064200-F GGT GAT ATG GTT TTA TTT CCT GTT A 154064211 
154064200-R Bio-TCA AAG GCA TTT GTT TGT ATG TG 154064076 
36 A>G 3´ UTR rs1050705 191799 154064200 
154064200-SQ GTT ATG TTT AAC TT  
136 
 
 Supplementary tables 
 
XXIX 
 
 
Table S 15: Primers used for amplification of unique variants found after NGS. 
SQ= Sequencing primer 
SNP Nr. Ref Base->SNP  F8 Position SNP  NG_0014031:g. X-Chr / F8 Position Name Sequence 5' to 3' Position on X Chr hg19 Length (bp) 
154167944 ATG TCC TTT CTG TTT GTT AG 154168261 
1 C>G Intron 13 new 88055 154167944 
154167944 GAA CTG GGT GGA GCC CCC CA 154167799 
463 
154161332-F BIO-GGT TTT TCC CTC AGC ACT TTA A 154164433 
154161332-R GAG CTT GAA GCC ATC CAG ATT T 154164335 
2 G_ins Intron 13 new 94667 154161332 
154161332-SQ TTG AAT GCA AAT GGG  
99 
154132892-F GTAACTTTCAGAAATCAGGCCTCT 154133275 
3 C>T Intron 16 new 123107 154132892 
154132892-R CAG AGC AAA TTC CTG TAC TGT CAC 154132718 
558 
154131652-F AGG GCA CCA GTA GTC ATC CA 154131865 
4 C>T Intron 18 new 124347 154131652 
154131652-R TGC AGT GGC ACT TTC ATA GC 154131522 
344 
154131240-F GCC CTG TAA CTT TTC TGC TCA 154131377 
5 G>A Intron 18 new 124759 154131240 
154131240-R CCA CCC AGA GTA AAG GTG GA 154130928 
450 
154125277-F BIO-TCC CAT TAT TCA CTC ATT CAT TCC 154125402 
154125277-R CAG TGA ACC CAT TTG AGT CAC CT 154125187 
6 A>C Intron 21 new 130722 154125277 
154125277-SQ GGG GTT AAA GAG TTA ATA CA  
216 
154117891-F GAATACCTCACAATGGGGAG 154118130 
7 G>T Intron 22 new 138108 154117891 
154117891-R TTG GGC TTC AGG AGA AGC CTC CTT 154117731 
400 
154095833-F TCC TGG ATT CAA GCG ATT CT 154095809 
8 A>G Intron 22 new 160166 154095833 
154095833-R AAG AAA AGC CCA GGA CCA AT 154095508 
302 
154065816-F Bio-CTG TGC TTT GCA GTG ACC AT  154066071 
154065816-R CCA CCA AAG AAA TGC AGG AC 154065730 
9 G>T 3´UTR new 190183 154065816 
154065816-SQ CAG GGA GGG ACA CTG  
342 
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List of Primers used for the qRT-PCR experiments 
 
Table S 16: Primers used for mRNA expression analysis for association studies with coagulation parameters. 
BHQ1= 3'-terminaler BlackHol  
Gene Name Sequence 5' to 3' Location 
hg 18 Probe-F8-Taq Fam- TGG CTA CAT AAT GGA TAC ACT ACC TGG CT -BHQ1 153785522 
F-F8Ex17-18-Taq AGA GAA TTA TCG CTT CCA TGC A 153785765 F8c R-F8Ex17-18-Taq CAG ATA CCA TCG AAT CCT TTG ATC 153785484 
Probe-PBGD-Taq Joe- CAA CGG CGG AAG AAA ACA GCC -BHQ1 118460979 
F-PBGD-Taq GGT AAC GGC AAT GCG GC 118460960 PBGD R-PBGD-Taq CCC ACG CGA ATC ACT CTC AT 118464198 
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Table S 17: Primers used for investigating the effect of intronic variations on F8 mRNA expression. 
 BHQ1= 3'-terminaler BlackHol  
Analyzed region F8 region 
SNP in F8 
Name Sequence 5' to 3' Location 
hg 19 qRT-ex13-F-N CTA TGA AGA CAC ACT CAC CCT 154176020 
qRT-ex14-R-N AAC TAG AAA CCT TCA GTA AG 154159896 
 
SNP1 
SNP2 
 
Intron 13 
Probe-ex13-14-F FAM-ACC CAG GTC TAT GGA TTC TGG GGT G-BHQ1 154159934 
qRT-ex16-F AGA TGA GTT TGA CTG CAA AG 154133115 
qRT-ex17-R CCT GTA CTG TCA CTT GTC TCC 154132726 
 
SNP3 
 
Intron 16 
Probe-ex16-17-F FAM-TGA TGT TGA CCT GGA AAA AGA TGT G-BHQ1 154133074 
qRT-ex17-F AGA GAA TTA TCG CTT CCA TGC A 154132676 
qRT-ex18-R CAG ATA CCA TCG AAT CCT TTG ATC 154132313 
 
SNP4 
SNP5 
 
Intron 18 
Probe-ex18-F FAM-TGG CTA CAT AAT GGA TAC ACT ACC TGG C-BHQ1 154132328 
qRT-ex20-21-F CAG GAC AAT ATG GAC AGT GGG 154129646 
qRT-ex22-R GGG TCT TGA TGC CGT GAA TA 154124465 
 
SNP6 
 
Intron 21 
Probe-ex21-22-F FAM-TCT TGG ATC AAG GTG GAT CTG TTG G-BHQ1 154128206 
qRT-ex22-F GTG GCA GAC TTA TCG AGG AAA 154124371 
qRT-ex23-R CGA ATG CTA TAA TGA GTT GGG TG 154091421 
 
SNP7 
SNP8 
 
Intron 22 
Probe-ex22-23-F FAM-GAA CCT TAA TGG TCT TCT TTG GCA ATG-BHQ1 154091358 
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Figure S 1: Map of pCR-XL-TOPO® plasmid.  
(Reference: https://products.invitrogen.com/ivgn/product/K470010) 
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